var title_f40_58_41888="Bakers cyst sonogram";
var content_f40_58_41888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Baker's cyst sonogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This transverse sonogram of the popliteal region shows a Baker's cyst taking the form of an X-shaped cross of St. Andrew. The gastrocnemius bursa lies around the medial head of the gastrocnemius tendon (GC) is filled with fluid (asterisks), as is the bursa of the semimembranosus tendon (SM), which lies just superficial to the femoral bone (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41888=[""].join("\n");
var outline_f40_58_41888=null;
var title_f40_58_41889="Subcostal view tetralogy of Fallot";
var content_f40_58_41889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1078px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PEDS/64797/Sub_view_tetra_Fallot.mp4?title=Subcostal+view+tetralogy+of+Fallot\" style=\"width:432px;height:304px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Subcostal parasagittal view in tetralogy of Fallot (TOF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This still frame from the accompanying echocardiographic video clip of the subcostal parasagittal view of a patient with tetralogy of Fallot (TOF) demonstrates the anterior deviation of the conal septum (arrow) and resultant infundibular obstruction of the right ventricular outflow tract (RVOT).",
"    <div class=\"footnotes\">",
"     RV: right ventricle; Ao: aorta; RPA: right pulmonary artery; LPA: left pulmonary artery; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41889=[""].join("\n");
var outline_f40_58_41889=null;
var title_f40_58_41890="Dysplastic neutrophils MDS";
var content_f40_58_41890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dysplastic neutrophils in myelodysplastic syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dysplastic neutrophils, peripheral blood. The cells are nearly agranular. The nuclear segmentation is also abnormal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Farhi DC. Myelodysplastic syndromes. In: Pathology of Bone Marrow and Blood Cells, 2nd ed, Farhi DC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41890=[""].join("\n");
var outline_f40_58_41890=null;
var title_f40_58_41891="MR normal placenta";
var content_f40_58_41891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of normal placental attachment (no accreta)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note homogeneity of the placental mass, no \"bulging\" of the placenta toward the bladder, and the well delineated uterine wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Resnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41891=[""].join("\n");
var outline_f40_58_41891=null;
var title_f40_58_41892="Reconstruction with a DIEP flap PI";
var content_f40_58_41892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Reconstruction with a DIEP flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 698px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Women who have reconstruction with a DIEP flap have a flap of tissue taken from their belly and attached to their chest. This surgery is different than the TRAM flap surgery, because the flap is made up of skin and fat, NOT muscle. DIEP stands for \"deep inferior epigastric perforator.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41892=[""].join("\n");
var outline_f40_58_41892=null;
var title_f40_58_41893="Pioglitazone and glimepiride: Patient drug information";
var content_f40_58_41893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pioglitazone and glimepiride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/23/34167?source=see_link\">",
"     see \"Pioglitazone and glimepiride: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3340525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Duetact&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause your body to keep extra fluid which can cause or make heart failure worse. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702202",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glimepiride, pioglitazone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem,  type 1 diabetes, or very weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bladder cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697216",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have eye problems from high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a chance of pregnancy in women of childbearing age who have not been ovulating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder cancer may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heart failure may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight or in the way you see color.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695917",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11829 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-C708E0D7D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41893=[""].join("\n");
var outline_f40_58_41893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3340525\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028052\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028054\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028053\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028058\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028059\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028061\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028056\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028057\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028062\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028063\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/23/34167?source=related_link\">",
"      Pioglitazone and glimepiride: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_58_41894="Foreign bodies A";
var content_f40_58_41894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68615%7EPULM%2F81535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68615%7EPULM%2F81535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examples of organic foreign bodies removed from children and adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examples of inorganic foreign bodies removed from children and adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41894=[""].join("\n");
var outline_f40_58_41894=null;
var title_f40_58_41895="Control of secondhand smoke exposure";
var content_f40_58_41895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Control of secondhand smoke exposure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41895/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41895/contributors\">",
"     Jonathan M Samet, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41895/contributors\">",
"     Marianna Sockrider, MD, DrPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41895/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41895/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41895/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41895/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41895/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/58/41895/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to secondhand smoke (SHS) takes place in many different microenvironments (ie, distinct places where time is spent). The contributions of various microenvironments to personal SHS exposures depend upon the amount of time spent in each setting, and on the concentrations of SHS in those environments. The contributions of different microenvironments also depend upon age, sex, and other sociodemographic factors that determine time-activity patterns. For children, the home is a dominant locus of exposure, whereas for adults the workplace and social environments may be significant loci.",
"   </p>",
"   <p>",
"    The concentration of SHS in a particular indoor environment depends upon the intensity of smoking (the strength of the source), the rate of exchange of air in the space with outdoor air or other \"clean\" air, and the presence and effectiveness of any air cleaning devices. For public and commercial buildings, ventilation requirements are set by code, generally following the standards published by the American Society of Heating, Refrigerating, and Air Conditioning Engineers (ASHRAE). The ventilation standard assumes that adequate indoor air quality cannot be achieved if smoking is allowed, even with additional ventilation, a view reaffirmed in a position statement by ASHRAE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/1\">",
"     1",
"    </a>",
"    ]. Air cleaning also is not sufficient if smoking is allowed. Elimination of smoking in an environment appears to be the only effective means of preventing SHS exposure in that location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies to prevent SHS exposure and the role of the healthcare provider are reviewed here. The adverse health effects of SHS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRATEGIES TO PREVENT SECONDHAND SMOKE EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four categories of strategies can be implemented to prevent SHS exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Education",
"     </li>",
"     <li>",
"      Regulation",
"     </li>",
"     <li>",
"      Legislation",
"     </li>",
"     <li>",
"      Litigation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Distinct control strategies are directed at different environments. Public places, workplaces, and transportation environments are subject to regulation, whereas the home is not. Education lays the groundwork for good compliance with legislation and regulation and in some areas (eg, the home) is the only intervention strategy that is available.",
"   </p>",
"   <p>",
"    Healthcare professionals should educate their patients and support legislation and regulations designed to protect nonsmokers and promote clean air. Regulatory strategies prohibiting smoking, when they exist and are enforced, have been associated with decreased population exposure to SHS. Indirect regulatory forces (eg, increased cigarette taxes, controls on cigarette advertising) can help address source control in the home, the major environment where SHS exposure still occurs in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is strong evidence that SHS exposure is decreasing in the United States, suggesting that these control strategies are having important effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. According to data from the National Health and Human Nutrition Examination Survey, 40 percent of nonsmokers had detectable serum cotinine concentrations (&gt;0.05",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    in 2007 through 2008, down from 84 percent in 1988 through 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recommendations of the Task Force on Community Preventive Services",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Task Force on Community Preventive Services (TFCPS) has made recommendations on the effectiveness of selected interventions to reduce exposure to environmental tobacco smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon existing evidence, the task force recommends:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Smoking bans and restrictions",
"     </li>",
"     <li>",
"      That healthcare providers discuss smoking cessation with their patients (or parents of patients) who smoke",
"     </li>",
"     <li>",
"      Patient telephone support (the provision of cessation counseling or assistance in attempting to quit and maintaining abstinence)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Air cleaners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various devices are available for air cleaning, ranging from complex and expensive systems that are incorporated into the heating, ventilation, and air conditioning (HVAC) systems of buildings to simple tabletop devices and \"smokeless ashtrays\" that are purported to control SHS exposure at its source. Cleaning air of SHS poses a technical challenge because of the strength of tobacco combustion as a source of indoor air pollution and the myriad gases and particles that are included in SHS. Air cleaning devices typically include filters or electrostatic precipitators to remove particles. Some devices, particularly those that are more costly, also include a sorbent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    , to remove gases. For SHS, both elements are needed.",
"   </p>",
"   <p>",
"    For any air cleaning device to be effective, it must be able to clean a sufficient volume of air in relation to the total volume of the space where it is operating. Few devices are able to clean sufficient volumes of air to be effective in managing smoking indoors, particularly if complete control is the goal. Small devices, like smokeless ashtrays and many table-top units, offer completely inadequate cleaning capacity. In general, healthcare providers should advise against purchase of an air cleaning device as a strategy for controlling SHS exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THE ROLE OF THE HEALTH CARE PROVIDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most smokers in the United States are now aware of tobacco health risks and also have a general knowledge of the risks of SHS exposure. However, they may not know about specific risks that might affect their decision to expose children or other family members to SHS. Personalizing the risks, through education of the smokers, may increase the effectiveness of counseling. Smokers may not know that SHS exposure can cause lung cancer and cardiovascular disease in their spouses or contribute to asthma and otitis media in their children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smokers may be more amenable to change at key points in their lives or the lives of their children. Healthcare providers should use these events as \"teachable moments\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Birth of a child",
"     </li>",
"     <li>",
"      Early childhood (eg, child begins to imitate smoking behavior or asks about smoking)",
"     </li>",
"     <li>",
"      Acute illness of the child that is related to smoking (eg, otitis media)",
"     </li>",
"     <li>",
"      Exacerbations of asthma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Obstetrics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetrical providers should address fetal tobacco exposure as early in pregnancy as possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/13\">",
"     13",
"    </a>",
"    ]. Expectant parents should know the benefits of providing a smoke-free environment for children before and after birth. They should know that smoking and exposure to SHS during pregnancy have predictable and possibly lasting consequences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although smoking during pregnancy has declined significantly, most mothers who smoked before pregnancy return to smoking postpartum, usually in the first six weeks after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/14\">",
"     14",
"    </a>",
"    ]. Risk factors for return to smoking postpartum include partners' smoking, low confidence for maintaining nonsmoking postpartum, having friends who smoke, and taking puffs of cigarettes late in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/15\">",
"     15",
"    </a>",
"    ]. Relapse prevention counseling should begin during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pediatrics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discussions about SHS exposure should be continued by the pediatric healthcare provider. The American Academy of Pediatrics calls on pediatric healthcare providers to address tobacco exposure and to prevent active smoking and exposure to secondhand smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Smoke exposure and smoking status of household members should be assessed at each well-child and acute-care visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/10\">",
"     10",
"    </a>",
"    ]. Providing parents who smoke with guidance in cessation or referral to cessation programs is considered part of family-centered care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some pediatric healthcare providers are concerned that parents may choose a new provider if they provide smoking control messages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/19\">",
"     19",
"    </a>",
"    ]. However, more than one-half of the caregivers who were surveyed report that they would like to receive smoking cessation advice from their child's pediatrician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In addition, nonsmoking caregivers who cared for a smoke-exposed child were interested in receiving advice on helping others to quit smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthcare providers should give a clear message that SHS exposure is a controllable factor in preventing and reducing illness.",
"     </li>",
"     <li>",
"      Families should be encouraged to actively control tobacco exposure as a way to serve as a role model on a smoke-free attitude for the child.",
"     </li>",
"     <li>",
"      Nonsmoking parents should be encouraged to advocate for smoke-free environments for their child. The provider should offer to communicate directly with household smokers about SHS exposure risks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Support for smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches for smoking cessation counseling are based upon the National Cancer Institute 5-A model (Ask, Advise, Assess, Assist, Arrange Follow-up) (",
"    <a class=\"graphic graphic_table graphicRef74402 \" href=\"mobipreview.htm?40/33/41500\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/10,21\">",
"     10,21",
"    </a>",
"    ] and the National Institutes of Health (NIH) and US Public Health Service six-component clinical practice guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anticipate &ndash; Provide age-appropriate education to parents and children",
"     </li>",
"     <li>",
"      Ask &ndash; Ask about SHS exposure and parental tobacco use at every visit",
"     </li>",
"     <li>",
"      Advise &ndash; Advise parents and youth who smoke to quit",
"     </li>",
"     <li>",
"      Assess &ndash; Assess if the smoker is ready to quit",
"     </li>",
"     <li>",
"      Assist &ndash; Provide information and referrals for those who are ready to quit",
"     </li>",
"     <li>",
"      Arrange follow-up &ndash; Provide encouragement and help with relapse prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional strategies for smoking cessation, including pharmacotherapy, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .) Evidence-based algorithms, clinical guidelines, and additional resources for healthcare providers are available at the following Web sites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPA smoke-free homes program:",
"      <a class=\"external\" href=\"file://www.epa.gov/smokefree/index.html\">",
"       www.epa.gov/smokefree/index.html",
"      </a>",
"     </li>",
"     <li>",
"      US Surgeon General:",
"      <a class=\"external\" href=\"file://www.surgeongeneral.gov/tobacco/\">",
"       www.surgeongeneral.gov/tobacco/",
"      </a>",
"     </li>",
"     <li>",
"      National Cancer Institute:",
"      <a class=\"external\" href=\"file://www.smokefree.gov/\">",
"       www.smokefree.gov",
"      </a>",
"     </li>",
"     <li>",
"      The American Academy of Pediatrics policy statements:",
"      <a class=\"external\" href=\"file://aappolicy.aappublications.org/\">",
"       file://aappolicy.aappublications.org/",
"      </a>",
"     </li>",
"     <li>",
"      The American Academy of Pediatrics Julius B. Richmond Center of Excellence for Children:",
"      <a class=\"external\" href=\"file://www2.aap.org/richmondcenter/\">",
"       file://www2.aap.org/richmondcenter/",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     THE HOME ENVIRONMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The home environment is the most important source of exposure to secondhand smoke for children. In a nationally representative sample in the United States, the mean serum level of cotinine (the principal nicotine metabolite) was nearly twenty-fold higher among children exposed to SHS in the home, as compared with those not exposed in the home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/26\">",
"     26",
"    </a>",
"    ]. The effect of home smoke exposure was strongest for infants and young children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22504314\">",
"    <span class=\"h2\">",
"     Effect of smoking bans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The air quality of homes is not subject to direct regulation, and effective educational strategies are needed to reduce exposures in homes. Smokers should be supported in quitting smoking for the benefit of their own health as well as the health of those around them. For those smokers who are unable or unwilling to quit, a policy should be established to have smokers smoke outside the home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/27\">",
"     27",
"    </a>",
"    ]. Allowing smoking in the house, but with restrictions, does not provide maximum protection. In cross-sectional surveys of households containing smokers and infants or toddlers, urinary cotinine levels were lower among children from households where smoking was not permitted in the house than among those from households using less strict harm-reduction measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among households of smokers in the United States, the proportion that do not allow smoking within the house varies by region, ranging from 36 percent in West Virginia to 66 percent in Arizona (median 45 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/30\">",
"     30",
"    </a>",
"    ]. Among households of nonsmokers, the proportion with a smoking ban ranges between 80 and 90 percent.",
"   </p>",
"   <p>",
"    Intermediate steps to reduce exposure include restricting smoking to a particular room with good ventilation, smoking after the children have gone to bed, and smoking away from children and other nonsmokers. Neither air cleaning nor increasing ventilation is a sufficient control measure. These measures may reduce the concentrations of gaseous and particulate components of tobacco smoke, but they do not completely eliminate them. Indoor air in homes exchanges with outdoor air largely through natural diffusion. The air exchange rate cannot be substantially increased by opening windows and doors and has been reduced by efforts to increase energy efficiency.",
"   </p>",
"   <p>",
"    Relatively few intervention studies have been published regarding secondhand smoke exposure control in the home. Some trials have demonstrated positive results in reducing SHS levels in the home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/18,31-39\">",
"     18,31-39",
"    </a>",
"    ], but others have not produced significant reductions in child exposure or in persuading parents to stop smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Those interventions showing the greatest sustained positive effect provided behavioral counseling delivered to individuals in the home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/18,32,36\">",
"     18,32,36",
"    </a>",
"    ] or in small groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/31,37,38\">",
"     31,37,38",
"    </a>",
"    ]. Several of these randomized studies also showed some benefit from clinician-delivered advice with provision of printed self-help materials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/31,33-35,38\">",
"     31,33-35,38",
"    </a>",
"    ], though the effect is less than that seen with motivational counseling and may decrease after the intervention without consistent reinforcement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/18,44\">",
"     18,44",
"    </a>",
"    ]. These studies suggest that structured clinician-delivered treatment that is only minimally more time intensive than usual care may provide substantial benefit using supportive, motivation-oriented messages and consistent follow-up reinforcement. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'The role of the health care provider'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is increasing attention to the spread of SHS within multi-family buildings from homes of smokers. As an example, in some California municipalities, new legislation is banning smoking indoors (Richmond and Redmond) and in common areas of such buildings (Santa Monica, Calabasas, and Glendale).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22504300\">",
"    <span class=\"h2\">",
"     Third-hand smoke exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third hand smoke exposure refers to exposure to smoke components and their metabolic by-products from contact with surfaces that have adsorbed smoke. The smoke leaves a residue of nicotine and other toxic substances in household dust and on surfaces. Although not yet well studied, there is concern that contact with thirdhand smoke will result in absorption of toxins through the skin or ingestion from contamination of the hands. Inhalation of resuspended dust is another potential route for entry into the body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Although direct health effects from third-hand smoke have not been established, many of the toxins that are deposited on surfaces are group 1 carcinogens, raising concerns about chronic exposure even if it is at low levels. The persistence of these substances in the home environment represents an unappreciated health hazard through dermal exposure, dust inhalation, and ingestion. Discussion of this exposure risk may be a further incentive for families to adopt home non-smoking policies. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     WORKPLACES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a remarkable shift in workplace smoking in the United States. Two decades ago, smoking was ubiquitous in workplaces; the majority of workplaces are now smoke-free. Model workplace smoking policies may involve either an outright ban or restriction of smoking to designated areas; some companies ban smoking altogether on their properties. In implementing a workplace smoking policy, smokers should be provided with opportunities to participate in smoking cessation programs, and informed communication is needed for all employees.",
"   </p>",
"   <p>",
"    The efficacy of workplace smoking policies has been documented in studies involving measurement of airborne nicotine and also of the biomarker cotinine. One study demonstrated that policies that ban smoking in the workplace are the most effective and generally lower all nicotine concentrations to less than 1",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef69319 \" href=\"mobipreview.htm?18/0/18446\">",
"     figure 1",
"    </a>",
"    ); by contrast, mean concentrations measured in workplaces that allow smoking generally range from 2 to 6",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    in offices, from 3 to 8",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    in restaurants, and from 1 to 6",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    in the workplaces of blue-collar workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/48\">",
"     48",
"    </a>",
"    ], which compares with mean nicotine concentrations from 1 to 3",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    that have been measured in the homes of smokers. For those workers still exposed to SHS during the workday, levels of cotinine are comparable to those coming from exposure at home. Elimination of workplace smoking is the only method to fully protect nonsmokers from exposure to secondhand smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To date, the United States lacks a federal regulation on SHS exposure in the workplace. A Healthy People 2010 objective was to establish laws in all 50 states and the District of Columbia that would make all indoor public places and worksites completely smoke-free. As of early 2010, 25 states had enacted statewide bans on smoking in workplaces, including workplaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/49\">",
"     49",
"    </a>",
"    ]. Several of these states have exemptions (eg, for casinos or very small workplaces).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PUBLIC PLACES AND TRANSPORTATION ENVIRONMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the mid-1980s, regulation in the United States has been increasing at the local and state level to restrict or eliminate smoking in public places, including municipal buildings and shopping malls. Most jurisdictions now have such regulations in place, although enforcement varies. At a minimum, smoking is restricted to designated areas in restaurants. In many states, such as California, smoking is not allowed in restaurants or bars. Although arguments were raised by the hospitality and tobacco industries concerning the economic impact of such restrictive policies, the experience in California and elsewhere has not shown that revenues have been compromised. Hospitals also are smoke-free in the United States. Transportation environments are smoke-free across the country, and cigarette smoking has been prohibited on all domestic airplane flights since 1989.",
"   </p>",
"   <p>",
"    Emerging evidence shows that smoke in a private vehicle is an important source of smoke exposure for children and adults. Studies show that smoke concentration may be quite high in vehicles while people are smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/50\">",
"     50",
"    </a>",
"    ]. Regulations have been passed in several places to protect children against in-vehicle exposure. As examples, the state of California has recently banned smoking in vehicles with a minor under age 18, while the state of Arkansas prohibits smoking in a motor vehicle carrying a child under age six years old who weighs less than 60 pounds and is in a car seat.",
"   </p>",
"   <p>",
"    Model policies and regulations have been developed and made available by many organizations, including the American Lung Association. Exposure can be completely eliminated by banning smoking indoors. Simply segregating smokers and nonsmokers within the same airspace may reduce the exposure of nonsmokers to SHS but does not eliminate it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/51\">",
"     51",
"    </a>",
"    ]. A study performed in restaurants in Albuquerque, NM, during the late 1980s showed that nicotine could be readily found in nonsmoking sections, often at levels similar to those found in smoking sections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/52\">",
"     52",
"    </a>",
"    ]. Depending upon the specific details of the heating, ventilating, and air-conditioning (HVAC) system in a building, air from a room in which smoking is taking place may be mixed with air distributed to other rooms.",
"   </p>",
"   <p>",
"    An increasing number of states and municipalities in the United States have passed laws establishing 100 percent smoke-free workplaces, restaurants, and bars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/49\">",
"     49",
"    </a>",
"    ]. Some municipalities have restricted smoking outdoors on public property. With increasing restriction of smoking indoors, nonsmokers are now likely to report SHS exposure outdoors and to link this exposure to odor and irritation. Updated lists of smoking restrictions in the United States are maintained by advocacy organizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study from Scotland suggests important improvements in cardiac disease that may be attributable to a nationwide ban of smoking in workplaces and other public spaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/53\">",
"     53",
"    </a>",
"    ]. After the smoking ban was enacted in 2006, there was a 14 percent reduction in admissions for acute coronary syndrome among smokers, a 19 percent reduction among former smokers, and a 21 percent reduction among nonsmokers. Reductions in coronary events were also seen in Rome after the institution of a smoking ban [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/54\">",
"     54",
"    </a>",
"    ]. A report by the Institute of Medicine concluded that data consistently demonstrates that secondhand-smoke exposure increases the risk of coronary heart disease and heart attacks and that smoking bans reduce this risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41895/abstract/55\">",
"     55",
"    </a>",
"    ]. Given the prevalence of heart attacks, and the resultant deaths, smoking bans can have a substantial impact on public health. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic(s) (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/37/595?source=see_link\">",
"       \"Patient information: Secondhand smoke: Risks to children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to secondhand smoke (SHS) is declining in the United States, but about 40 percent of nonsmokers have biochemical evidence of SHS exposure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Strategies to prevent secondhand smoke exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommended strategies to reduce SHS exposure are a combination of smoking bans and restrictions, mandates that healthcare providers discuss smoking cessation with their patients (or parents of patients) who smoke, and provision of telephone support or other services to help smokers attempt to quit and maintain abstinence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Recommendations of the Task Force on Community Preventive Services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Air cleaning devices are generally ineffective in ameliorating SHS exposure, and should not be recommended. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Air cleaners'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The home environment is the most important source of exposure to secondhand and thirdhand smoke for children. Smokers should be supported in quitting smoking for the benefit of their own health as well as the health of those around them. In homes of smokers who are unable or unwilling to quit, a complete ban on indoor smoking is helpful; partial restrictions on smoking in the home are less effective. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'The home environment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health care providers have an important role in reducing SHS exposure among their patients by communicating specific and personalized messages about risks and strategies for smoking cessation. These messages are particularly important and may be more effective during important life events, such as pregnancy, birth of a child, or early childhood. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'The role of the health care provider'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinician support for smoking cessation includes direct counseling, referral, and sometimes pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Support for smoking cessation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Samet JM, Bohanon HR, Jr., Coultas DB, Houston TP, Persily AK, Schoen LJ, Spengler J, Callaway CA, ASHRAE's Environmental Tobacco Smoke Position Document Committee. ASHRAE position document on environmental tobacco smoke. Atlanta, GA. American Society of Heating Refrigeration and Air Conditioning, 2005.",
"    </li>",
"    <li>",
"     Institute of Medicine. Chapter 7: Exposure to environmental tobacco smoke. In: Clearing the Air: Asthma and Indoor Air Exposures, National Academy Press, Washington, DC 2000. p.263.",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National C, 2006.",
"    </li>",
"    <li>",
"     World Health Organization. Protection From Exposure to Second-hand Tobacco Smoke, WHO Press, Geneva 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/5\">",
"      Davis RM. Exposure to environmental tobacco smoke: identifying and protecting those at risk. JAMA 1998; 280:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/6\">",
"      Pirkle JL, Bernert JT, Caudill SP, et al. Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988-2002. Environ Health Perspect 2006; 114:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/7\">",
"      Stranges S, Bonner MR, Fucci F, et al. Lifetime cumulative exposure to secondhand smoke and risk of myocardial infarction in never smokers: results from the Western New York health study, 1995-2001. Arch Intern Med 2006; 166:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: nonsmokers' exposure to secondhand smoke --- United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2010; 59:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/9\">",
"      Task Force on Community Preventive Services. Recommendations regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med 2001; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Available at: www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf (Accessed on September 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/11\">",
"      Winickoff JP, Hillis VJ, Palfrey JS, et al. A smoking cessation intervention for parents of children who are hospitalized for respiratory illness: the stop tobacco outreach program. Pediatrics 2003; 111:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/12\">",
"      Winickoff JP, Buckley VJ, Palfrey JS, et al. Intervention with parental smokers in an outpatient pediatric clinic using counseling and nicotine replacement. Pediatrics 2003; 112:1127.",
"     </a>",
"    </li>",
"    <li>",
"     Association of Reproductive Health Professionals. Current issues in smoking and reproductive health. 1996; ARHP Clinical Proceedings. Available at: www.arhp.org/healthcareproviders/onlinepublications/clinicalproceedings.cfm (Accessed on October 16, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/14\">",
"      Mullen PD, Quinn VP, Ershoff DH. Maintenance of nonsmoking postpartum by women who stopped smoking during pregnancy. Am J Public Health 1990; 80:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/15\">",
"      Mullen PD, Richardson MA, Quinn VP, Ershoff DH. Postpartum return to smoking: who is at risk and when. Am J Health Promot 1997; 11:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/16\">",
"      Tobacco-free environment: an imperative for the health of children and adolescents. American Academy of Pediatrics Committee on Substance Abuse. Pediatrics 1994; 93:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/17\">",
"      Environmental tobacco smoke: a hazard to children. American Academy of Pediatrics Committee on Environmental Health. Pediatrics 1997; 99:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/18\">",
"      Emmons KM, Hammond SK, Fava JL, et al. A randomized trial to reduce passive smoke exposure in low-income households with young children. Pediatrics 2001; 108:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/19\">",
"      Frankowski BL, Weaver SO, Secker-Walker RH. Advising parents to stop smoking: pediatricians' and parents' attitudes. Pediatrics 1993; 91:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/20\">",
"      Hopper JA, Craig KA. Environmental tobacco smoke exposure among urban children. Pediatrics 2000; 106:E47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/21\">",
"      Epps RP, Manley MW. A physicians's guide to preventing tobacco use during childhood and adolescence. Pediatrics 1991; 88:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/22\">",
"      Sims TH, Committee on Substance Abuse. From the American Academy of Pediatrics: Technical report--Tobacco as a substance of abuse. Pediatrics 2009; 124:e1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/23\">",
"      Klein JD. Incorporating effective smoking prevention and cessation counseling into practice. Pediatr Ann 1995; 24:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/24\">",
"      A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000; 283:3244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/25\">",
"      Committee on Substance Abuse. American Academy of Pediatrics: Tobacco's toll: implications for the pediatrician. Pediatrics 2001; 107:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/26\">",
"      Marano C, Schober SE, Brody DJ, Zhang C. Secondhand tobacco smoke exposure among children and adolescents: United States, 2003-2006. Pediatrics 2009; 124:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/27\">",
"      Johansson A, Hermansson G, Ludvigsson J. How should parents protect their children from environmental tobacco-smoke exposure in the home? Pediatrics 2004; 113:e291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/28\">",
"      Blackburn C, Spencer N, Bonas S, et al. Effect of strategies to reduce exposure of infants to environmental tobacco smoke in the home: cross sectional survey. BMJ 2003; 327:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/29\">",
"      Spencer N, Blackburn C, Bonas S, et al. Parent reported home smoking bans and toddler (18-30 month) smoke exposure: a cross-sectional survey. Arch Dis Child 2005; 90:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). State-specific secondhand smoke exposure and current cigarette smoking among adults - United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/31\">",
"      Wahlgren DR, Hovell MF, Meltzer SB, et al. Reduction of environmental tobacco smoke exposure in asthmatic children. A 2-year follow-up. Chest 1997; 111:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/32\">",
"      Greenberg RA, Strecher VJ, Bauman KE, et al. Evaluation of a home-based intervention program to reduce infant passive smoking and lower respiratory illness. J Behav Med 1994; 17:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/33\">",
"      Wall MA, Severson HH, Andrews JA, et al. Pediatric office-based smoking intervention: impact on maternal smoking and relapse. Pediatrics 1995; 96:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/34\">",
"      Keintz MK, Fleisher L, Rimer BK. Reaching mothers of preschool-aged children with a targeted quit smoking intervention. J Community Health 1994; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/35\">",
"      McIntosh NA, Clark NM, Howatt WF. Reducing tobacco smoke in the environment of the child with asthma: a cotinine-assisted, minimal-contact intervention. J Asthma 1994; 31:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/36\">",
"      Irvine L, Crombie IK, Clark RA, et al. Advising parents of asthmatic children on passive smoking: randomised controlled trial. BMJ 1999; 318:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/37\">",
"      Hovell MF, Zakarian JM, Matt GE, et al. Effect of counselling mothers on their children's exposure to environmental tobacco smoke: randomised controlled trial. BMJ 2000; 321:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/38\">",
"      Hovell MF, Meltzer SB, Zakarian JM, et al. Reduction of environmental tobacco smoke exposure among asthmatic children: a controlled trial. Chest 1994; 106:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/39\">",
"      Hovell MF, Meltzer SB, Wahlgren DR, et al. Asthma management and environmental tobacco smoke exposure reduction in Latino children: a controlled trial. Pediatrics 2002; 110:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/40\">",
"      Groner JA, Ahijevych K, Grossman LK, Rich LN. The impact of a brief intervention on maternal smoking behavior. Pediatrics 2000; 105:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/41\">",
"      Woodward A, Owen N, Grgurinovich N, et al. Trial of an intervention to reduce passive smoking in infancy. Pediatr Pulmonol 1987; 3:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/42\">",
"      Eriksen W, S&oslash;rum K, Bruusgaard D. Is there an increased lability in parents' smoking behaviour after a childbirth? Scand J Prim Health Care 1996; 14:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/43\">",
"      Chilmonczyk BA, Palomaki GE, Knight GJ, et al. An unsuccessful cotinine-assisted intervention strategy to reduce environmental tobacco smoke exposure during infancy. Am J Dis Child 1992; 146:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/44\">",
"      Severson HH, Andrews JA, Lichtenstein E, et al. Reducing maternal smoking and relapse: long-term evaluation of a pediatric intervention. Prev Med 1997; 26:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/45\">",
"      Winickoff JP, Friebely J, Tanski SE, et al. Beliefs about the health effects of \"thirdhand\" smoke and home smoking bans. Pediatrics 2009; 123:e74.",
"     </a>",
"    </li>",
"    <li>",
"     Benowitz NL, Hukkanen J, Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. In: Nicotine Psychopharmacology, Handbook of Experimental Pharmacology, Henningfield JE (Ed), Springer-Verlag, Berlin 2009. Vol 192, p.29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/47\">",
"      Sleiman M, Gundel LA, Pankow JF, et al. Formation of carcinogens indoors by surface-mediated reactions of nicotine with nitrous acid, leading to potential thirdhand smoke hazards. Proc Natl Acad Sci U S A 2010; 107:6576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/48\">",
"      Hammond SK. Exposure of U.S. workers to environmental tobacco smoke. Environ Health Perspect 1999; 107 Suppl 2:329.",
"     </a>",
"    </li>",
"    <li>",
"     American Nonsmokers Rights' Foundation. 100% Smokefree ordinance list. Available at: www.no-smoke.org/goingsmokefree.php (Accessed on January 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/50\">",
"      Rees VW, Connolly GN. Measuring air quality to protect children from secondhand smoke in cars. Am J Prev Med 2006; 31:363.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services (USDHHS). The health consequences of involuntary smoking: A report of the Surgeon General. DHHS Publication No. (CDC) 87-8398, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/52\">",
"      Lambert WE, Samet JM, Spengler JD. Environmental tobacco smoke concentrations in no-smoking and smoking sections of restaurants. Am J Public Health 1993; 83:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/53\">",
"      Pell JP, Haw S, Cobbe S, et al. Smoke-free legislation and hospitalizations for acute coronary syndrome. N Engl J Med 2008; 359:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41895/abstract/54\">",
"      Cesaroni G, Forastiere F, Agabiti N, et al. Effect of the Italian smoking ban on population rates of acute coronary events. Circulation 2008; 117:1183.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence, The National Academies Press, Washington, DC 2010.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6376 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41895=[""].join("\n");
var outline_f40_58_41895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRATEGIES TO PREVENT SECONDHAND SMOKE EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recommendations of the Task Force on Community Preventive Services",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Air cleaners",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THE ROLE OF THE HEALTH CARE PROVIDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Obstetrics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pediatrics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Support for smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      THE HOME ENVIRONMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22504314\">",
"      Effect of smoking bans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22504300\">",
"      Third-hand smoke exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      WORKPLACES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PUBLIC PLACES AND TRANSPORTATION ENVIRONMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6376\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6376|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/0/18446\" title=\"figure 1\">",
"      Effect of workplace smoking policy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6376|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/33/41500\" title=\"table 1\">",
"      Five As for smoking cessation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/37/595?source=related_link\">",
"      Patient information: Secondhand smoke: Risks to children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_58_41896="Presbycusis";
var content_f40_58_41896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Presbycusis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41896/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41896/contributors\">",
"     Nikolas H Blevins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41896/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41896/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41896/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/58/41896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11135885\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presbycusis, or age-related hearing loss, is a common cause of hearing loss in adults worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/1\">",
"     1",
"    </a>",
"    ]. Presbycusis is a complex and multifactorial disorder, characterized by symmetrical progressive loss of hearing over many years. It usually affects the high frequencies of hearing, although its presentation and clinical course can be variable. Presbycusis has a tremendous impact on the quality of life of millions of older individuals and is becoming an increasingly prevalent disorder as the population ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will focus on the pathophysiology, clinical presentation, evaluation, and management of presbycusis. The etiology and evaluation of other specific causes for hearing loss, as well as hearing amplification, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=see_link\">",
"     \"Hearing amplification in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455452151\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of hearing loss increases with age, with up to 80 percent of functionally-significant hearing loss occurring in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/3\">",
"     3",
"    </a>",
"    ]. In one population cohort in the United States, the prevalence of hearing loss (defined by audiometry) increased steadily with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      11 percent ages 44 to 54",
"     </li>",
"     <li>",
"      25 percent ages 55 to 64",
"     </li>",
"     <li>",
"      43 percent ages 65 to 84",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Presbycusis affects more than half of all adults by age 75 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Presbycusis is more common in men than women, but this finding may be related to higher levels of noise exposure seen in men.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) estimates that in 2025, there will be 1.2 billion people over 60 years of age worldwide, with more than 500 million individuals who will suffer significant impairment from presbycusis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455452871\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors can influence the onset and severity of presbycusis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/10\">",
"     10",
"    </a>",
"    ]. These factors include low socioeconomic status, noise exposure, ototoxins (eg, aminoglycosides, chemotherapeutic agents, heavy metals), infections, smoking, hypertension, diabetes, vascular disease, immunologic disorders, and hormonal factors (eg, estrogen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. A genetic component also predisposes individuals to age-related hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11135892\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal ear can be divided into three anatomic areas: the external ear, middle ear, and inner ear (",
"    <a class=\"graphic graphic_figure graphicRef66873 \" href=\"mobipreview.htm?29/39/30328\">",
"     figure 1",
"    </a>",
"    ). Disorders of any of these areas can contribute to hearing loss. The external ear includes the pinna and the external auditory canal, which directs sounds to the middle ear. The middle ear includes the tympanic membrane, tympanic cavity, ossicles, and the eustachian tube. The middle ear functions to pass sound vibrations from the external ear to the inner ear. The inner ear is a geometrically complex, fluid-filled organ that resides within the dense otic capsule in the temporal bone. The inner ear is the organ of hearing (cochlea) and balance (vestibular system), both of which translate motion of fluid around hair cells (from either sound or head acceleration) into neural signals (",
"    <a class=\"graphic graphic_figure graphicRef80127 \" href=\"mobipreview.htm?37/10/38056\">",
"     figure 2",
"    </a>",
"    ). The stria vascularis, a system of small blood vessels, produces the fluid (or endolymph) for the scala media, one of three fluid-filled compartments of the cochlea. The neural signals produced by the hair cells and surrounding fluid enter the spiral ganglion and are subsequently carried to the brain by the vestibulocochlear (eighth) cranial nerve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology of hearing loss in adults\", section on 'Anatomy and physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757158545\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss can be subdivided into two broad categories: conductive and sensorineural. Conductive hearing loss is characterized by the inability to mechanically transmit sound vibrations from the environment to the inner ear. Conductive loss is due to disorders of the external and middle ears. Sensorineural hearing loss is characterized by the inability to effectively transduce sound information into usable neural signals. The majority of sensorineural loss is the result of disorders of the inner ear itself and is not directly related to dysfunction of the vestibulocochlear nerve. Thus, the term &ldquo;nerve deafness&rdquo; is often a misnomer given that the primary dysfunction occurs in the inner ear, not the nerve. Presbycusis is a true sensorineural loss, in which both cochlear hair cells and, to a lesser extent, the spiral ganglion cells in the vestibulocochlear nerve can be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/2,20,21\">",
"     2,20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of hearing loss in adults\", section on 'Classification of hearing loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Temporal bone histology provides some insight to the underlying pathophysiology of presbycusis. In the histopathology classification system, presbycusis is subdivided based on the associated audiometric pattern of loss, with abnormalities of inner ear vasculature, hair cells, and membranes all contributing to audiometric findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. The three main types of presbycusis proposed by this system include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;Sensory,&rdquo; characterized by loss of hair cells and a high-frequency hearing deficit",
"     </li>",
"     <li>",
"      &ldquo;Metabolic,&rdquo; characterized by loss of stria vascularis and a low-frequency hearing deficit",
"     </li>",
"     <li>",
"      &ldquo;Neural,&rdquo; characterized by loss of ganglion cells and a variable pattern of hearing loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite its continued usage, the validity of this histopathologic classification system has been questioned, since it appears that no single histopathologic finding can reliably account for the clinical variability seen in presbycusis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/23-27\">",
"     23-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies of temporal bones from patients with typical presbycusis, the degree of hearing loss was associated with disorders of a number of vital cochlear anatomic structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/1\">",
"     1",
"    </a>",
"    ]. These include degeneration of the stria vascularis, spiral ganglion cells, and hair cells. Consistent with findings seen in other causes of sensory hearing loss, the outer hair cells were the predominant structures affected. Thus, presbycusis appears to be most related to loss of inner ear sensory structures, although the underlying inciting events for this remain unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11135906\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of presbycusis is the progressive, symmetric loss of high-frequency hearing over many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/2\">",
"     2",
"    </a>",
"    ]. Hearing loss can also be accompanied by tinnitus, vertigo, and disequilibrium leading to falls. Presbycusis can greatly impact quality of life, causing low self-esteem, isolation, and depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Presbycusis may also be associated with dementia, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=see_link&amp;anchor=H17#H17\">",
"     \"Risk factors for dementia\", section on 'Others'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161357\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progression of hearing loss is variable, but the typical course is a slow, persistent decline in hearing with age (",
"    <a class=\"graphic graphic_figure graphicRef80255 \" href=\"mobipreview.htm?10/59/11188\">",
"     figure 3",
"    </a>",
"    ). The hearing loss begins in the sixth decade and is typically symmetrical, beginning in the high-frequency range (",
"    <a class=\"graphic graphic_figure graphicRef80255 \" href=\"mobipreview.htm?10/59/11188\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The frequencies most affected by presbycusis are those above 2 KHz. Over time, the high frequencies will continue to drop, and the mid and low frequencies (0.5 to 2 KHz), associated with human speech, also become progressively involved. The low and mid frequencies of human speech carry the majority of energy of the sound wave. This includes most of the vowel information of words (",
"    <a class=\"graphic graphic_figure graphicRef55824 \" href=\"mobipreview.htm?18/10/18607\">",
"     figure 4",
"    </a>",
"    ). It is the high frequencies, however, that carry the consonant sounds, and therefore the majority of speech information. These consonant sounds tend to be not only high pitched, but also soft, which makes them particularly difficult for patients with presbycusis to hear. As a result of their hearing loss pattern, patients with high-frequency hearing loss will often report being able to hear when someone is speaking (from the louder, low-frequency vowels), but not being able to understand what is being said (due to the loss of consonant information).",
"   </p>",
"   <p>",
"    Hearing deficits are exacerbated in the presence of competing background noise. The missing high frequencies are essential to allow the inner ear to focus on sounds of particular interest and pick those sounds out from competing ambient noise. Patients with presbycusis will often perform quite well in one-on-one communication in a quiet room, but the ability to hear will decline when there is even a small amount of competing noise. This experience is often referred to as the &ldquo;cocktail party effect,&rdquo; which emphasizes the difficulty that patients experience with communication in social settings. Patients also will often complain that they have more difficulty hearing women than men, which is the result of the inherently higher pitch of women&rsquo;s voices.",
"   </p>",
"   <p>",
"    Many patients will wait for several years before seeking help for presbycusis and are often brought to medical attention at the insistence of family members. This is in part due to the insidious onset of the disorder, as well as the negative stigma associated with hearing aid use. Older individuals may accept some degree of hearing loss as inevitable, and do not consider it a treatable disorder. Left unrecognized, hearing loss in older adults can lead to progressive social withdrawal, depression, isolation, and significant familial stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/29\">",
"     29",
"    </a>",
"    ]. This can be further compounded by the higher incidence of hearing loss in individuals with other coexisting functional limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common finding in patients with inner ear hearing loss is a paradoxical hypersensitivity to loud sounds. Patients will often complain that sounds become too loud at levels that would easily be tolerated by persons with normal hearing. This is the result of &ldquo;recruitment,&rdquo; a disordered processing of sound in the inner ear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/31\">",
"     31",
"    </a>",
"    ]. The simultaneous elevation of the threshold needed to hear quiet sounds, and the reduction of tolerable loud sounds, results in a narrowing of the individual&rsquo;s dynamic range. This can complicate fitting hearing aids for affected individuals, where careful upper output limits must be set to maintain comfort levels. Recruitment explains why shouting at patients with presbycusis is often quite counterproductive, since it is primarily the low vowel frequencies that are amplified by shouting, which carry little of the missing speech information and can be quite uncomfortable to the listener.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161364\">",
"    <span class=\"h2\">",
"     Tinnitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinnitus can be an important problem as hearing loss progresses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The tinnitus is most commonly a steady ringing, rushing, or &ldquo;static&rdquo; sound, but may be described as a broad range of sensations, including musical tones, bells, or &ldquo;chirping.&rdquo; The sound is usually described as affecting both ears or presents diffusely &ldquo;in the head.&rdquo; Tinnitus occurring in only one ear should prompt the clinician to initiate further evaluation for other etiologies. In addition, the presence of a pulse-synchronous rushing sound may require additional imaging to exclude vascular disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26727?source=see_link\">",
"     \"Etiology and diagnosis of tinnitus\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H671161378\">",
"     'Diagnostic imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161371\">",
"    <span class=\"h2\">",
"     Dizziness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associated loss of vestibular end-organ function, termed &ldquo;presbyastasis,&rdquo; can contribute to vertigo, disequilibrium, and falls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/34\">",
"     34",
"    </a>",
"    ]. The consequences of the loss of peripheral vestibular function is exacerbated by the presence of coexisting disorders, such as peripheral neuropathy, arthritis, peripheral vascular disease, and decreased visual acuity. Such conditions can limit the ability of an older individual to compensate for peripheral vestibular dysfunction. With the early recognition of presbycusis and dizziness, patients and caregivers can initiate measures to increase function and mobility while reducing the risk of falls and their potentially devastating complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=see_link\">",
"     \"Approach to the patient with dizziness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=see_link\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11135920\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of presbycusis should be suspected based upon a history of slowly progressive, symmetrical hearing loss in the older patient. The physical examination may be helpful in determining the type of hearing loss (conductive versus sensorineural), possible contributing factors for hearing loss (eg, cerumen), or other causes of hearing impairment (eg, tumors such as acoustic neuroma). Patients with hearing loss require formal audiogram testing to confirm the diagnosis, determine severity, and to direct management. Other testing such as blood testing, specialized audiologic assessment, and diagnostic imaging should be performed only if indicated by specific symptoms or signs of other disease. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus regarding population screening for hearing loss. An evidence-based review for the United States Preventive Services Task Force (USPSTF) determined that additional research is needed on the effectiveness of screening for hearing loss, with a particular focus on health outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/35\">",
"     35",
"    </a>",
"    ]. The USPSTF is preparing a recommendation statement on screening for hearing loss in older adults, which should be available in 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/36\">",
"     36",
"    </a>",
"    ]. The American Speech-Language-Hearing Association has advised that individuals over 50 years of age should have complete audiometric testing every three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/37\">",
"     37",
"    </a>",
"    ]. However, concerns have been raised about the resource implications without proven benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/38\">",
"     38",
"    </a>",
"    ]. Taking a careful hearing history from all patients over 50 years of age, and further testing those who report hearing difficulties will identify most individuals with significant hearing deficits from presbycusis. &nbsp;",
"   </p>",
"   <p>",
"    Clinicians should practice methods to facilitate communication with hearing-impaired patients. Facing the patients will allow them to use lip-reading cues. Speaking slowly, and not changing topics abruptly, will allow them to continue to put new information into context. Speaking clearly, without shouting or over-articulating (and using a lower-pitched voice) can aid comprehension. Patients with hearing loss may nod and appear to follow a conversation even when they are not. By engaging them actively in the conversation the clinician can ensure that they are indeed receiving information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161408\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple potential etiologies of hearing loss should be considered prior to making the diagnosis of presbycusis (",
"    <a class=\"graphic graphic_table graphicRef53903 \" href=\"mobipreview.htm?4/62/5101\">",
"     table 1",
"    </a>",
"    ). A careful history of associated factors, such as family history, ototoxic medications, trauma, and concurrent otologic symptoms can help elucidate potential etiologies. The diagnosis of presbycusis should be questioned if the hearing loss is asymmetric, which should lead to evaluation for other conditions, such as otitis media, tumors, trauma, or asymmetric noise exposure (as often occurs from firearms exposure or the long term use of power tools on one side). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to asking about hearing loss, a questionnaire can be helpful in eliciting a more detailed hearing history. The Hearing Handicap Inventory for the Elderly-Screening (HHIE-S) is a simple questionnaire that can help identify older adult patients with significant hearing impairment (",
"    <a class=\"graphic graphic_table graphicRef73718 \" href=\"mobipreview.htm?41/33/42524\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/30,39,40\">",
"     30,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presbycusis develops over many years, and the rate of hearing loss progression can help to establish a diagnosis. It is often difficult for a patient or family member to give an accurate history of the onset and progression of hearing loss. However, the history of sudden decrease in hearing (noticed over days or weeks rather than years) should raise suspicion for other etiologies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38296?source=see_link\">",
"     \"Sudden sensorineural hearing loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161423\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination generally includes otoscopy, in addition to the whispered ear test and tuning forks for the assessment of hearing loss. The full ear examination is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of hearing loss in adults\", section on 'Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination of the outer ears should be normal in presbycusis. The otoscopic examination may be useful for assessing other potential causes of hearing loss such as cerumen impaction, infection, tympanic membrane perforation, or tumors (eg, exostosis, osteoma, polyps).",
"   </p>",
"   <p>",
"    Although audiometry is the most widely accepted diagnostic test for hearing loss, the whispered voice test is a simple test that can be performed in the primary care clinician&rsquo;s office without equipment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/41\">",
"     41",
"    </a>",
"    ]. To perform a whispered voice test, stand at arm's length behind the patient (to prevent lip reading) and mask hearing in one ear by occluding the ear canal and rubbing the tragus with a circular motion. Whisper a short sequence of letters and numbers and ask the patient to repeat them. Test the other ear in a similar manner. A tone-emitting otoscope is another reliable method for detecting hearing loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of hearing loss in adults\", section on 'Office hearing evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Weber and Rinne tests, using tuning forks, can help distinguish conductive or sensorineural hearing loss, and identify an asymmetrical hearing loss (",
"    <a class=\"graphic graphic_figure graphicRef58032 \" href=\"mobipreview.htm?40/5/41043\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74212 \" href=\"mobipreview.htm?13/29/13787\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of hearing loss in adults\", section on 'Weber and Rinne tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161415\">",
"    <span class=\"h2\">",
"     Audiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing is measured by standardized audiometric testing which assesses both the ability to hear tones and understand words. Pure tone thresholds are determined by presenting the subject with a variety of tones of frequencies varying between 250 Hz and 8 KHz. In a patient with presbycusis, an audiogram will show downward-sloping pure tone thresholds with relative preservation of word recognition scores (",
"    <a class=\"graphic graphic_figure graphicRef80255 \" href=\"mobipreview.htm?10/59/11188\">",
"     figure 3",
"    </a>",
"    ). The thresholds needed to just perceive these tones are recorded, with normal values falling below 25 decibels (dB). Human speech is mainly comprised of sounds falling between 500 Hz and 4 kHz, with average conversational levels falling at about 50 dB of loudness. Vowels tend to be lower and louder, while the consonants, which carry the majority of meaning of words, fall in the higher and softer range (",
"    <a class=\"graphic graphic_figure graphicRef55824 \" href=\"mobipreview.htm?18/10/18607\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to measuring pure tone thresholds, complete audiometric analysis includes a measure of the ability to understand a standardized list of words presented at a comfortable listening level. This is termed the &ldquo;word recognition score,&rdquo; with normal hearing individuals being able to correctly identify 90 percent or more of words presented. This is a measure of the subject&rsquo;s ability to process sound, and often decreases disproportionately in cases of neural or central dysfunction. Good word recognition scores predict favorable response to amplification, since they indicate that the patient can understand words if they are amplified to comfortable levels. Further aspects of the audiologic assessment are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of hearing loss in adults\", section on 'Formal audiologic assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older patients with suspected hearing loss require formal audiogram testing to confirm the diagnosis, determine severity, and to direct management. Monitoring the patient with a follow-up audiogram is also advisable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/42\">",
"     42",
"    </a>",
"    ]. These may be scheduled yearly or more frequently if deterioration of hearing is observed or new otologic symptoms develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161378\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies, including MRI and CT, are not indicated for the diagnosis of presbycusis. An MRI may be indicated to exclude neural or central pathology in cases where there is significant asymmetry of hearing loss, or other indications of possible tumor, such as vestibular schwannoma or other skull base lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/43\">",
"     43",
"    </a>",
"    ]. This should be particularly considered if there is associated unilateral or pulsatile tinnitus, vertigo, or other cranial nerve deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11135927\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the high prevalence and impact of presbycusis, a directed treatment to prevent or reverse its effects is not available. However, multiple options can compensate for hearing loss and improve daily function and well-being [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/9\">",
"     9",
"    </a>",
"    ]. Simple recognition of the problem can be a major positive step, as hearing loss in older adults is often mistaken for cognitive impairment. The identification of hearing loss can be reassuring for many patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/44\">",
"     44",
"    </a>",
"    ]. If the diagnosis of presbycusis is made, one can attempt to identify and avoid additional factors that can contribute to hearing loss, such as ongoing noise exposure or the use of potentially ototoxic medications.",
"   </p>",
"   <p>",
"    Most patients with significant age-related hearing loss will benefit from use of a hearing aid. Cochlear implantation is utilized for hearing loss refractory to hearing aids. Assistive listening devices and auditory rehabilitation may also be helpful in the management of presbycusis. Interventions to improve hearing are particularly important in older patients with dementia because hearing impairment further exacerbates cognitive impairment and functional decline in these individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161444\">",
"    <span class=\"h2\">",
"     Hearing aids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing aids can improve hearing function for most cases of presbycusis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/45\">",
"     45",
"    </a>",
"    ]. The progression of hearing loss rarely becomes so severe that hearing aids are not effective in restoring the ability to communicate. The use of appropriately-fit hearing aids can ameliorate the withdrawal, depression, and emotional impact that are commonly associated with presbycusis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/46\">",
"     46",
"    </a>",
"    ]. Specific issues related to hearing amplification are discussed separately, including identification of appropriate candidates, choosing the type of hearing aid, and fitting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=see_link\">",
"     \"Hearing amplification in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients have had negative experiences with hearing aids, or have heard other patients&rsquo; negative reactions to hearing aids. At times, hearing amplification is not tolerated either because patients produce too much cerumen, which plugs the device, the meatus is too small, or the device has increased static or noise. The aid may also cause discomfort, and it is a cosmetic concern to many patients. Finally, it may not allow the patient to understand speech any better, but rather only allows the patient to hear noise at a louder level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/47\">",
"     47",
"    </a>",
"    ]. Unfavorable experiences can be avoided through careful testing, counseling, device selection, and fitting by an experienced audiologist. Most dispensing audiologists will offer trial periods to minimize the financial risk to the patient. Technological advancements in hearing aids, such as direction-specific microphones, improved speech processing strategies, and additional customization options, may have improved performance significantly from when patients last tried amplification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no strict criteria when hearing amplification should be recommended. When the high-frequency thresholds are greater than 40 dB on the audiogram, a trial of hearing amplification is generally indicated. Lesser degrees of hearing loss may warrant amplification when employment, educational needs, or social needs require finer hearing.",
"   </p>",
"   <p>",
"    Well-fit hearing aids will also help with the tinnitus experienced by many patients with presbycusis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/33\">",
"     33",
"    </a>",
"    ]. There is a balance between sounds heard externally and those generated internally. The restoration of missing frequencies will often noticeably reduce the perception of bothersome tinnitus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25495?source=see_link\">",
"     \"Treatment of tinnitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the fact that hearing aids offer potential help, only a small percentage of patients with presbycusis actually receive effective treatment with amplification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/48\">",
"     48",
"    </a>",
"    ]. Studies in Western countries suggest that only 10 to 20 percent of adults with significant hearing loss actually have a hearing aid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/2,30,48\">",
"     2,30,48",
"    </a>",
"    ]. In addition, as many as 25 to 40 percent of adults who have hearing aids underutilize or abandon hearing aid use. This emphasizes the need for well-trained hearing professionals to provide counseling, fitting, assistive listening devices,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rehabilitation services to maximize the chance of benefit. (See",
"    <a class=\"local\" href=\"#H158677206\">",
"     'Assistive listening devices'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H158677394\">",
"     'Auditory rehabilitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161437\">",
"    <span class=\"h2\">",
"     Cochlear implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients so severely affected by presbycusis that conventional amplification strategies are no longer effective, cochlear implantation offers hope to restore hearing. Cochlear implantation involves the placement of an electrode array within the inner ear to bypass the damaged cochlea, and stimulate the remaining cochlear neurons directly with electrical stimulation (",
"    <a class=\"graphic graphic_figure graphicRef70810 \" href=\"mobipreview.htm?28/54/29541\">",
"     figure 6",
"    </a>",
"    ). This procedure can be performed safely, even in octogenarians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/49\">",
"     49",
"    </a>",
"    ]. Cochlear implant outcomes in presbycusis patients may be limited by the age-related reduction in ability to process sound information, as well as age-related cognitive deficits. Hearing impairment can also result from a loss of cochlear nerve fibers that the implant stimulates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/13,50\">",
"     13,50",
"    </a>",
"    ]. Despite these considerations, the great majority of patients undergoing cochlear implantation for presbycusis can be expected to achieve significant functional improvement, similar to that seen in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/47,51-54\">",
"     47,51-54",
"    </a>",
"    ]. Cochlear implants are indicated for people with bilateral severe hearing loss that is not significantly improved with hearing aids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=see_link&amp;anchor=H11#H11\">",
"     \"Hearing amplification in adults\", section on 'Cochlear implants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158677206\">",
"    <span class=\"h2\">",
"     Assistive listening devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of assistive listening devices can reduce the impact of presbycusis on daily life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/55\">",
"     55",
"    </a>",
"    ]. These may be linked with hearing aids, such as telecoils for telephone use or frequency-modulation systems that transmit sound information directly to an individual&rsquo;s hearing aid. Assistive listening devices may also be independent of hearing aids, such as tactile or visual alerts that can compensate for lack of auditory input (eg, flashing lights for a doorbell).",
"   </p>",
"   <p>",
"    Patient satisfaction with assistive listening devices is generally good, although there is some variability depending on the specific listening environment in which they are applied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/56\">",
"     56",
"    </a>",
"    ]. High-fidelity frequency-modulation systems that transmit sound directly to a user&rsquo;s ears are a popular option, and can be of particular benefit in theaters and lecture halls with otherwise adverse acoustics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. They can be helpful for listening to television, and can reduce the stress of trying to find the right volume for a number of television viewers. The use of captioning for television viewing can also significantly improve comprehension for patients with presbycusis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/9\">",
"     9",
"    </a>",
"    ]. Assistive listening devices can be used in several settings, including at home, at work, and in the classroom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158677394\">",
"    <span class=\"h2\">",
"     Auditory rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auditory or aural rehabilitation is defined as sensory management, instruction, perceptual training, and counseling for hearing impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/61\">",
"     61",
"    </a>",
"    ]. Auditory rehabilitation includes interventions such as active listening training, speech reading, and communication enhancement. Specific examples include education on reading facial expressions or lip contours of speakers, interpreting contextual cues such as posture to overcome fast speech, and maximizing environmental factors such as ensuring adequate lighting or phasing out competing sound sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/14\">",
"     14",
"    </a>",
"    ]. These treatments are usually administered through one-on-one training, as well as in the group setting. Auditory rehabilitation, when available, is usually practiced in combination with hearing devices.",
"   </p>",
"   <p>",
"    Patients can use specific strategies to improve their communication abilities. Selecting restaurants and venues with favorable acoustics can significantly improve the experience, as can positioning companions on the side of a more favorable ear. One of the most important strategies is for those with hearing loss to actively inform companions about hearing loss. In this way their companions can make a habit of using beneficial communication techniques (eg, speaking slowly and clearly while facing the individual with hearing loss).",
"   </p>",
"   <p>",
"    A systematic review of auditory rehabilitation found that there is little evidence that rehabilitation improves communication due to hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, it is not known which methods of rehabilitation are most likely to be helpful in which populations, alone or in combination with hearing devices. Despite lack of efficacy, auditory rehabilitation is still routinely performed, and newer rehabilitation methods are being developed such as speech tracking and analytic auditory training in computerized forms that may offer benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H671161451\">",
"    <span class=\"h2\">",
"     Future interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Future treatments for hearing loss may include genetic, cellular, or pharmacotherapy to induce the regeneration of hair cells to repopulate the damaged regions of the cochlea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/64\">",
"     64",
"    </a>",
"    ]. The identification of endogenous stem cells within the inner ear offers hope for stem cell therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41896/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. The ability to unlock the regenerative potential of such cells could help to address the fundamental deficits in presbycusis. Further understanding is needed of the underlying causes of age-related hearing loss so that more targeted interventions can be developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/26/33186?source=see_link\">",
"       \"Patient information: Age-related hearing loss (presbycusis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11135934\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presbycusis, or age-related hearing loss, is a common cause of hearing loss worldwide, affecting more than half of all adults by age 75 years. (See",
"      <a class=\"local\" href=\"#H455452151\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple factors influence the onset and severity of presbycusis. These factors include genetic predisposition, low socioeconomic status, noise exposure, ototoxins (eg, aminoglycosides, chemotherapeutic agents, heavy metals), infections, smoking, hypertension, diabetes, vascular disease, immunologic disorders, and hormonal factors. (See",
"      <a class=\"local\" href=\"#H455452871\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hallmark of presbycusis is the progressive, symmetric loss of high-frequency hearing. High-frequency speech carries the consonant sounds, and therefore the majority of speech information. Hearing loss can also be accompanied by tinnitus, vertigo, and disequilibrium. Presbycusis can cause low self-esteem, isolation, and depression. (See",
"      <a class=\"local\" href=\"#H11135906\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of presbycusis should be suspected based upon a history of symmetrical hearing loss over many years in an older individual. The physical examination may be helpful in determining the type of hearing loss (conductive versus sensorineural), possible contributing factors for hearing loss (eg, cerumen), or other causes of hearing impairment (eg, tumors such as acoustic neuroma). Patients with hearing loss that impairs social functioning or quality of life will require formal audiogram testing to confirm the diagnosis, determine severity, and direct management. (See",
"      <a class=\"local\" href=\"#H11135920\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A directed treatment to prevent or reverse the effects of presbycusis is not available. However, most patients with significant age-related hearing loss will benefit from use of hearing aids. There are no strict criteria when hearing amplification should be recommended. Hearing aids are generally indicated when high-frequency hearing thresholds reach 40 dB on an audiogram. (See",
"      <a class=\"local\" href=\"#H671161444\">",
"       'Hearing aids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=see_link\">",
"       \"Hearing amplification in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cochlear implants are utilized for patients with severe hearing loss that is not significantly improved with hearing aids. Assistive listening devices and auditory rehabilitation may be helpful for presbycusis and are usually employed in addition to hearing amplification devices. (See",
"      <a class=\"local\" href=\"#H671161437\">",
"       'Cochlear implantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H158677206\">",
"       'Assistive listening devices'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H158677394\">",
"       'Auditory rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/1\">",
"      Nelson EG, Hinojosa R. Presbycusis: a human temporal bone study of individuals with downward sloping audiometric patterns of hearing loss and review of the literature. Laryngoscope 2006; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/2\">",
"      Gates GA, Mills JH. Presbycusis. Lancet 2005; 366:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/3\">",
"      Davis AC. Epidemiological profile of hearing impairments: the scale and nature of the problem with special reference to the elderly. Acta Otolaryngol Suppl 1990; 476:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/4\">",
"      Nash SD, Cruickshanks KJ, Klein R, et al. The prevalence of hearing impairment and associated risk factors: the Beaver Dam Offspring Study. Arch Otolaryngol Head Neck Surg 2011; 137:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/5\">",
"      Gates GA, Cooper JC. Incidence of hearing decline in the elderly. Acta Otolaryngol 1991; 111:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/6\">",
"      Helzner EP, Cauley JA, Pratt SR, et al. Race and sex differences in age-related hearing loss: the Health, Aging and Body Composition Study. J Am Geriatr Soc 2005; 53:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/7\">",
"      Gopinath B, Rochtchina E, Wang JJ, et al. Prevalence of age-related hearing loss in older adults: Blue Mountains Study. Arch Intern Med 2009; 169:415.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nlm.nih.gov/medlineplus/ency/article/001045.htm (Accessed on March 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/9\">",
"      Sprinzl GM, Riechelmann H. Current trends in treating hearing loss in elderly people: a review of the technology and treatment options - a mini-review. Gerontology 2010; 56:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/10\">",
"      Van Eyken E, Van Camp G, Van Laer L. The complexity of age-related hearing impairment: contributing environmental and genetic factors. Audiol Neurootol 2007; 12:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/11\">",
"      Hultcrantz M, Simonoska R, Stenberg AE. Estrogen and hearing: a summary of recent investigations. Acta Otolaryngol 2006; 126:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/12\">",
"      Ohlemiller KK. Mechanisms and genes in human strial presbycusis from animal models. Brain Res 2009; 1277:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/13\">",
"      Bao J, Ohlemiller KK. Age-related loss of spiral ganglion neurons. Hear Res 2010; 264:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/14\">",
"      Huang Q, Tang J. Age-related hearing loss or presbycusis. Eur Arch Otorhinolaryngol 2010; 267:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/15\">",
"      Uchida Y, Sugiura S, Ando F, et al. Diabetes reduces auditory sensitivity in middle-aged listeners more than in elderly listeners: a population- based study of age-related hearing loss. Med Sci Monit 2010; 16:PH63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/16\">",
"      Fowler PD, Jones NS. Diabetes and hearing loss. Clin Otolaryngol Allied Sci 1999; 24:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/17\">",
"      Cruickshanks KJ, Nondahl DM, Tweed TS, et al. Education, occupation, noise exposure history and the 10-yr cumulative incidence of hearing impairment in older adults. Hear Res 2010; 264:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/18\">",
"      Christensen K, Frederiksen H, Hoffman HJ. Genetic and environmental influences on self-reported reduced hearing in the old and oldest old. J Am Geriatr Soc 2001; 49:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/19\">",
"      McMahon CM, Kifley A, Rochtchina E, et al. The contribution of family history to hearing loss in an older population. Ear Hear 2008; 29:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/20\">",
"      SCHUKNECHT HF. FURTHER OBSERVATIONS ON THE PATHOLOGY OF PRESBYCUSIS. Arch Otolaryngol 1964; 80:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/21\">",
"      Cohn ES. Hearing loss with aging: presbycusis. Clin Geriatr Med 1999; 15:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/22\">",
"      Schuknecht HF, Gacek MR. Cochlear pathology in presbycusis. Ann Otol Rhinol Laryngol 1993; 102:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/23\">",
"      Suga F, Lindsay JR. Histopathological observations of presbycusis. Ann Otol Rhinol Laryngol 1976; 85:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/24\">",
"      Jennings CR, Jones NS. Presbyacusis. J Laryngol Otol 2001; 115:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/25\">",
"      Nelson EG, Hinojosa R. Presbycusis: a human temporal bone study of individuals with flat audiometric patterns of hearing loss using a new method to quantify stria vascularis volume. Laryngoscope 2003; 113:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/26\">",
"      Ohlemiller KK. Age-related hearing loss: the status of Schuknecht's typology. Curr Opin Otolaryngol Head Neck Surg 2004; 12:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/27\">",
"      Ohlemiller KK, Gagnon PM. Apical-to-basal gradients in age-related cochlear degeneration and their relationship to \"primary\" loss of cochlear neurons. J Comp Neurol 2004; 479:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/28\">",
"      Lin FR, Metter EJ, O'Brien RJ, et al. Hearing loss and incident dementia. Arch Neurol 2011; 68:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/29\">",
"      Arlinger S. Negative consequences of uncorrected hearing loss--a review. Int J Audiol 2003; 42 Suppl 2:2S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/30\">",
"      L&oacute;pez-Torres Hidalgo J, Boix Gras C, T&eacute;llez Lapeira J, et al. Functional status of elderly people with hearing loss. Arch Gerontol Geriatr 2009; 49:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/31\">",
"      Katsarkas A, Ayukawa H. Hearing loss due to aging (presbycusis). J Otolaryngol 1986; 15:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/32\">",
"      Nicolas-Puel C, Faulconbridge RL, Guitton M, et al. Characteristics of tinnitus and etiology of associated hearing loss: a study of 123 patients. Int Tinnitus J 2002; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/33\">",
"      Zag&oacute;lski O. Management of tinnitus in patients with presbycusis. Int Tinnitus J 2006; 12:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/34\">",
"      Belal A Jr, Glorig A. Dysequilibrium of ageing (presbyastasis). J Laryngol Otol 1986; 100:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/35\">",
"      Chou R, Dana T, Bougatsos C, et al. Screening adults aged 50 years or older for hearing loss: a review of the evidence for the U.S. preventive services task force. Ann Intern Med 2011; 154:347.",
"     </a>",
"    </li>",
"    <li>",
"     United States Preventive Services Task Force. Screening for hearing loss in older adults: recommendation statement. file://www.uspreventiveservicestaskforce.org/uspstf/uspshear.htm (Accessed on April 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/37\">",
"      Audiologic screening. Ad Hoc Committee on Screening for Impairment, Handicap, and Middle Ear Disorders. American Speech-Language-Hearing Association (ASHA). ASHA 1994; 36:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/38\">",
"      Yueh B, Collins MP, Souza PE, et al. Long-term effectiveness of screening for hearing loss: the screening for auditory impairment--which hearing assessment test (SAI-WHAT) randomized trial. J Am Geriatr Soc 2010; 58:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/39\">",
"      Lichtenstein MJ, Bess FH, Logan SA. Diagnostic performance of the hearing handicap inventory for the elderly (screening version) against differing definitions of hearing loss. Ear Hear 1988; 9:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/40\">",
"      McBride WS, Mulrow CD, Aguilar C, Tuley MR. Methods for screening for hearing loss in older adults. Am J Med Sci 1994; 307:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/41\">",
"      Gnatyshak AI, Loginski VE, Mazurok AA. [Homo- and autotransplantation of bone marrow in radiation and chemotherapy of oncologic patients]. Vrach Delo 1973; 4:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/42\">",
"      Schneider JM, Gopinath B, McMahon CM, et al. Role of general practitioners in managing age-related hearing loss. Med J Aust 2010; 192:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/43\">",
"      Roehm PC, Gantz BJ. Management of Acoustic Neuromas in Patients 65 Years or Older. Otol Neurotol 2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/44\">",
"      Bogardus ST Jr, Yueh B, Shekelle PG. Screening and management of adult hearing loss in primary care: clinical applications. JAMA 2003; 289:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/45\">",
"      Stark P, Hickson L. Outcomes of hearing aid fitting for older people with hearing impairment and their significant others. Int J Audiol 2004; 43:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/46\">",
"      Mulrow CD, Tuley MR, Aguilar C. Sustained benefits of hearing aids. J Speech Hear Res 1992; 35:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/47\">",
"      Yueh B, Souza PE, McDowell JA, et al. Randomized trial of amplification strategies. Arch Otolaryngol Head Neck Surg 2001; 127:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/48\">",
"      Popelka MM, Cruickshanks KJ, Wiley TL, et al. Low prevalence of hearing aid use among older adults with hearing loss: the Epidemiology of Hearing Loss Study. J Am Geriatr Soc 1998; 46:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/49\">",
"      Eshraghi AA, Rodriguez M, Balkany TJ, et al. Cochlear implant surgery in patients more than seventy-nine years old. Laryngoscope 2009; 119:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/50\">",
"      Lindenberger U, Ghisletta P. Cognitive and sensory declines in old age: gauging the evidence for a common cause. Psychol Aging 2009; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/51\">",
"      Francis HW, Chee N, Yeagle J, et al. Impact of cochlear implants on the functional health status of older adults. Laryngoscope 2002; 112:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/52\">",
"      Leung J, Wang NY, Yeagle JD, et al. Predictive models for cochlear implantation in elderly candidates. Arch Otolaryngol Head Neck Surg 2005; 131:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/53\">",
"      Vermeire K, Brokx JP, Wuyts FL, et al. Quality-of-life benefit from cochlear implantation in the elderly. Otol Neurotol 2005; 26:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/54\">",
"      Orabi AA, Mawman D, Al-Zoubi F, et al. Cochlear implant outcomes and quality of life in the elderly: Manchester experience over 13 years. Clin Otolaryngol 2006; 31:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/55\">",
"      Kricos PB. Hearing assistive technology considerations for older individuals with dual sensory loss. Trends Amplif 2007; 11:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/56\">",
"      Harkins J, Tucker P. An internet survey of individuals with hearing loss regarding assistive listening devices. Trends Amplif 2007; 11:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/57\">",
"      Kricos PB. Audiologic management of older adults with hearing loss and compromised cognitive/psychoacoustic auditory processing capabilities. Trends Amplif 2006; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/58\">",
"      Chisolm TH, Noe CM, McArdle R, Abrams H. Evidence for the use of hearing assistive technology by adults: the role of the FM system. Trends Amplif 2007; 11:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/59\">",
"      Odelius J, Johansson O. Self-assessment of classroom assistive listening devices. Int J Audiol 2010; 49:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/60\">",
"      Hartley D, Rochtchina E, Newall P, et al. Use of hearing AIDS and assistive listening devices in an older Australian population. J Am Acad Audiol 2010; 21:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/61\">",
"      Boothroyd A. Adult aural rehabilitation: what is it and does it work? Trends Amplif 2007; 11:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/62\">",
"      Sweetow R, Palmer CV. Efficacy of individual auditory training in adults: a systematic review of the evidence. J Am Acad Audiol 2005; 16:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/63\">",
"      Sweetow RW, Sabes JH. Technologic advances in aural rehabilitation: applications and innovative methods of service delivery. Trends Amplif 2007; 11:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/64\">",
"      Oshima K, Suchert S, Blevins NH, Heller S. Curing hearing loss: Patient expectations, health care practitioners, and basic science. J Commun Disord 2010; 43:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/65\">",
"      Rivolta MN, Li H, Heller S. Generation of inner ear cell types from embryonic stem cells. Methods Mol Biol 2006; 330:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/66\">",
"      Martinez-Monedero R, Oshima K, Heller S, Edge AS. The potential role of endogenous stem cells in regeneration of the inner ear. Hear Res 2007; 227:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41896/abstract/67\">",
"      Oshima K, Senn P, Heller S. Isolation of sphere-forming stem cells from the mouse inner ear. Methods Mol Biol 2009; 493:141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15359 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41896=[""].join("\n");
var outline_f40_58_41896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11135934\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11135885\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455452151\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455452871\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11135892\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H757158545\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11135906\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161357\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161364\">",
"      Tinnitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161371\">",
"      Dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11135920\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161408\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161423\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161415\">",
"      Audiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161378\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11135927\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161444\">",
"      Hearing aids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161437\">",
"      Cochlear implantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158677206\">",
"      Assistive listening devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H158677394\">",
"      Auditory rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H671161451\">",
"      Future interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11135934\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/15359\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15359|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/39/30328\" title=\"figure 1\">",
"      Adult ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/10/38056\" title=\"figure 2\">",
"      Cochlear and vestibular anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/59/11188\" title=\"figure 3\">",
"      Audiogram presbycusis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/10/18607\" title=\"figure 4\">",
"      Audiogram with consonant and vowel sounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/5/41043\" title=\"figure 5\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/54/29541\" title=\"figure 6\">",
"      Cochlear implants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15359|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/62/5101\" title=\"table 1\">",
"      Causes of hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/33/42524\" title=\"table 2\">",
"      Hearing handicap inventory for the elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/29/13787\" title=\"table 3\">",
"      Interpreting Weber and Rinne tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26727?source=related_link\">",
"      Etiology and diagnosis of tinnitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=related_link\">",
"      Etiology of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=related_link\">",
"      Hearing amplification in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/26/33186?source=related_link\">",
"      Patient information: Age-related hearing loss (presbycusis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38296?source=related_link\">",
"      Sudden sensorineural hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25495?source=related_link\">",
"      Treatment of tinnitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_58_41897="T helper subsets: Differentiation and role in disease";
var content_f40_58_41897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   T helper subsets: Differentiation and role in disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41897/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41897/contributors\">",
"     Zuhair K Ballas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41897/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41897/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/58/41897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The division of T helper responses along a Th1 or a Th2 pathway has aided in the understanding of numerous basic immunologic pathways and diseases. As more knowledge is gained, it is apparent that these subsets represent the tip of the iceberg in the multiple checks and balances that are characteristic of the immune system. After the discovery of the",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    dichotomy, most research was dedicated to understanding their cytokine polarization. The emphasis then shifted to examining the signals required for",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    differentiation. The focus then shifted yet again to examining the role of dendritic cell subsets, rediscovered regulatory T cells, and newly discovered Th17 cells in modulating immune responses. The next wave of research in this area may yield insight not only into the modulation of Th subsets, but into potential therapeutic manipulation of these subsets in human disease.",
"   </p>",
"   <p>",
"    There is detailed understanding of the modulation of T helper cell responses in mice. However, data in humans are less complete and the exact characteristics of Th17 cells and T regulatory cells are still being determined. This topic will focus on human immunology, using murine studies only to clarify a point, and will elucidate the known characteristics of these subsets, their differentiation, and their involvement in various diseases. Other details of cellular immunity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Categorization",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells can be categorized based upon cell surface expression of either CD4 or CD8. CD4 positive cells recognize antigen presented in the context of Class II major histocompatibility complex (MHC), while CD8 positive cells recognize antigen presented in the context of Class I MHC.",
"   </p>",
"   <p>",
"    CD4 positive T helper subsets include Th1, Th2, and Th17 cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/1\">",
"     1",
"    </a>",
"    ]. There is evidence that each of these subsets is involved in the defense against a certain subset of microorganisms. Th1 are pivotal in defense against intracellular microorganisms in general and mycobacteria in particular. Patients with mutations in the IFN-gamma receptor or IL-12 receptor present with recurrent infections with mycobacteria and Salmonella (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=see_link\">",
"     \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"    </a>",
"    ). Th2 cells are integral in expelling parasitic infestations. Th17 seem to play a significant role in defense against extracellular bacteria and some fungi.",
"   </p>",
"   <p>",
"    Th1 and Th17 cells play major roles in autoimmunity, where as Th2 cells are the hallmark of atopic disease. T regulatory (Treg) cells represent a major subset of CD4+ T cells that may be involved in regulating and attenuating the activity of the three Th subsets.",
"   </p>",
"   <p>",
"    Of note, in vitro generation of a single Th subset is possible, since culture conditions are such that they favor the development of that particular subset while suppressing other subsets. In patients, however, the polarization of Th subsets is not absolute and other subsets are present at the same time. It is more appropriate to assign Th subset preponderance, rather than polarization, when one is talking about lymphocyte responses in patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Historic perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a seminal observation, it was established that murine CD4 clones could be divided into two major categories defined by the cytokines they secreted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/2\">",
"     2",
"    </a>",
"    ]. One subset, designated Th1, secreted IL-2, IFN-gamma, and TNF-beta. The other subset, designated Th2, secreted IL-4 and IL-5. Some cytokines (TNF-alpha, G-CSF) were secreted by both subsets.",
"   </p>",
"   <p>",
"    These subsets also had functional differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/3\">",
"     3",
"    </a>",
"    ]. Th1 cells were involved in the generation of cellular immunity, including delayed type hypersensitivity (DTH) reactions and cytotoxic T lymphocytes (CTL) differentiation. Both subsets appeared to be involved in antibody generation, but Th2 cells were exclusively involved in class-switching to IgE.",
"   </p>",
"   <p>",
"    Since those seminal observations, the function and involvement of Th1 and Th2 cells in disease have been further refined and a third T helper subset, Th17, has been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Functional differences of Th subsets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th subsets secrete different cytokines that are able to modulate various immune responses. The cytokines secreted by Th1, Th2, and Th17 cells may be responsible for their functional roles. Our understanding of the various cytokines in Th subsets is not complete and continues to evolve. Nevertheless, each Th subset has a unique pattern of dominant cytokines, with other cytokines playing significant, but hitherto not well documented, roles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Cytokine profiles'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Th1 cells secrete IFN-gamma and therefore are poised to activate macrophages and help in the eradication of intracellular microorganisms, such as mycobacteria. Th1 cells also promote cytotoxic T cell development and delayed type hypersensitivity (DTH) reactions. Hence, Th1 cells are pro-inflammatory and may be involved in the pathogenesis and maintenance of some autoimmune diseases.",
"   </p>",
"   <p>",
"    Th2 cells, by virtue of their IL-4 and IL-13 secretion, are important in the promotion of IgE synthesis. They help mediate immunity against parasitic infestations, and are pivotal in the development of allergy and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Th17 cells secrete IL-17, which induces production of pro-inflammatory cytokines and chemokines, and recruits neutrophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/5\">",
"     5",
"    </a>",
"    ]. Th17 cells appear to be involved in the early response to numerous extracellular pathogens, including bacteria and fungi, and play an important role in autoimmunity and tissue inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. They may also play a role in the neutrophil, rather than eosinophil, predominant forms of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other Th subsets have a role in tolerance rather than immunity. These include Tr1 cells (secrete IL-10), Th3 cells (secrete TGF-beta), and Treg cells (secrete IL-10 and TGF-beta). The biologic relevance of these subsets is discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Modulation by regulatory T cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional Th subsets continue to be discovered. These include T follicular helper (TFH) cells, Th9 cells, and Th22 cells. The TFH cell subset is preponderant in the germinal centers and is believed to play a major role in helping B cells make antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In mice, TFH cells differentiate in response to IL-6, IL-21, and type I interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. TFH development is mediated by transcription factor Bcl-6 and inhibited by transcription factor Blimp-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This Th subset differentiates from Th2 cells in reactive lymph nodes in response to helminth infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In humans, on the other hand, it appears that IL-12 may be crucial to TFH development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/19\">",
"     19",
"    </a>",
"    ]. Human TFH cells are not yet fully characterized and will not be discussed further here.",
"   </p>",
"   <p>",
"    Th9 cells are believed to be induced in the presence of TGF-beta and IL-4 and are characterized by the secretion of IL-9 and IL-10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Th9 development is mediated by transcription factors STAT-6 and PU.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Functionally, Th9 are thought to be important in resistance to parasites and may be involved in asthma and other allergic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Most of the Th9 studies have been done in mice.",
"   </p>",
"   <p>",
"    It is thought that na&iuml;ve CD4 cells, in the presence of TNF-alpha and IL6, develop into Th22 cells that secrete IL-22 and TNF-alpha. These cells may be involved in epidermal immunity and remodeling in inflammatory skin diseases such as psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. It is not yet clear as to whether Th22 are a distinct lineage or whether they are a subset of Th17, since Th17 can also secrete IL-22 and TNF-alpha.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cytokine profiles",
"    </span>",
"    &nbsp;&mdash;&nbsp;T helper subsets were initially described in mice. It took several years before a similar division in humans was firmly established, albeit with less clear cut polarization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/4\">",
"     4",
"    </a>",
"    ]. There is general agreement that the cytokines produced by Th subsets segregate as detailed in the figure (",
"    <a class=\"graphic graphic_figure graphicRef58150 \" href=\"mobipreview.htm?37/45/38615\">",
"     figure 1",
"    </a>",
"    ). IFN-gamma is the major cytokine secreted by Th1 cells, IL-4 is the cardinal marker of Th2 cells, and secretion of IL-17 defines Th17 cells. Initially it was thought that IL-2 was produced exclusively by Th1 cells. Evidence suggests that IL-2 may be important in the maintenance of Th2 cells, expansion of memory Th17 cells, and induction of Treg as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been numerous attempts at finding a unique surface marker that is expressed exclusively on each Th subset. Since these subsets secrete and respond to distinct cytokines, a logical approach was to examine their expression of cytokine receptors. Th1 cells express both chains of the IL-12 receptor (IL-12Rbeta1 and IL-12Rbeta2), while Th2 and Th17 cells seem to express only IL-12Rbeta1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/5,29\">",
"     5,29",
"    </a>",
"    ]. Th2 cells also express IL-4 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/30\">",
"     30",
"    </a>",
"    ]. Th17 cells express the IL-23 receptor, a heterodimer comprised of IL-12Rbeta1 and a unique IL-23R chain, in addition to receptors for IL-6, IL-21, and TGF-beta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/5,31\">",
"     5,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Th subsets may be differentiated by their chemokine receptors. Specific chemokine receptors are expressed on the three Th subsets. CXCR3 and CCR5 are expressed by Th1 cells; CCR3, CCR8, and CCR10 by Th2 cells; and CCR2 and CCR6 by Th17 cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/5,32-34\">",
"     5,32-34",
"    </a>",
"    ]. However, the expression of these markers does not appear to be exclusive, universal, or stable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     T HELPER CELL DIFFERENTIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The processes leading to maturation along the various pathways are not well understood. The existence of a Th0 precursor (a T helper cell that produces both Th1 and Th2 cytokines) is well documented in vitro, but is not well delineated in vivo. Most studies suggest that early reports of Th0 cells were most likely a mixed Th1 and Th2 population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathway of T cell differentiation is determined by antigens, antigen presenting cells, and the cytokine milieu, as shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef58150 \" href=\"mobipreview.htm?37/45/38615\">",
"     figure 1",
"    </a>",
"    ). Antigen is taken up by antigen presenting cells, most commonly dendritic cells (DCs). DCs process the antigen and present it to na&iuml;ve CD4 positive T cells. Two signals are needed for T cell activation: ligation of the T cell receptor to MHC class II and a costimulatory signal (CD28 binding of",
"    <span class=\"nowrap\">",
"     CD80/CD86).",
"    </span>",
"    T cell activation proceeds intracellularly via signaling and activation molecules.",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    balance can be influenced at each step of the above cascade. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link&amp;anchor=H2#H2\">",
"     \"The adaptive cellular immune response\", section on 'Antigen presenting cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link&amp;anchor=H4#H4\">",
"     \"The adaptive cellular immune response\", section on 'T cell activation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Modulation by antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mouse models, T helper differentiation is modulated by several factors related to the antigen, including dose, affinity, type of antigen, and length of stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In general, smaller doses of antigen and alum adjuvants are more likely to induce Th2 responses, whereas larger doses of antigen and mycobacterial adjuvants (Freund's adjuvant) are more likely to induce Th1 responses.",
"   </p>",
"   <p>",
"    It is not yet clear whether Th differentiation is similarly modulated in humans, especially since alum is the most common adjuvant used in human vaccines. Mycobacterial adjuvants are not used in human vaccines. However, experimental data using CpG oligodeoxynucleotides, which are derived from mycobacterial DNA fragments and bind to TLR9, seem to support the induction of Th1 responses in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Some vaccines (eg, human papilloma virus vaccine) contain monophosphoryl lipid A, a TLR4 ligand, as an adjuvant, but its effect on polarization of Th subsets is not well examined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Modulation by cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation of na&iuml;ve CD4 cells along a particular Th subset pathway or a Treg fate is influenced by multiple cytokines, signaling molecules, and transcription factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/43\">",
"     43",
"    </a>",
"    ]. For each subset there is a dominant cytokine that sets the stage for the initial polarization by activation of a characteristic transcription factor. This initial polarization is followed by an amplification loop that also involves a dominant cytokine and a dominant transcription factor (",
"    <a class=\"graphic graphic_figure graphicRef58150 \" href=\"mobipreview.htm?37/45/38615\">",
"     figure 1",
"    </a>",
"    ). This is a simplified model; each passing day brings the description of a new cytokine or modulator that complicates the picture further, especially for Th17.",
"   </p>",
"   <p>",
"    IL-12 is the dominant initial cytokine for the differentiation of Th1 cells. IL-12 is secreted by DCs and binds to IL-12 receptor (IL-12Rbeta2) on na&iuml;ve CD4+ T cells, resulting in the activation of STAT4. STAT4 activates the transcription factor T-bet, which induces the secretion of interferon gamma (IFN-gamma). IFN-gamma acts as an amplifier by binding to its receptor on Th1 cells and activating STAT1, which then engages T-bet. IL-12 also induces natural killer (NK) cells to secrete IFN-gamma, which further promotes Th1 development. This pathway links innate and adaptive immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. IL-18 acts in synergy with IL-12 to promote Th1 responses as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Type 1 interferons (IFN-alpha and IFN-beta), which are secreted by DCs, can also induce maturation along the Th1 pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important cytokine in the development of Th2 responses is IL-4. IL-4 can be secreted by several cells including T cells, mast cells, eosinophils, and natural killer T (NKT) cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/53-58\">",
"     53-58",
"    </a>",
"    ]. The role of IL-4 in Th2 development is not as well delineated as the role of IL-12 in Th1 development. It appears that IL-4 acts as its own amplification loop. IL-4 activates STAT6, which then engages the transcription factor GATA3, leading to secretion of IL-4. Thymic stromal lymphopoietin (TSLP) is an epithelial cell cytokine that also promotes the development of na&iuml;ve Th cells into inflammatory Th2 cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differentiation of human na&iuml;ve CD4+ T cells into Th17 cells requires exposure to IL-1beta and IL-6 or IL-1beta and IL-21, although it appears that IL-6 stimulation is the dominant pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/5,61\">",
"     5,61",
"    </a>",
"    ]. IL-1, IL-21, and IL-6 all activate STAT3, which engages the transcription factor ROR-gamma-t. This leads to secretion of IL-17a, IL-17f, and IL-21. IL-21 then amplifies Th17 proliferation. IL-23 and TGF-beta may also be required for Th 17 differentiation and IL-17 production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/62\">",
"     62",
"    </a>",
"    ]. In a murine study, it was found that Th17 cells induced by TGF-beta-3 in addition to IL-6 and IL-23 are highly pathogenic, whereas Th17 cells induced by TGF-beta-1 and IL-6 are not pathogenic unless they have further prolonged exposure to IL-23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/63\">",
"     63",
"    </a>",
"    ]. Initial TGF-beta-3 production is induced by IL-6, but IL-23 is required for continued TGF-beta-3 expression. While IL-7 is not required for Th17 differentiation, it is essential for expansion and survival of pathogenic Th17 cells in a mouse model of autoimmunity and in humans with multiple sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Th17 cells are an important part of the adaptive immunity, but may not be the only, or the most important, source of IL-17. Extensive literature in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/65\">",
"     65",
"    </a>",
"    ] suggests that several innate immunity cell types are major producers of IL-17 and therefore function as sentinels of the immune system, particularly in mucosal barriers. These cell types include gdT cells, invariant NKT cells, NK cells, Paneth cells, and lymphoid-tissue inducer (LTi) cells.",
"   </p>",
"   <p>",
"    T-bet (also called TBX21 or T-box 21) is pivotal for Th1 maturation, GATA3 for Th2 maturation, and ROR-gamma-t for Th17 maturation (",
"    <a class=\"graphic graphic_figure graphicRef58150 \" href=\"mobipreview.htm?37/45/38615\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. T-bet promotes Th1 development by direct induction of IFN-gamma and IL-12Rbeta2 chain gene transcription. In addition, T-bet appears to inhibit IL-4, IL-5, and IL-17 secretion. T-bet may also inhibit Th2 differentiation by preventing GATA3 from interacting with its target DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/68\">",
"     68",
"    </a>",
"    ]. GATA3 inhibits Th1 maturation in a mouse model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/69\">",
"     69",
"    </a>",
"    ]. Overexpression of ROR-gamma-t and ROR-alpha block Th1 and Th2 differentiation in mouse models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/31\">",
"     31",
"    </a>",
"    ]. Thus, particular cytokines not only induce the differentiation of a certain Th subset, but may also block the induction of other Th subsets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Modulation by dendritic cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells mount a response only when the antigen is processed by antigen presenting cells (APCs). Dendritic cells (DCs) are the most potent APCs. There are at least five human DC subsets. The two major functional DC subsets are DC1 and DC2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. DC1s are CD11c positive, CD123 low while DC2s are CD11c negative, CD123 high. DC1 cells are thought to secrete IL-12 and type 1 IFN that polarize na&iuml;ve T cells toward Th1. DC2 cells are thought to polarize cells toward a Th2 pathway, although the detailed molecular mechanisms are not as well worked out as they are for Th1. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DC1 and DC2 cells arise from different precursors (plasmacytoid versus myeloid, respectively) and their differentiation may be affected by the nature of the antigen they encounter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]. DCs express molecules known as Toll-like receptors (TLRs). Each TLR recognizes a distinct pathogen-associated molecular pattern (PAMP) expressed on various microorganisms. Monocyte-derived DCs (DC2) are more likely to express TLR3, TLR4, and TLR8. Plasmacytoid-derived DCs (DC1), on the other hand, are more likely to express TLR7 and TLR9. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ligation of TLRs activates DCs and stimulates the production of various cytokines. Ligation of TLR9, which recognizes CpG motifs of bacterial DNA, results in the secretion of IL-12 and IFN-gamma that polarize T cells towards a Th1 differentiation pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/70-76\">",
"     70-76",
"    </a>",
"    ]. TLR ligation by parasites may induce DCs to promote Th2 responses. Ligation of TLR2 and TLR4 may also polarize differentiation along the Th2 pathway. Mouse models suggest TLR4, TLR7, TLR8, and TLR 9 may be involved in Th17 polarization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ligation of TLRs on DCs initiates a process of DC maturation: upregulating MHC II expression, increasing surface expression of CD80 and CD86, and inducing transcription and translation of various cytokines. Depending upon the cytokines secreted, DCs can then influence maturation along Th1, Th2, Th17, or regulatory T cell pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/31,70-76\">",
"     31,70-76",
"    </a>",
"    ]. Results from a mouse model of autoimmunity suggest that Th17 differentiation also depends upon the activation of TGF-beta by integrins on DCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Modulation by regulatory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation and function of Th subsets is subject to another level of control by a CD4+ subset whose main function is the regulation or suppression of immune response; these are the so-called regulatory T cells, or Treg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/82-86\">",
"     82-86",
"    </a>",
"    ]. Treg cells may suppress responder na&iuml;ve and effector T cells via several mechanisms, including secretion of inhibitory cytokines, cytolytic enzymes, and suppressive molecules; metabolic disruption; expression of surface receptors that can affect dendritic cell function; and induction of target cell senescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/87-90\">",
"     87-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mice, Treg can be divided into thymic or \"natural\" and peripheral or \"induced\" subsets. Natural Treg are CD4positiveCD25bright and express Foxp3. Natural Treg appear to exert their effect by cell-to-cell contact with little involvement of cytokines. Induced Treg are generated upon activation by antigen presenting cells. The older literature referred to Th subsets that were called Tr1 (Th that secrete high levels of IL-10) or Th3 (Th subsets that secrete TGF-beta). These probably represent Treg subsets.",
"   </p>",
"   <p>",
"    The best studied role of regulatory T cells in humans is in helminth infestation. Helminths have strong polarizing effects towards a Th2 response. However, the incidence of atopy (Th2-associated disease) is markedly decreased in geographic areas where helminth infestations are endemic. Helminths appear to induce Treg maturation. Tregs secreting high levels of IL-10",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    TGF-beta were isolated from patients with onchocerciasis (a helminth infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is thought that Treg cells represent the dominant T cell response to common environmental allergens in healthy individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/84\">",
"     84",
"    </a>",
"    ]. The development of an allergic response can be due either to blocking a Treg pathway or enhancing a Th2 pathway. High exposure to some pets early in life might prevent IgE response by promoting Treg responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/73,84,93\">",
"     73,84,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be a reciprocal relationship between production of Th17 and natural Treg cells. IL-6 inhibits the generation of Treg cells and IL-2 interferes with Th17 development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/31\">",
"     31",
"    </a>",
"    ]. IL-27 is involved in determining Th17 versus Treg production and Treg cells inhibit Th17 polarization.",
"   </p>",
"   <p>",
"    The induction and maintenance of Treg also seem to follow the same tenets outlined above for Th1, Th2, and Th17 (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Modulation by cytokines'",
"    </a>",
"    above). The dominant cytokines for Treg induction in humans are TGF-beta and IL-2. Induction of these cytokines leads to the activation of STAT5, which engages the transcription factor Foxp3. Treg secrete IL-10, TGF-beta, and IL-35. TGF-beta acts as the amplifying cytokine for Treg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Modulation by glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (GCs) exert profound effects on Th balance. GCs have been shown to inhibit",
"    <span class=\"nowrap\">",
"     Th1/Th17",
"    </span>",
"    response and upregulate",
"    <span class=\"nowrap\">",
"     Th2/Treg",
"    </span>",
"    response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. GCs inhibit the secretion of TNF-alpha and IFN-gamma. This action is most likely mediated by the effect of GCs on antigen presenting cells, resulting in the inhibition of IL-12, and to a lesser extent, IL-18 (both of which are necessary for the induction of IFN-gamma secretion). GCs also downregulate the expression of IL-12 receptors on T and NK cells. GCs promote Th2 responses by acting directly on Th2 cells, upregulating IL-4 and IL-13 production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/96,98-101\">",
"     96,98-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These effects of GCs are in concordance with their clinical use as antiinflammatory agents, since Th1 cells are involved in promoting inflammatory responses. However, these effects are at odds with the clinical practice of using GCs to control extrinsic asthma (the paradigm of Th2-mediated disease). GCs appear to have a different effect on the bronchial mucosa than they do on lymphocytes. GC therapy results in upregulation of IL-12 and IL-13 in bronchial cells of steroid-sensitive (but not steroid-resistant) patients with asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One explanation of these findings is that asthma is associated with eosinophilic inflammation. Eosinophils are a source of IL-5. GC induction of eosinophilic apoptosis may decrease IL-5 production, and thus decrease Th2 generation. Alternatively, these paradoxical effects may reflect differences between systemic and mucosal immunity, may indicate redistribution of various cell subsets, or may indicate that Th subsets are much more complicated than a simple \"bipolar\" distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/102\">",
"     102",
"    </a>",
"    ]. Indeed, in a mouse model, Th17 cells appeared to mediate steroid-resistant airway inflammation and hyperresponsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Modulation by the environment (the hygiene hypothesis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a marked increase in certain diseases in the industrialized world over the past two to three decades. This near epidemic includes diseases thought to be Th1 mediated (eg, Crohn's disease, multiple sclerosis, type 1 diabetes) as well as diseases thought to be Th2 mediated (eg, allergic rhinitis and asthma). Conflicting explanations have been introduced depending upon whether a Th1- or a Th2-associated disease was being examined.",
"   </p>",
"   <p>",
"    Initial theories to explain the near-epidemic of asthma and atopy in the industrialized world focused on the role of early life infections in down-regulation of Th2. This was supported by epidemiologic associations showing decreased incidence of asthma and atopy in children born on farms, children who attend daycare, and children who have older siblings. However, these apparently protective factors were also protective in Th1-associated diseases. Therefore, the immune mechanisms that regulate not only the maturation of each Th subset, but the overall balance and activity of each subset, needed to be considered.",
"   </p>",
"   <p>",
"    The leading candidates for such regulation are the regulatory T cells detailed above (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Modulation by regulatory T cells'",
"    </a>",
"    above). Decreased Treg function may be responsible for the increase in Th1-, Th2-, and Th17-associated diseases. In support of this hypothesis, geographic areas with endemic parasitic infestations tend to have a decreased incidence of both autoimmune and atopic diseases. As discussed above, it appears that helminth infestation may stimulate DC subsets that might preferentially induce the development of Treg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/104-109\">",
"     104-109",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'T helper subsets in disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The possible protective effect of infections in early life may be mediated by molecular determinants derived from microorganisms (eg, endotoxin, bacterial DNA, or single-stranded RNA) that bind certain TLRs on DCs. These stimulated DCs lead to the generation of Treg that in turn maintain the",
"    <span class=\"nowrap\">",
"     Th1/Th2/Th17",
"    </span>",
"    balance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/73-76,82,83,110,111\">",
"     73-76,82,83,110,111",
"    </a>",
"    ]. The exact mechanisms by which Treg establish and maintain a Th balance remain to be elucidated, especially in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15633800\">",
"    <span class=\"h1\">",
"     INTERACTION OF T HELPER SUBSETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was previously thought that once a helper cell differentiated along one pathway (ie, Th1 or Th2, etc), it remained committed to that pathway. However, no genetic deletion of a particular cytokine has been demonstrated in Th subsets, unlike B cells that undergo gene deletion when they commit to an isotype switch. A particular Th subset secretes a dominant cytokine, but can secrete other cytokines, albeit in minimal amounts, that overlap with other Th subsets. There is some suggestion that a particular Th subset may change &ldquo;type&rdquo; depending on its milieu. This phenomenon has been called plasticity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/112\">",
"     112",
"    </a>",
"    ] or multitasking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     T HELPER SUBSETS IN DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of Th response to pathogens or autoantigens may determine the disease manifestation. Altering the Th subset may change the disease phenotype rather than attenuate the disease.",
"   </p>",
"   <p>",
"    The paradigm of the role of",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    balance in disease outcome was first established in a mouse model of leishmaniasis. Mice strains that mount a Th1 response are able to control the disease, while mice strains that mount a Th2 response are more likely to succumb [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, the role of",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    balance is illustrated in leprosy and thyroiditis. A Th1 immune response upon infection with Mycobacterium leprae is more likely to result in tuberculoid leprosy, while a Th2 response is more likely to result in lepromatous leprosy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. In thyroid disease, Hashimoto's thyroiditis is thought to be associated with Th1 responses, while Graves' disease is more likely to be associated with a Th2 response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with these findings, changing a Th1 to a Th2 response, or vice versa, may change the disease phenotype rather than ameliorate the disease. In a mouse asthma model, for example, Th1 cells did not attenuate Th2-induced airway hyperreactivity, but instead caused acute lung injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Th2 response to an aeroallergen is more likely to result in a clinically significant allergic response and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/119\">",
"     119",
"    </a>",
"    ]. In the gastrointestinal tract, a Th1 response appears to be associated with inflammatory bowel disease, Crohn's disease in particular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/120\">",
"     120",
"    </a>",
"    ]. The Th1 versus Th2 balance in ulcerative colitis is not as well established and may vary in different stages of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/120\">",
"     120",
"    </a>",
"    ]. In",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    Th1 responses are associated with slower progression and Th2 responses become progressively dominant as the infection evolves into AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The search for another Th subset in autoimmune and autoinflammatory diseases where Th1 could not be demonstrated resulted in the discovery of Th17. The discovery of Th17 cells and rediscovery of regulatory T cells has led to a shift in the",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    paradigm. Examination of the role of Th17 in various disorders has just begun [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/122-129\">",
"     122-129",
"    </a>",
"    ]. The cytokines responsible for the production and maintenance of Th17 activate STAT3. Thus, the in vivo function of Th17 can be assessed in patients who have STAT3 mutations, such as those with hyper-IgE syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/130-132\">",
"     130-132",
"    </a>",
"    ]. It is not yet clear if all of the abnormalities seen in this syndrome are directly attributable to Th17 dysregulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=see_link\">",
"     \"Hyperimmunoglobulin E syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perhaps one of the most compelling discoveries illustrating the importance of a T lymphocyte homeostatic balance is the finding that patients with mutations in Foxp3 (the pivotal transcription factor for the development of Treg) present with a characteristic constellation of symptoms referred to as IPEX: Immunodeficiency, polyendocrinopathy, and enteropathy, X-linked. These patients also have severe atopic dermatitis and multiple food allergies. Therefore, the lack of Treg cells seems to result in the development of diseases normally associated with increased Th1, Th2, and possibly, Th17 diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41897/abstract/133\">",
"     133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25850?source=see_link\">",
"     \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T helper subsets include Th1, Th2, and Th17 cells. Th1 cells are involved in immunity to intracellular pathogens, Th2 cells are important in defense against parasites, and Th17 cells respond to extracellular bacteria and fungi. Th1 and Th17 cells play major roles in autoimmunity, whereas Th2 cells are the hallmark of atopic disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Th subsets can be characterized by their cytokine profiles and effector functions. They are also able to counter-regulate each other. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Functional differences of Th subsets'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Cytokine profiles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Modulation by cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Th differentiation is modified by a number of factors, including antigen, cytokines, dendritic cells, regulatory T cells, medications such as glucocorticoids, and the environment. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'T helper cell differentiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type of Th response to pathogens or autoantigens determines the disease manifestation. Altering the Th phenotype may change the disease phenotype rather than abolish the disease. Homeostasis or balance among Th1, Th2, and Th17 cells is probably maintained by Treg lymphocytes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'T helper subsets in disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/1\">",
"      Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/2\">",
"      Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/3\">",
"      Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/4\">",
"      Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/5\">",
"      Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/6\">",
"      Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/7\">",
"      Crome SQ, Wang AY, Levings MK. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 2010; 159:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/8\">",
"      Cosmi L, Liotta F, Maggi E, et al. Th17 cells: new players in asthma pathogenesis. Allergy 2011; 66:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/9\">",
"      Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009; 10:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/10\">",
"      King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008; 26:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/11\">",
"      King C. New insights into the differentiation and function of T follicular helper cells. Nat Rev Immunol 2009; 9:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/12\">",
"      Nurieva RI, Chung Y, Hwang D, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008; 29:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/13\">",
"      Vogelzang A, McGuire HM, Yu D, et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008; 29:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/14\">",
"      Cucak H, Yrlid U, Reizis B, et al. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 2009; 31:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/15\">",
"      Nurieva RI, Chung Y, Martinez GJ, et al. Bcl6 mediates the development of T follicular helper cells. Science 2009; 325:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/16\">",
"      Johnston RJ, Poholek AC, DiToro D, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009; 325:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/17\">",
"      King IL, Mohrs M. IL-4-producing CD4+ T cells in reactive lymph nodes during helminth infection are T follicular helper cells. J Exp Med 2009; 206:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/18\">",
"      Glatman Zaretsky A, Taylor JJ, King IL, et al. T follicular helper cells differentiate from Th2 cells in response to helminth antigens. J Exp Med 2009; 206:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/19\">",
"      Schmitt N, Morita R, Bourdery L, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 2009; 31:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/20\">",
"      Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008; 9:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/21\">",
"      Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008; 9:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/22\">",
"      Goswami R, Jabeen R, Yagi R, et al. STAT6-dependent regulation of Th9 development. J Immunol 2012; 188:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/23\">",
"      Ramming A, Druzd D, Leipe J, et al. Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. Blood 2012; 119:4665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/24\">",
"      Staudt V, Bothur E, Klein M, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010; 33:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/25\">",
"      Soroosh P, Doherty TA. Th9 and allergic disease. Immunology 2009; 127:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/26\">",
"      Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009; 10:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/27\">",
"      Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119:3573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/28\">",
"      L&eacute;tourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 2009; 123:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/29\">",
"      Zhai Y, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW. Th1 and Th2 cytokines in organ transplantation: paradigm lost? Crit Rev Immunol 1999; 19:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/30\">",
"      Nakamura T, Kamogawa Y, Bottomly K, Flavell RA. Polarization of IL-4- and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells. J Immunol 1997; 158:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/31\">",
"      Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol 2008; 28:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/32\">",
"      Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/33\">",
"      Jung S, Littman DR. Chemokine receptors in lymphoid organ homeostasis. Curr Opin Immunol 1999; 11:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/34\">",
"      Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/35\">",
"      Bucy RP, Karr L, Huang GQ, et al. Single cell analysis of cytokine gene coexpression during CD4+ T-cell phenotype development. Proc Natl Acad Sci U S A 1995; 92:7565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/36\">",
"      Kelso A, Groves P, Troutt AB, Francis K. Evidence for the stochastic acquisition of cytokine profile by CD4+ T cells activated in a T helper type 2-like response in vivo. Eur J Immunol 1995; 25:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/37\">",
"      Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/38\">",
"      Rogers PR, Croft M. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance. J Immunol 1999; 163:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/39\">",
"      Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/40\">",
"      Vicari AP, Schmalbach T, Lekstrom-Himes J, et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther 2007; 12:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/41\">",
"      McAleer JP, Vella AT. Understanding how lipopolysaccharide impacts CD4 T-cell immunity. Crit Rev Immunol 2008; 28:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/42\">",
"      Ingale S, Wolfert MA, Buskas T, Boons GJ. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem 2009; 10:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/43\">",
"      Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009; 9:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/44\">",
"      Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/45\">",
"      Manetti R, Gerosa F, Giudizi MG, et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/46\">",
"      Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A 1993; 90:10188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/47\">",
"      Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/48\">",
"      Barbulescu K, Becker C, Schlaak JF, et al. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol 1998; 160:3642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/49\">",
"      Kohno K, Kataoka J, Ohtsuki T, et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/50\">",
"      Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003; 73:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/51\">",
"      Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 2003; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/52\">",
"      Farrar JD, Murphy KM. Type I interferons and T helper development. Immunol Today 2000; 21:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/53\">",
"      Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994; 12:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/54\">",
"      Murphy KM, Ouyang W, Farrar JD, et al. Signaling and transcription in T helper development. Annu Rev Immunol 2000; 18:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/55\">",
"      Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/56\">",
"      MacGlashan D Jr, White JM, Huang SK, et al. Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994; 152:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/57\">",
"      Shinkai K, Mohrs M, Locksley RM. Helper T cells regulate type-2 innate immunity in vivo. Nature 2002; 420:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/58\">",
"      Yoshimoto T, Paul WE. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994; 179:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/59\">",
"      Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006; 203:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/60\">",
"      Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 2008; 9:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/61\">",
"      Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/62\">",
"      Burgler S, Ouaked N, Bassin C, et al. Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009; 123:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/63\">",
"      Lee Y, Awasthi A, Yosef N, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012; 13:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/64\">",
"      Liu X, Leung S, Wang C, et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med 2010; 16:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/65\">",
"      Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/66\">",
"      Collins A, Littman DR, Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol 2009; 9:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/67\">",
"      Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol 2009; 9:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/68\">",
"      Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005; 307:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/69\">",
"      Zhu J, Min B, Hu-Li J, et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat Immunol 2004; 5:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/70\">",
"      Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/71\">",
"      Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/72\">",
"      de Jong EC, Smits HH, Kapsenberg ML. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol 2005; 26:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/73\">",
"      O'Neill LA. TLRs: Professor Mechnikov, sit on your hat. Trends Immunol 2004; 25:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/74\">",
"      Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/75\">",
"      Smits HH, Hartgers FC, Yazdanbakhsh M. Helminth infections: protection from atopic disorders. Curr Allergy Asthma Rep 2005; 5:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/76\">",
"      Zambrano-Villa S, Rosales-Borjas D, Carrero JC, Ortiz-Ortiz L. How protozoan parasites evade the immune response. Trends Parasitol 2002; 18:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/77\">",
"      Kattah MG, Wong MT, Yocum MD, Utz PJ. Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cells. Arthritis Rheum 2008; 58:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/78\">",
"      Marta M, Andersson A, Isaksson M, et al. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008; 38:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/79\">",
"      Pociask DA, Kolls JK. Integral role of integrins in Th17 development. J Clin Invest 2010; 120:4185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/80\">",
"      Melton AC, Bailey-Bucktrout SL, Travis MA, et al. Expression of &alpha;v&beta;8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest 2010; 120:4436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/81\">",
"      Acharya M, Mukhopadhyay S, Pa&iuml;dassi H, et al. &alpha;v Integrin expression by DCs is required for Th17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice. J Clin Invest 2010; 120:4445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/82\">",
"      Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/83\">",
"      O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/84\">",
"      Robinson DS, Larch&eacute; M, Durham SR. Tregs and allergic disease. J Clin Invest 2004; 114:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/85\">",
"      Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/86\">",
"      Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009; 123:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/87\">",
"      Ye J, Huang X, Hsueh EC, et al. Human regulatory T cells induce T-lymphocyte senescence. Blood 2012; 120:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/88\">",
"      Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/89\">",
"      Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/90\">",
"      Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/91\">",
"      Doetze A, Satoguina J, Burchard G, et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol 2000; 12:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/92\">",
"      Satoguina J, Mempel M, Larbi J, et al. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect 2002; 4:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/93\">",
"      Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/94\">",
"      Tsuji-Takayama K, Suzuki M, Yamamoto M, et al. The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J Immunol 2008; 181:3897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/95\">",
"      Nakamura S, Suzuki M, Sugimoto A, et al. IL-2-independent generation of FOXP3(+)CD4(+)CD8(+)CD25(+) cytotoxic regulatory T cell lines from human umbilical cord blood. Exp Hematol 2007; 35:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/96\">",
"      Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci 2004; 1024:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/97\">",
"      Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008; 324:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/98\">",
"      DeKruyff RH, Fang Y, Umetsu DT. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol 1998; 160:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/99\">",
"      Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 1996; 108:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/100\">",
"      Elenkov IJ, Chrousos GP. Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol Metab 1999; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/101\">",
"      Ram&iacute;rez F, Fowell DJ, Puklavec M, et al. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol 1996; 156:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/102\">",
"      Naseer T, Minshall EM, Leung DY, et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 1997; 155:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/103\">",
"      McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181:4089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/104\">",
"      Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/105\">",
"      Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004; 112:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/106\">",
"      Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/107\">",
"      Weiss ST. Eat dirt--the hygiene hypothesis and allergic diseases. N Engl J Med 2002; 347:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/108\">",
"      Ponsonby AL, van der Mei I, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 2005; 293:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/109\">",
"      Aalberse RC, Platts-Mills TA. How do we avoid developing allergy: modifications of the TH2 response from a B-cell perspective. J Allergy Clin Immunol 2004; 113:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/110\">",
"      Akbari O, Umetsu DT. Role of regulatory dendritic cells in allergy and asthma. Curr Allergy Asthma Rep 2005; 5:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/111\">",
"      McGuirk P, Higgins SC, Mills KH. Regulatory cells and the control of respiratory infection. Curr Allergy Asthma Rep 2005; 5:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/112\">",
"      O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010; 327:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/113\">",
"      Wan YY. Multi-tasking of helper T cells. Immunology 2010; 130:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/114\">",
"      Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/115\">",
"      Yamamura M, Wang XH, Ohmen JD, et al. Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992; 149:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/116\">",
"      Jullien D, Sieling PA, Uyemura K, et al. IL-15, an immunomodulator of T cell responses in intracellular infection. J Immunol 1997; 158:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/117\">",
"      Stassi G, Di Liberto D, Todaro M, et al. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol 2000; 1:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/118\">",
"      Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999; 103:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/119\">",
"      Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001; 344:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/120\">",
"      Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/121\">",
"      Clerici M, Hakim FT, Venzon DJ, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993; 91:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/122\">",
"      Ochs HD, Oukka M, Torgerson TR. TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol 2009; 123:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/123\">",
"      Nembrini C, Marsland BJ, Kopf M. IL-17-producing T cells in lung immunity and inflammation. J Allergy Clin Immunol 2009; 123:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/124\">",
"      Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009; 123:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/125\">",
"      Mucida D, Salek-Ardakani S. Regulation of TH17 cells in the mucosal surfaces. J Allergy Clin Immunol 2009; 123:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/126\">",
"      Zhao Y, Yang J, Gao YD, Guo W. Th17 immunity in patients with allergic asthma. Int Arch Allergy Immunol 2010; 151:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/127\">",
"      Sarkar S, Cooney LA, Fox DA. The role of T helper type 17 cells in inflammatory arthritis. Clin Exp Immunol 2010; 159:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/128\">",
"      Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/129\">",
"      Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010; 62:2876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/130\">",
"      Renner ED, Rylaarsdam S, Anover-Sombke S, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 2008; 122:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/131\">",
"      Levy DE, Loomis CA. STAT3 signaling and the hyper-IgE syndrome. N Engl J Med 2007; 357:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/132\">",
"      Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41897/abstract/133\">",
"      Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007; 120:744.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3973 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41897=[""].join("\n");
var outline_f40_58_41897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Categorization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Historic perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Functional differences of Th subsets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cytokine profiles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      T HELPER CELL DIFFERENTIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Modulation by antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Modulation by cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Modulation by dendritic cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Modulation by regulatory T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Modulation by glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Modulation by the environment (the hygiene hypothesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15633800\">",
"      INTERACTION OF T HELPER SUBSETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      T HELPER SUBSETS IN DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3973|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/45/38615\" title=\"figure 1\">",
"      Human Th subsets",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_58_41898="Complications of bariatric surgery";
var content_f40_58_41898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of bariatric surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     Jamie D Adair, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     James C Ellsmere, MD, MSc, FRCSC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     Daniel Jones, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/58/41898/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/58/41898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bariatric surgery is one of the fastest growing hospital procedures performed in the United States. It is estimated that 220,000 weight-loss surgeries were performed in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications following surgical treatment of severe obesity vary based upon the procedure performed and can be as high as 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Due to the high surgical volume, improving the safety of these operations has become a high priority, leading to the development of strict criteria for center accreditation, guidelines for safe and effective bariatric surgery, and careful monitoring of surgical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link&amp;anchor=H297563#H297563\">",
"     \"Surgical management of severe obesity\", section on 'Accreditation of bariatric programs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the major complications of bariatric surgery, focusing on the three most commonly performed procedures in the United States: the Roux-en-Y gastric bypass (RYGB), the laparoscopic adjustable gastric band (GB), and the sleeve gastrectomy (SG). We will also discuss complications of bariatric surgical procedures that are no longer performed, as patients may present with late complications of these procedures. An overview of bariatric procedures and a review of management of critically ill bariatric patients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link\">",
"     \"Postoperative management of the critically ill obese patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic and imaging findings after bariatric surgery are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28489?source=see_link\">",
"     \"Endoscopy in patients who have undergone bariatric surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link\">",
"     \"Imaging studies after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bariatric surgery is associated with both mortality and morbidity. Risk factors for adverse outcomes have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall 30-day mortality for bariatric surgical procedures is less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/3,9-13\">",
"     3,9-13",
"    </a>",
"    ]. This compares favorably with the hospital mortality of other frequently performed major surgical procedures including hip replacement (0.3 percent), abdominal aneurysm repair (3.9 percent), craniotomy (10.7 percent), esophageal resection (9.1 percent), and pancreatic resection (8.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common causes of early mortality are pulmonary emboli and complications related to leaks. Several factors have been associated with an increased mortality risk:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Older age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher mortality rates have been reported, particularly in patients over the age of 65. A study of 16,155 Medicare beneficiaries (mean age, 47.7 years) who underwent bariatric procedures reported 30 day, 90 day and 1-year mortality rates of 2.0, 2.8, and 4.6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/15\">",
"     15",
"    </a>",
"    ]. Mortality rates were significantly higher for those aged 65 and older compared with younger patients (4.8 versus 1.7 percent at 30 days, 6.9 versus 2.3 percent at 90 days, and 11.1 versus 3.9 percent at one year). Similar results were reported in a second study of a similar population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 65 and older population, the 30 day mortality rate (4.8 percent) was higher than has been described with coronary revascularization (~2 percent) or hip replacement (~1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Male gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male gender is also a risk factor for increasing mortality. In the Medicare study discussed above, men had higher rates of early death than women at 30 days (3.7 versus 1.5 percent), 90 days (4.8 versus 2.1 percent), and one year (7.5 versus 3.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/15\">",
"     15",
"    </a>",
"    ]. Similar results have been reported in a large population-based study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Chronic disease and superobesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic disease and super-obesity (BMI &gt;50) contribute to an increased risk of death with bariatric surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/18\">",
"     18",
"    </a>",
"    ]. The super-obese patients are at increased risk for wound infections, dehiscence, venous thromboembolism and are likely to have multiple severe obesity related medical comorbidities. Diagnostic cost group (DCG) risk adjustment measure can be used as a reflection of the level of medical comorbidities. In a review of 856 patients who underwent bariatric surgery in Veteran Affairs (VA) Hospitals, those with a DCG score of &ge;2 had a significantly increased risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/18\">",
"     18",
"    </a>",
"    ]. These patients had increased rates of severe chronic health conditions including heart failure and stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Low-volume surgeons and hospitals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased mortality is associated with low surgeon and hospital volume of bariatric procedures. Both in-hospital and 30-day mortality are decreased when bariatric surgery is performed by surgeons and hospitals that perform more than 100 procedures a year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/17\">",
"     17",
"    </a>",
"    ]. For these reasons, volume is one of the criteria utilized by the American Society of Metabolic and Bariatric Surgery and the American College of Surgeons for the accreditation of bariatric center of excellence programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some improvements in perioperative mortality have been documented with the introduction of laparoscopic and robotic techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. A two-year study of 5777 patients in the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database demonstrated that the 30-day mortality for laparoscopic RYGB was 0.17 percent, as compared to 0.79 for open RYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Predicting mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk assessment and stratification is important in the decision to perform weight-loss surgery. A scoring system to predict mortality in gastric bypass patients has been derived and then validated in a separate population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Using body mass index (BMI), male gender, hypertension, pulmonary embolus risk, and age, patients were grouped into three risk categories: low (Class A), intermediate (Class B) and high (Class C). The mortality rate among the three risk classes was significant; Class A, 0.3 percent, Class B, 1.9 percent and Class C, 7.6 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of procedure affects the morbidity rate. For example, the morbidity associated with GB appears to be less than is seen with laparoscopic RYGB. A one-year analysis of 4756 patients from the ACS NSQIP database showed the GB carried a lower 30-day rate of major complications than laparoscopic RYGB (1 versus 3.3 percent), return visits to the operating room (0.9 versus 3.6 percent), and shorter postoperative stay (median 1 versus 2 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/19\">",
"     19",
"    </a>",
"    ]. There was no difference in the 30-day mortality between the two procedures.",
"   </p>",
"   <p>",
"    Similarly, analysis of the ACS NSQIP database showed that patients who had open surgery had significantly higher morbidity than those who underwent laparoscopic RYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/19\">",
"     19",
"    </a>",
"    ]. The patients who had open surgery had higher rates of major complications (7.4 versus 3.4 percent), return visits to the operating room (4.9 versus 3.6 percent), and postoperative length of stay (median three versus two days) than patients who had laparoscopic RYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     REHOSPITALIZATION AND REOPERATION RATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from bariatric procedures may lead to the need for rehospitalization and reoperation. Given the large numbers of bariatric procedures performed, rehospitalizations and reoperations for bariatric surgery represent significant costs for hospitals and insurance companies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/11,25,26\">",
"     11,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report from American Society for Metabolic and Bariatric Center of Excellence facilities, the readmission rate was 5 percent and reoperation rate was 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, the readmission and reoperation rates will vary with the type of procedure. A study of 24,678 patients in California who underwent RYGB and were followed for at least three years reported that 20, 18, and 15 percent of patients required readmission at one, two, and three years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/29\">",
"     29",
"    </a>",
"    ]. In a study of 1939 consecutive bariatric operations at a high volume bariatric center, laparoscopic RYGB had the highest readmission rate of 24 percent while the GB had the lowest readmission rate of 13 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the rate of re-operation is significantly higher with GB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely obese patients have a variety of factors which make surgery technically difficult. A thick abdominal wall and extensive visceral fat can make visualization difficult even for the most experienced laparoscopic surgeon. Trocar placement, blind insertion of the laparoscopic instruments, the torque required to safely maneuver laparoscopic instruments, thermal injury or excess",
"    <span class=\"nowrap\">",
"     traction/manipulation",
"    </span>",
"    of organs can contribute to some of the more common intraoperative complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Trocar injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trocar and Veress needle placement in the obese patient can be difficult. Many structures are at risk of injury during the introduction of the trocar or Veress needle and some injuries can be life-threatening.",
"   </p>",
"   <p>",
"    Trocar injury can be minimized by using the left upper quadrant as the access site for percutaneous induction of pneumoperitoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/32\">",
"     32",
"    </a>",
"    ]. All entry techniques, such as Veress or Hassan, can be done safely in experienced hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. A review of 17 randomized controlled trials that included a total of 3040 patients showed no statistical difference in the rates of major complications in open, closed or optical view laparoscopic entry techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Splenic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen can be injured during weight-loss surgery, especially during vertical sleeve gastrectomy, but bleeding can usually be controlled with hemostatic agents and splenectomy is rarely required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Portal vein injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portal vein injury is rare, but can be devastating if thrombosis of the portal vein occurs, as these patients require liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3993?source=see_link\">",
"     \"Extrahepatic portal vein obstruction (portal vein thrombosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bowel ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to detail is important during several key parts of the surgery to avoid bowel ischemia.",
"   </p>",
"   <p>",
"    Ischemia of the bowel may result if the root of the mesentery is compromised or undermined during transection of the small bowel. When performing a retrocolic anastomosis, it is important to make sure the mesentery is not twisted or under excessive tension to avoid compromising the vascular supply.",
"   </p>",
"   <p>",
"    Internal hernias at Petersen's defect (between the Roux limb mesentery and the transverse colon mesentery) or the jejunojejunostomy site can also lead to ischemia and, therefore, these defects must be closed (",
"    <a class=\"graphic graphic_figure graphicRef60840 \" href=\"mobipreview.htm?16/34/16932\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Internal hernias'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Misconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper bowel orientation must be maintained to avoid misconstruction of the Roux-en-Y. Misconstructions with an anastomosis between the distal aspect of the biliopancreatic limb and the gastric pouch have been reported and lead to chronic bilious vomiting (\"Roux-en-O\") (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57903 \" href=\"mobipreview.htm?25/49/26392\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65134 \" href=\"mobipreview.htm?18/14/18664\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62513 \" href=\"mobipreview.htm?30/24/31104\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef77877 \" href=\"mobipreview.htm?41/38/42592\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/38\">",
"     38",
"    </a>",
"    ]. Other examples of misconstruction include Roux limb inversion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75325 \" href=\"mobipreview.htm?5/1/5144\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55376 \" href=\"mobipreview.htm?2/63/3062\">",
"     figure 4",
"    </a>",
"    ) and short Roux limb (",
"    <a class=\"graphic graphic_figure graphicRef80144 \" href=\"mobipreview.htm?1/60/1985\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68135 \" href=\"mobipreview.htm?0/11/183\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EARLY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early complications include bleeding, leaks, deep venous thrombosis, pulmonary embolism, cardiovascular and pulmonary complications. An autopsy series found that technical problems such as leaks were responsible for approximately 50 percent of deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/39\">",
"     39",
"    </a>",
"    ]. The other main cause (30 percent) was pulmonary embolus.",
"   </p>",
"   <p>",
"    Surgical experience may influence complication rates; for example, some studies suggest that leaks are more likely to occur early in a surgeon's experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The learning curve for laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) may be as high as 100 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant bleeding after gastric bypass has been described in 0.6 to 4.0 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/41-48\">",
"     41-48",
"    </a>",
"    ]. A higher rate of postoperative gastrointestinal bleeding was observed following laparoscopic versus open GBP in a prospective randomized study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early bleeding typically occurs from one of the surgical anastomotic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    staple lines, and may be intra- or extraluminal, although it is most commonly intraluminal. Patients frequently present with tachycardia, a decreased hematocrit, and melena [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/49\">",
"     49",
"    </a>",
"    ]. Such bleeding typically resolves without surgical intervention, but may require transfusion of blood products and reversal of anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/41,42,46\">",
"     41,42,46",
"    </a>",
"    ]. Careful endoscopic examination and therapy is appropriate for ongoing bleeding with high transfusion requirements. Surgery is reserved for hemodynamic instability, intraluminal bleeding not amenable to endoscopic therapy (eg, staple line of the excluded stomach) or continued bleeding despite restoration of normal coagulation status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of wound infection are significantly greater with open (10 to 15 percent) than laparoscopic (3 to 4 percent) gastric bypass procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/37,42,43\">",
"     37,42,43",
"    </a>",
"    ]. The incidence of wound infection in open cases can be decreased by almost 50 percent if the fascia is closed in a running fashion rather than in an interrupted manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/51\">",
"     51",
"    </a>",
"    ]. Among laparoscopic techniques, rates of wound infection vary depending upon the technique used, with a higher rate of wound infections associated with the use of circular stapling devices to create the gastrojejunostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of wound infections can be decreased by perioperative administration of antibiotics. Data support the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    , or in patients allergic to penicillins and cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    PLUS one of the following:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/54\">",
"     54",
"    </a>",
"    ]. Choice of antibiotics is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=see_link&amp;anchor=H2235476#H2235476\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\", section on 'Esophageal and duodenal surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of wound infections include unexplained fever, fluctuance, erythema, or drainage. Treatment consists of opening the affected area for drainage of infected fluid or pus, debridement of any devitalized tissue, and antibiotics if the surrounding skin suggests signs of cellulitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;A gastrointestinal leak after laparoscopic or open bariatric surgery has been documented in up to 6 percent of patients, and is one of the most challenging complications of weight-loss surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/41-48,55,56\">",
"     41-48,55,56",
"    </a>",
"    ]. The rate of anastomotic leak in RYBG is 1.5 to 6 percent and can be as high as 35 percent in revisional surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/57\">",
"     57",
"    </a>",
"    ]. Most leaks occur early in the first week after surgery but can occur up to a month after the operation. If not diagnosed in a timely fashion, the mortality rate can be as high as 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many different intraoperative techniques have been used to decrease the incidence of leaks. Over-sewing staple lines, buttressing materials for the staple line and fibrin glue have been used, but there is no evidence that these methods reliably decrease the leak rate after bypass surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/58-65\">",
"     58-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    dye or endoscopy can be used intraoperatively to test for a leak during a gastric bypass. For the dye test, methylene blue tinged saline is injected via the nasogastric tube while the bowel distal to the gastrojejunostomy is clamped. A leak is detected by the presence of methylene blue around the staple line. Alternatively, the pouch can be evaluated for a leak under direct visualization with an endoscope. For endoscopy evaluation, the gastrojejunostomy is submerged in saline and the roux limb is clamped, then the endoscope is used to insufflate the pouch. The presence of air bubbles in the saline around the pouch during insufflation indicates a leak may be present.",
"   </p>",
"   <p>",
"    Several studies of patients undergoing upper GI series on postoperative day one show a 3 percent leak rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Whether postoperative upper gastrointestinal series should be ordered routinely or selectively remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. We routinely perform an upper GI series on all our patients postoperative day one. In the rare event that a leak is present, we can address this quickly and avoid any delay.",
"   </p>",
"   <p>",
"    Early clinical symptoms of a leak are subtle and require clinical vigilance for signs such as low-grade fevers, respiratory compromise, or unexplained tachycardia greater than 120 bpm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/71\">",
"     71",
"    </a>",
"    ]. These signs may also be present in the setting of pulmonary embolism. A leak may be radiographically confirmed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow or contrast computed tomography (CT) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74948 \" href=\"mobipreview.htm?43/18/44334\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/68\">",
"     68",
"    </a>",
"    ]. If a leak is suspected clinically, emergent surgical exploration should be performed even if the imaging is negative, given the rapid progression to sepsis in the severely obese patient with comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/69,72\">",
"     69,72",
"    </a>",
"    ]. A negative exploration that does not reveal a leak should not be considered a complication but rather evidence of good surgical judgment. Multiple studies have shown that re-exploration is safe when compared to missing or delaying the treatment of a leak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. In experienced hands, surgical exploration and management of a leak is often feasible via a laparoscopic approach.",
"   </p>",
"   <p>",
"    The surgical principles in treating a leak include (",
"    <a class=\"graphic graphic_figure graphicRef73658 \" href=\"mobipreview.htm?35/50/36641\">",
"     figure 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Broad-spectrum antibiotic coverage",
"     </li>",
"     <li>",
"      Identification and repair of the defect",
"     </li>",
"     <li>",
"      Irrigation and control of contamination",
"     </li>",
"     <li>",
"      Wide external drainage of the contaminated area",
"     </li>",
"     <li>",
"      Enteral access for feeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Percutaneous drainage of a contained fluid collection may be an option in patients who are stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical therapies for persistent gastric leak are technically difficult and often unsuccessful. New approaches using minimally-invasive endoscopic repair techniques appear safe and effective in some patients. These include use of glue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/76\">",
"     76",
"    </a>",
"    ], or placement of covered stents across the leak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pulmonary embolism and deep venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary embolism (PE) remains the most common cause of mortality in the perioperative period after weight-loss surgery and can account for more than 50 percent of deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/39,78\">",
"     39,78",
"    </a>",
"    ]. The most common risk factors associated with fatal PE include severe venous stasis disease, BMI &gt;60, truncal obesity, and obesity-hypoventilation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of PE in morbidly obese patients can be problematic because use of standard diagnostic modalities (such as a nuclear lung scan, CT-angiography, pulmonary angiography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower extremity duplex scan) may not be physically feasible in extremely obese patients. Immediate anticoagulation is prescribed for patients for whom there is a high level of clinical suspicion. In patients in whom anticoagulation is contraindicated, a mechanical filter can be placed in the inferior vena cava to lower the risk of continued clot embolization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal strategies for preventing",
"    <span class=\"nowrap\">",
"     DVT/PE",
"    </span>",
"    in the gastric bypass setting have not been established. Most bariatric surgeons use both pneumatic compression devices in conjunction with subcutaneous unfractionated or low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/80\">",
"     80",
"    </a>",
"    ]. Preoperative risk stratification may be a useful tool for identifying high-risk patients for more aggressive prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/81\">",
"     81",
"    </a>",
"    ]. In patients identified preoperatively as high-risk for PE, due to previous medical history or inability to ambulate (ie, wheelchair-bound), heparin may be prescribed for an extended period even after discharge from the hospital. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cardiovascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular complications, including myocardial infarction and cardiac failure, are a common cause of mortality in the perioperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. An analysis of 13,871 morbidly obese patients from a national registry reported that the mortality from cardiovascular events ranged from 12.5 to 17.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory failure accounts for 11.3 percent of perioperative mortality after weight-loss surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/55,83\">",
"     55,83",
"    </a>",
"    ]. Atelectasis is common after all types of surgery that require general anesthesia, and is more prevalent in the morbidly obese. Early ambulation and incentive spirometry after surgery are important to decrease the incidence of pulmonary complications. Preoperative identification of the presence of significant obstructive sleep apnea and initiation of continuous positive airway pressure (CPAP) therapy also reduces the risk of pulmonary complications in the postoperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=see_link\">",
"     \"Overview of the management of postoperative pulmonary complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LATE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late complications of bariatric surgery include cholelithiasis, nutritional deficiencies, and neurologic and psychiatric complications. These will be discussed in the context of specific procedures below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF SPECIFIC BARIATRIC PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Roux-en-Y gastric bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;RYGB involves the creation of a small gastric pouch and an anastomosis to a Roux limb of jejunum that bypasses 75 to 150 cm of small bowel, thereby restricting food and limiting absorption (",
"    <a class=\"graphic graphic_figure graphicRef52350 \" href=\"mobipreview.htm?25/10/25761\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/85\">",
"     85",
"    </a>",
"    ]. This procedure is the most common weight-loss procedure performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Complications of RYGB (",
"    <a class=\"graphic graphic_figure graphicRef79256 \" href=\"mobipreview.htm?32/35/33329\">",
"     figure 8",
"    </a>",
"    ) are diverse and vary based upon the specific technique. Some complications are relatively specific to the surgical approach (open versus laparoscopic). Certain complications are seen during the early postoperative periods, while others may present weeks to months following the surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Gastric remnant distension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric remnant distension is a rare but potentially lethal complication following gastric bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. The gastric remnant is a blind pouch and may become distended if paralytic ileus or distal mechanical obstruction occurs postoperatively. Iatrogenic injury to vagal fibers along the lesser curvature may also contribute, possibly by leading to impaired emptying of the bypassed stomach. Progressive distension can ultimately lead to rupture, spillage of massive gastric contents, and subsequent severe peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/90\">",
"     90",
"    </a>",
"    ]. The combination of the large size of inoculum (liters) and the injurious contents (acid, bile, pancreatic enzymes, and bacteria) makes this complication much more serious than leakage occurring at the gastrojejunostomy.",
"   </p>",
"   <p>",
"    Clinical features include pain, hiccups, left upper quadrant tympany, shoulder pain, abdominal distension, tachycardia, or shortness of breath. Radiographic assessment may demonstrate a large gastric air bubble.",
"   </p>",
"   <p>",
"    Treatment consists of emergent operative decompression with a gastrostomy tube or percutaneous gastrostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/91\">",
"     91",
"    </a>",
"    ]. Immediate operative exploration and decompression are required if percutaneous drainage is not feasible, or if perforation is suspected. Although gastrostomy is not performed routinely by most surgeons at the initial gastric bypass operation, drainage of the gastric remnant can prevent this rare but sometimes fatal complication. Routine gastrostomy should be considered in the elderly, super-obese patients, patients with diabetic gastropathy and as part of revisional surgeries where gastric emptying may be delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Stomal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal (anastomotic) stenosis has been described in 6 to 20 percent of patients who have undergone RYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/56\">",
"     56",
"    </a>",
"    ]. The etiology is uncertain, although tissue ischemia or increased tension on the gastrojejunal anastomosis is believed to have a role. The stomal stenosis rate is higher in LRYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/43\">",
"     43",
"    </a>",
"    ], and may be related to the use of the small-diameter circular staplers by many surgeons, which is now losing favor.",
"   </p>",
"   <p>",
"    Patients typically present several weeks after surgery with nausea, vomiting, dysphagia, gastroesophageal reflux, and eventually an inability to tolerate oral intake. The diagnosis is usually established by endoscopy or with an upper gastrointestinal series.",
"   </p>",
"   <p>",
"    Endoscopic balloon dilation is usually successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Repeat dilation sessions may be required for some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/94\">",
"     94",
"    </a>",
"    ]. The complication rate for dilation is approximately 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/94\">",
"     94",
"    </a>",
"    ]. Careful communication between the endoscopist and the surgeon regarding the details of the original operation is important to minimize the risk of endoscopic complications. Surgical revision (required in less than 0.05 percent of patients) is reserved for those who have persistent stenosis despite repeated dilations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Marginal ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marginal ulcers have been reported in 0.6 to 16 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/46,93,95-98\">",
"     46,93,95-98",
"    </a>",
"    ]. Marginal ulcers occur near the gastrojejunostomy and result from acid injuring the jejunum, or they can be associated with a gastrogastric fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Causes of marginal ulcers include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/95,96,99,100\">",
"     95,96,99,100",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor tissue perfusion due to tension or ischemia at the anastomosis",
"     </li>",
"     <li>",
"      Presence of foreign material, such as staples or nonabsorbable suture",
"     </li>",
"     <li>",
"      Excess acid exposure in the gastric pouch due to gastrogastric fistulas",
"     </li>",
"     <li>",
"      Nonsteroidal anti-inflammatory drug use",
"     </li>",
"     <li>",
"      Helicobacter pylori infection",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with marginal ulcers present with nausea, pain, bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforation. The diagnosis of a marginal ulcer is established by upper endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28489?source=see_link&amp;anchor=H25#H25\">",
"     \"Endoscopy in patients who have undergone bariatric surgery\", section on 'Marginal ulcers and acute gastrointestinal bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial medical treatment consisting of gastric acid suppression, with or without the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    , is successful in the majority of patients (95 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/93\">",
"     93",
"    </a>",
"    ]. Nonsteroidal antiinflammatory drugs should be discontinued and patients should be encouraged to stop smoking.",
"   </p>",
"   <p>",
"    The prevalence of H. pylori infection in patients undergoing weight-loss surgery is high, and a significant proportion of them have postoperative foregut symptoms. Observational studies have shown that patients with H. pylori colonization have a higher incidence of marginal ulcer formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/100-103\">",
"     100-103",
"    </a>",
"    ]. Furthermore, in one study, preoperative testing and treatment of H. pylori significantly reduced the incidence of postoperative marginal ulcers (2.4 versus 6.8 percent in unscreened patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical treatment for marginal ulcers is indicated if persistent pain or recurrent bleeding occurs, despite maximal medical management. Medical management is usually successful and surgical intervention is rarely needed, but, when required, revision of the gastrojejunostomy with truncal vagotomy should be performed if the patient is hemodynamically stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/93,104\">",
"     93,104",
"    </a>",
"    ]. Management of a perforated ulcer is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link&amp;anchor=H493274985#H493274985\">",
"     \"Surgical management of complications of peptic ulcer disease\", section on 'Perforated ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Cholelithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholelithiasis develops in as many as 38 percent of patients within six months of surgery, and up to 41 percent of such patients become symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/105\">",
"     105",
"    </a>",
"    ]. Rapid weight loss can also contribute to the development of gallstones by increasing the lithogenicity of bile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/106\">",
"     106",
"    </a>",
"    ]. The high frequency of cholelithiasis can be reduced to as low as 2 percent with a six month course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodiol",
"    </a>",
"    , a synthetic bile salt) given prophylactically after weight-loss surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to perform a cholecystectomy at the time of bypass is controversial. Some surgeons recommend performing cholecystectomy at the time of bypass if a patient has symptomatic gallstones preoperatively. The surgical opinion about asymptomatic gallstones is more divided, and studies have failed to demonstrate a benefit for simultaneous cholecystectomy for incidental gallstones at the time of RYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients can also develop choledocholithiasis (stones in the common bile duct), which can be difficult to treat in the postoperative RYGB patient. Diagnosis of choledocholithiasis can be confirmed by ultrasound or magnetic resonance cholangiopancreatography (MRCP); however, endoscopic intervention and management can be difficult because of the relative inaccessibility to the duodenum due to the altered anatomy of the Roux-en-Y configuration. As a result, successful endoscopic retrograde cholangiopancreatography (ERCP) with cannulation of the papilla is very difficult to perform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. Thus, treatment of choledocholithiasis may require surgery or transhepatic percutaneous access. Alternatively, placement of a gastrostomy tube into bypassed stomach at the time of gastric bypass, with the addition of a radiopaque marker to facilitate future percutaneous access to the gastric remnant has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/112\">",
"     112",
"    </a>",
"    ]. Surgical gastrostomy for pancreatobiliary and duodenal access following RYGB has been done with good results and may be an option when traditional endoscopic approaches are impossible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Ventral incisional hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventral incisional hernias occur with a frequency of 0 to 1.8 percent in laparoscopic series and as high as 24 percent in open series, underscoring a clear advantage of the laparoscopic approach in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/41,43,45,46,114\">",
"     41,43,45,46,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incisional hernias present with an enlarging bulge, pain, or obstructive symptoms. Severe obesity is associated with increased intra-abdominal pressure and thus, a high risk of hernia development after a laparotomy. Many surgeons postpone a formal repair until significant weight loss occurs (&gt;1 year). Indications for early surgical repair include significant pain, bowel obstruction, and rapid enlargement of the hernia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Internal hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Roux-en-Y anatomy is associated with potential internal spaces through which herniation of the small intestine can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/115\">",
"     115",
"    </a>",
"    ]. Internal hernias have been described in 0 to 5 percent of patients undergoing laparoscopic bariatric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/43,46\">",
"     43,46",
"    </a>",
"    ]. Hernias through the transverse mesocolon are the most common and require operative treatment (",
"    <a class=\"graphic graphic_figure graphicRef60840 \" href=\"mobipreview.htm?16/34/16932\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three potential areas of internal herniation are between:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mesenteric defect at the jejuno-jejunostomy",
"     </li>",
"     <li>",
"      The space between the transverse mesocolon and Roux-limb mesentery (Peterson's hernias)",
"     </li>",
"     <li>",
"      The defect in the transverse mesocolon if the Roux-limb is passed retrocolic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To reduce the incidence of internal hernias, all areas of potential herniation should be closed with nonabsorbable sutures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/46\">",
"     46",
"    </a>",
"    ]. In one study, the small bowel obstruction rate was decreased from 6 to 3 percent when all such defects were closed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Internal hernias can be intermittent and, therefore, difficult to detect radiographically. Several studies have shown that the \"mesenteric swirl\" sign on computed tomography (CT) scan is the best indicator of an internal hernia following gastric bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. The mesenteric swirl sign shows a swirled appearance of mesenteric vessels or fat at the root of the mesentery. This finding is easily recognized by experienced radiologists, with high interobserver agreement and high sensitivity (78 to 100 percent) and specificity (80 to 90 percent) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76574 \" href=\"mobipreview.htm?40/30/41441\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/118\">",
"     118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link&amp;anchor=H20337974#H20337974\">",
"     \"Imaging studies after bariatric surgery\", section on 'Internal hernia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patient is suspected to have an internal hernia as the etiology of abdominal pain, urgent surgical exploration is indicated, as a strangulated hernia may require extensive small bowel resection and potentially result in the development of short bowel syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Short bowel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;RYGB and other bariatric procedures can be complicated by short bowel syndrome (SBS) that result from small bowel resections for internal hernias or bowel obstruction from adhesions. In a retrospective review of 265 patients, 11 developed SBS following bariatric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/120\">",
"     120",
"    </a>",
"    ]. In some cases, this complication may require intestinal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30601?source=see_link\">",
"     \"Pathophysiology of the short bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Dumping syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dumping syndrome can occur in up to 50 percent of postgastric bypass patients when high levels of simple carbohydrates are ingested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/122\">",
"     122",
"    </a>",
"    ]. Dumping may contribute to weight loss in part by causing the patient to modify",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    eating habits.",
"   </p>",
"   <p>",
"    There are two types of dumping syndrome: early and late.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early dumping syndrome &mdash; Early dumping syndrome has a rapid onset, usually within 15 minutes. It is the result of rapid emptying of food into the small bowel. Due to the hyperosmolality of the food, rapid fluid shifts from the plasma into the bowel occur, resulting in hypotension and a sympathetic nervous system response. Patients often present with colicky abdominal pain, diarrhea, nausea, and tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/123\">",
"       123",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients should avoid foods that are high in simple sugar content and replace them with a diet consisting of high fiber, complex carbohydrate, and protein rich foods. Behavioral modification, such as small, frequent meals, and separating solids from liquid intake by 30 minutes, are also advocated. Usually, early dumping is self-limiting and resolves within 7 to 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/122\">",
"       122",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=see_link&amp;anchor=H12#H12\">",
"       \"Role of surgery in the management of peptic ulcer disease\", section on 'Dumping syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Late dumping syndrome &mdash; Late dumping syndrome is a result of the hyperglycemia and the subsequent insulin response leading to hypoglycemia that occurs 2 to 3 hours after a meal. Patients present with dizziness, fatigue, diaphoresis and weakness. The treatment is similar to early dumping syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Metabolic and nutritional derangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic and nutritional derangements are common in severely obese patients and can be exacerbated following after bariatric surgery, making postoperative life-long compliance with appropriate dietary choices and vitamin supplementation imperative. Decreased oral intake as well as altered absorption of food from the stomach and small bowel reduces absorption of various micronutrients, particularly iron, calcium, vitamin B12, thiamine and folate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26362?source=see_link&amp;anchor=H11#H11\">",
"     \"Medical management of patients after bariatric surgery\", section on 'Nutritional deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperoxaluria and nephrolithiasis have been reported following Roux-en-Y gastric bypass surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14879976\">",
"    <span class=\"h3\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased absorption of calcium oxalate leads to deposition in the renal parenchyma, resulting in oxalate nephropathy and renal failure. While uncommon after RYGB, a retrospective review of 11 patients with oxalate nephropathy found that all were hypertensive and nine were diabetic before the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/124\">",
"     124",
"    </a>",
"    ]. Renal biopsies revealed diffuse tubular degenerative changes, abundant tubular calcium oxalate deposits, and varying degrees of tubulointerstitial scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Postoperative hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of patients develop blackouts and seizures after weight-loss surgery due to a severe form of recurrent hyperinsulinemic hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/125\">",
"     125",
"    </a>",
"    ]. Pancreatic nesidioblastosis has been proposed as a mechanism for the pathologic finding of beta islet hypertrophy in these patients, although a few cases of insulinomas have been found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. Gastric-bypass-induced weight loss may unmask an underlying beta cell defect or contribute to pathological islet hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/126\">",
"     126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44614?source=see_link&amp;anchor=H8#H8\">",
"     \"Noninsulinoma pancreatogenous hypoglycemia syndrome\", section on 'Nesidioblastosis after Roux-en-Y gastric bypass surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/11/3255?source=see_link\">",
"     \"Postprandial (reactive) hypoglycemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A wide variety of clinical approaches have been proposed to address severe hypoglycemia after gastric bypass. We suggest beginning with simpler and safer interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with symptomatic hypoglycemia respond well to dietary modification (low carbohydrate diet) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/128\">",
"       128",
"      </a>",
"      ]. Those patients that are refractory to a low carbohydrate diet can be treated with the alpha-glucosidase inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44197?source=see_link\">",
"       acarbose",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Based on the theory that severe, disabling hypoglycemia after gastric bypass surgery occurs in a subset of patients with loss of gastric restriction, with resultant rapid food passage and absorption, restoration of gastric restriction can result in symptom resolution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/129\">",
"       129",
"      </a>",
"      ]. Gastric restriction can be restored by surgical placement of a silastic ring or an adjustable gastric band around the pouch. In one series, symptoms resolved in 11 of 12 patients with this approach.",
"     </li>",
"     <li>",
"      Subtotal pancreatectomy or total pancreatectomy has been recommended by some surgeons to control hypoglycemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/127\">",
"       127",
"      </a>",
"      ]. This should be reserved for patients who are refractory to less radical interventions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Change in bowel habits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loose stool and diarrhea are more common after BPD and RYGB. Constipation is more common after gastric banding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/130\">",
"     130",
"    </a>",
"    ]. In a study of 290 severely obese patients undergoing bariatric surgery, 126 underwent RYGB, BPD was performed in 103 patients, and 61 patients had gastric banding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/130\">",
"     130",
"    </a>",
"    ]. After RYGB, the proportion of patients with loose stools, diarrhea or frequent flatus increased significantly (46 versus 8 percent preoperatively). After BPD, 55 percent of the patients reported an increase in loose stools or diarrhea or frequent flatus versus 8 percent preoperatively. Conversely, after gastric banding, 39 percent of patients complained of constipation.",
"   </p>",
"   <p>",
"    Steatorrhea and more frequent stools can occur with excessive fat intake. In addition, these symptoms can be due to subclinical lactose intolerance, which is only recognized when dairy products are used in an effort to achieve adequate protein intake after bariatric surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Failure to lose weight and weight regain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to lose weight following Roux-en-Y gastric bypass is rare, and is often due to maladaptive eating patterns during the early postoperative period.",
"   </p>",
"   <p>",
"    On the other hand, significant late weight regain occurs in up to 20 percent of patients, especially those with super-obesity (BMI &gt;50",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    at the time of the initial operation. It is often due to progressive noncompliant eating and other behavioral habits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/131\">",
"     131",
"    </a>",
"    ], development of a functional gastrogastric fistula, gradual enlargement of the gastric pouch, or dilatation of the gastrojejunal anastomosis.",
"   </p>",
"   <p>",
"    A gastrogastric fistula can also be the cause of weight gain. &nbsp;A gastrogastric fistula is seen when a channel develops between the gastric pouch and the excluded stomach remnant, allowing ingested food to enter the bypassed foregut (stomach and duodenum). When significant weight regain is seen in a post-GBP patient, particularly in the setting of recurrent or new onset gastroesophageal reflux symptoms, an upper gastrointestinal series should be performed to exclude a gastrogastric fistula as a cause.",
"   </p>",
"   <p>",
"    In the early days of gastric bypass, surgeons stapled the stomach without completely dividing the gastric remnant from the pouch. The gastric pouch and gastric remnant stapled in continuity was associated with a 49 percent rate of gastrogastric fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/132\">",
"     132",
"    </a>",
"    ]. The introduction of complete transection of these two segments has decreased the rate of gastrogastric fistula to 0 to 3 percent (",
"    <a class=\"graphic graphic_figure graphicRef79256 \" href=\"mobipreview.htm?32/35/33329\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/132-134\">",
"     132-134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although revisional bariatric procedures are associated with high complication rates, as compared to primary bariatric procedures, surgical repair of the fistula may be indicated for these patients, especially if significant comorbidities are still present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/135\">",
"     135",
"    </a>",
"    ]. In experienced hands, even laparoscopic revisions can be performed safely with an acceptable complication rate of about 22 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/91\">",
"     91",
"    </a>",
"    ]. Endoscopic approaches with stenting have been reported, but experience is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/136\">",
"     136",
"    </a>",
"    ]. Others have used endoscopic suturing techniques to close these gastrogastric fistulas, although the recurrence rates remain high.",
"   </p>",
"   <p>",
"    Dilatation of gastric pouch or the gastrojejunal anastomosis may be responsible for weight gain in other patients. The stretched pouch",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the outlet are thought to arise from repeated overdistension due to excessive food intake. These patients usually do not benefit from the high-risk revisional surgery. However, less invasive endoscopic procedures aimed at suture reduction of the pouch size or tightening of the stoma have been successful, at least with short-term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/137,138\">",
"     137,138",
"    </a>",
"    ]. The long-term efficacy of these therapies is not known, and is being formally assessed as part of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Gastric banding",
"    </span>",
"    &nbsp;&mdash;&nbsp;GB is a purely restrictive procedure that involves placement of an adjustable silicone device at the gastric cardia near the gastroesophageal junction, limiting the amount of food consumed. Restriction can be adjusted by injecting saline into a subcutaneous port connected to the band (",
"    <a class=\"graphic graphic_figure graphicRef60081 \" href=\"mobipreview.htm?21/54/22368\">",
"     figure 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GB is the second most common weight-loss surgery performed in the United States. From 2004 to 2007 there has been an increase of 329 percent in the number of GB procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/139\">",
"     139",
"    </a>",
"    ]. GB has the lowest mortality rate among all bariatric procedures. The Australian Safety and Efficacy Register of New Interventional Procedures reported three deaths out of 5827 gastric banding procedures (0.05 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, GB has been associated with several complications. An initial trial of GB in the United States showed disappointing weight loss outcomes and high complication rates, associated with relatively high revisional surgery rate (40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/141\">",
"     141",
"    </a>",
"    ]. Following changes in the surgical technique, subsequent trials in Europe, Australia, and the United States have shown fewer complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/141-144\">",
"     141-144",
"    </a>",
"    ]. Long term results from a series of 78 GB patients showed that nearly 40 percent of patients experienced major complications, 22 percent had minor complications, and almost half of the patients required reoperation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/145\">",
"     145",
"    </a>",
"    ]. Major complications included pouch dilation (11 percent), band erosion (28 percent), and band infection (1 percent). Minor complications included incisional hernias (5 percent), port-tubing disconnections (20 percent), and port infections (2 percent).",
"   </p>",
"   <p>",
"    Complications of GB can occur early or late. Early complications include acute stomal obstruction, band infection, gastric perforation, hemorrhage, bronchopneumonia, and delayed gastric emptying and pulmonary embolism. Pulmonary embolism was the most common cause of early mortality in a series of 9682 GB patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/82\">",
"     82",
"    </a>",
"    ]. Late complications include band erosion, band slippage or prolapse, port or tubing malfunction, leakage at the port site tubing or band, pouch or esophageal dilatation and esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/141,142,146-148\">",
"     141,142,146-148",
"    </a>",
"    ]. Almost 50 percent of patients will need surgical revision or removal of the band. Failed bands (due either to complications or inadequate weight loss) can generally be converted to other bariatric procedures such as RYGB or a duodenal switch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/91,149,150\">",
"     91,149,150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the rate of long-term complications and rates of reoperation are higher with LAGB compared with RYGB. In a prospective study of 442 patients matched for age, gender, and BMI, patients undergoing LAGB had a significantly higher rate of long-term complications compared with patients undergoing RYGB (41.6 versus 19.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/151\">",
"     151",
"    </a>",
"    ]. Patients undergoing LAGB also had a higher rate of reoperation at six years of follow-up (26.7 versus 12.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Stomal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute stomal obstruction is an early complication that can occur in up to 14 percent of GB patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. Obstruction is usually caused by inclusion of excess perigastric fat, use of a band of insufficient diameter for the thickness of the tissue or significant tissue edema. Patients usually present with persistent nausea, vomiting, and inability to tolerate secretions or oral intake. The diagnosis is confirmed with an upper gastrointestinal series demonstrating no passage of contrast beyond the band.",
"   </p>",
"   <p>",
"    Acute stomal obstruction due to edema can initially be treated conservatively with nasogastric tube decompression until the edema subsides, although a potential for aspiration pneumonia and stomach ischemia exists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/91\">",
"     91",
"    </a>",
"    ]. Persistent obstruction requires surgical revision or removal of the band. Meticulous removal of excess perigastric fat at the time of initial band placement may help prevent this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/154\">",
"     154",
"    </a>",
"    ]. The use of larger diameter bands may also help to reduce the incidence of acute postoperative obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Port infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Port infection has been reported in 0.3 to 9 percent of GB patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/144,155,156\">",
"     144,155,156",
"    </a>",
"    ]. Because the port is a foreign body, port infection is treated with surgical removal, especially in association with band erosion. Overall, the incidence of port site infection ranges from 0.3 to 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/144,156\">",
"     144,156",
"    </a>",
"    ]. Band erosion is first ruled out via upper endoscopy since post infections may be one of the first signs indicating the presence of an erosion. If an isolated port infection is found, the infected port is removed and a new port is reimplanted once the infection clears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Band erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Band erosion through the wall of the stomach has been reported in up to 7 percent of GB patients, and it is thought to occur as a result of either gastric wall ischemia from an excessively tight band, mechanical trauma related to the band buckle or thermal trauma from electrosurgical energy sources used during band placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/157,158\">",
"     157,158",
"    </a>",
"    ]. Band erosion is a late complication and occurs at a mean of 22 months after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/157\">",
"     157",
"    </a>",
"    ]. Introduction of new band technology and placement technique is likely to result in a reduction of band erosions, as reported by more recent studies (",
"    <a class=\"graphic graphic_figure graphicRef76700 \" href=\"mobipreview.htm?11/13/11472\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical signs of band erosion include infection, failure of weight loss, or nausea and vomiting. Epigastric pain and hematemesis can also signal erosion of the lap band into the left gastric artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/148\">",
"     148",
"    </a>",
"    ]. This can happen when the lap band erodes into the posterior part of the stomach near the cardioesophageal junction. This complication can be avoided by careful placement during the initial surgery, making sure not to include the ascending branch of the left gastric artery during band placement.",
"   </p>",
"   <p>",
"    Band erosion can be diagnosed by endoscopy and treatment involves removal of the band, which can be done laparoscopically. Successful endoscopic removal has also been reported when the buckle of the band is visible endoscopically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/159-161\">",
"     159-161",
"    </a>",
"    ]. It is generally recommended that revision to another bariatric procedure be delayed for at least 2 to 3 months after an episode of band erosion, as the complication rate with immediate revision is increased. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28489?source=see_link&amp;anchor=H20#H20\">",
"     \"Endoscopy in patients who have undergone bariatric surgery\", section on 'Band erosion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Band slippage and gastric prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Band slippage involves prolapse of part of the stomach through the band, with varying degrees of gastric obstruction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior prolapse involves migration of the band cephalad which creates an acute angle with the stomach pouch and esophagus, resulting in obstruction.",
"     </li>",
"     <li>",
"      Posterior gastric prolapse occurs when the stomach migrates cephalad, displacing the band caudally and creating a new pouch (",
"      <a class=\"graphic graphic_figure graphicRef81074 \" href=\"mobipreview.htm?12/24/12673\">",
"       figure 11",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Slippage rates were as high as 24 percent in the initial FDA trial, but more recent series show a much lower incidence of 2 to 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/146,162\">",
"     146,162",
"    </a>",
"    ]. An early technique (involving perigastric dissection with placement of a Lap-Band directly on the stomach wall) was associated with frequent gastric prolapse. A newer technique (via pars flaccida without exposure of the stomach wall) has decreased this complication significantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/163-165\">",
"     163-165",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastric prolapse is characterized by food intolerance, epigastric pain, and acid reflux. Diagnosis is confirmed with an upper gastrointestinal series demonstrating either malposition of the band or dilatation and prolapse of the gastric pouch. (See",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link&amp;anchor=H168815156#H168815156\">",
"     \"Imaging studies after bariatric surgery\", section on 'Band slippage and gastric prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery is required urgently or emergently, depending on the presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/166,167\">",
"     166,167",
"    </a>",
"    ]. Repair of the prolapse can sometimes be accomplished by repositioning the band, but often the band needs to be replaced or removed altogether, especially if significant inflammation is found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Port malfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Port malfunction results if the tubing disconnects, subcutaneous port flips, or leakage within the system occurs. Such problems lead to inability to titrate the instilled volume of saline in the system. Reported incidence of port and tubing malfunction ranges from 0.4 to 7.0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/146,168\">",
"     146,168",
"    </a>",
"    ]. These problems usually become evident as an inability to access port and maintain band volume, or the development of weight gain. These complications require surgical repair or exchange of the hardware to attain band adjustability. Port dislocation can be reduced by attaching the port to a broad surface mesh first before anchoring to the rectus fascia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/169\">",
"     169",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link&amp;anchor=H20337901#H20337901\">",
"     \"Imaging studies after bariatric surgery\", section on 'Tubing migration or disconnection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagitis and reflux are infrequent complications following Lap-Band [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/162\">",
"     162",
"    </a>",
"    ]. Deflation of the band and acid-suppression therapy are the mainstays of treatment. However, if intractable to medical therapy, band removal or conversion to other procedure such as RYGB may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Esophageal dilatation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal dilatation proximal to the band device has been observed in as many as 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/147\">",
"     147",
"    </a>",
"    ]. This so-called \"pseudoachalasia syndrome\" may develop when the band is excessively inflated or in the setting of excessive amounts of food intake. Pouch dilatation has also been associated with a history of binge eating behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/170\">",
"     170",
"    </a>",
"    ]. Patients often present with food and saliva intolerance, reflux and epigastric discomfort. The diagnosis can be confirmed with an upper gastrointestinal series. (See",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link&amp;anchor=H20337824#H20337824\">",
"     \"Imaging studies after bariatric surgery\", section on 'Esophageal dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment should be removal of all the fluid from the band and behavioral diet modifications. This is usually successful in reversing esophageal dilatation. However, persistent dilatation may require replacement of the band in a new location on the stomach or conversion to a different procedure.",
"   </p>",
"   <p>",
"    Deflation of the band alone is usually successful in reversing esophageal dilatation. However, persistent dilatation may require replacement of the band to a new location on the stomach or conversion to a different procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1199440331\">",
"    <span class=\"h3\">",
"     Hiatus hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hiatus hernia is often a pre-existing but unrecognized condition in patients undergoing bariatric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/171\">",
"     171",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    This can lead to ongoing intractable reflux necessitating reoperation or band removal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82446 \" href=\"mobipreview.htm?43/24/44431\">",
"     image 7",
"    </a>",
"    ). Thus, a simple crural repair can be performed at the initial operation to avoid these complications. A retrospective review of 1298 patients who underwent GB alone and 520 patients who underwent GB with concurrent hiatal hernia repair showed that the rate of reoperation was significantly reduced in patients who had hiatal repair at the time of GB as compared with those who had GB alone (1.7 versus 5.6 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/171\">",
"     171",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link&amp;anchor=H20337858#H20337858\">",
"     \"Imaging studies after bariatric surgery\", section on 'Hiatus hernia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7527?source=see_link&amp;anchor=H10#H10\">",
"     \"Hiatus hernia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Sleeve gastrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic sleeve gastrectomy (SG) is a restrictive procedure initially developed as part of a staged approach for high-risk super-obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/172,173\">",
"     172,173",
"    </a>",
"    ]. SG is increasingly being performed as a standalone operation with good weight loss and resolution of obesity related comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/174-177\">",
"     174-177",
"    </a>",
"    ]. A study of 14,776 sleeve gastrectomies confirmed that SG was intended as the sole operation in 86.3 percent of the procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sleeve gastrectomy involves creating a \"sleeve\" of stomach over a bougie and removes a large portion of the greater curvature of the stomach leaving a small tube along the lesser curvature. SG also produces a decrease in ghrelin levels for up to a year, which may reduce the desire for food (",
"    <a class=\"graphic graphic_figure graphicRef54612 \" href=\"mobipreview.htm?35/40/36480\">",
"     figure 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/179,180\">",
"     179,180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant advantages of SG include low complication (3 to 24 percent) and mortality (0.39 percent) rates, the ease of performing the procedure, preservation of the pylorus, maintenance of physiological food passage and the avoidance of foreign material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/4,178,181-188\">",
"     4,178,181-188",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common complications of SG include bleeding, narrowing or stenosis of the stoma, and leaks:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88503966\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding can occur from the gastric or short gastric vessels during dissection of the greater curve. Most of the bleeding problems associated with SG occur from the staple line after transection of the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/181,189,190\">",
"     181,189,190",
"    </a>",
"    ]. The bleeding is most likely a result of the large staples used for the thick tissue in the distal stomach. Large staples are not adequate to seal small vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/191\">",
"     191",
"    </a>",
"    ]. This has led many surgeons to reinforce the staple line by over-sewing, buttressing or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88503973\">",
"    <span class=\"h3\">",
"     Stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narrowing or stenosis can create gastric outlet obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/181\">",
"     181",
"    </a>",
"    ]. The presentation varies depending on the severity of the obstruction and can include dysphagia, vomiting, dehydration and the inability to tolerate an oral diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/192,193\">",
"     192,193",
"    </a>",
"    ]. The gastroesophageal junction and the incisura angularis are the two most common areas where stenosis occurs, and this can be diagnosed by an upper gastrointestinal series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/192\">",
"     192",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link&amp;anchor=H20339394#H20339394\">",
"     \"Imaging studies after bariatric surgery\", section on 'Stricture or stenosis of the SG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common reasons for the development of narrowing or stenosis are over-sewing the staple line and using a bougie that is too small. The preferable bougie size is currently debated in the literature and can range from 30 to 60 French. In most cases, surgeons use a 36 to 40 French bougie for the sleeve construction and the larger sizes of bougies are reserved for when SG is being performed as part of a staged procedure.",
"    <br/>",
"    <br/>",
"    Management of stenosis primarily consists of endoscopic dilation. If the area of stenosis is too long, surgical intervention may be necessary with conversion to a RYGB, gastric stricturoplasty or resection with gastrogastrostomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88503994\">",
"    <span class=\"h3\">",
"     Gastric leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric leaks after SG are one of the most serious complications and can occur in up to 5.3 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/173,176,182,186,190,194-200\">",
"     173,176,182,186,190,194-200",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link\">",
"     \"Imaging studies after bariatric surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=see_link&amp;anchor=H20339698#H20339698\">",
"     \"Imaging studies after bariatric surgery\", section on 'Leak after SG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most leaks are due to local factors at the site of the staple line, such as inadequate blood supply and oxygenation, which impede the healing process. Leaks can also be due to gastric-wall heat ischemia, a consequence of the heat generated by the cautery used during dissection of the greater curve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/196\">",
"     196",
"    </a>",
"    ]. Although the blood supply to the stomach is robust, the gastroesophageal junction tends to be an area of decreased vascularity and thus more prone to leaks. Additionally, the stomach tends to be thinner at the angle of His and some authors suggest that the large staple height used by many surgeons may not adequately seal this area of the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/189,201\">",
"     189,201",
"    </a>",
"    ]. Some surgeons recommend leaving a small portion of stomach distal to the angle of His and then imbricating with a running silk suture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/176\">",
"     176",
"    </a>",
"    ]. However, clinical studies have not provided evidence that reinforcing the suture line decreases the rate of leak after sleeve gastrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/202\">",
"     202",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Sleeve gastrectomy produces high intragastric pressure, which can affect the healing process and lengthen the amount of time for a leak to close [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/203\">",
"     203",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Reoperation with primary repair during the early postoperative course is the best option for a leak following SG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/196\">",
"     196",
"    </a>",
"    ]. Clinically stable patients may be able to undergo percutaneous drainage, antibiotic therapy, and parenteral nutrition until the leak is healed. Endoscopic therapy with the use of stents has also been employed for management of leaks, but migration of the stents has been a problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/204-207\">",
"     204-207",
"    </a>",
"    ]. Early diagnosis, adequate drainage and gastric decompression are the mainstay of treatment for leaks. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Leaks'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32787735\">",
"    <span class=\"h3\">",
"     Reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux after SG presents with classic symptoms such as burning pain, heartburn, and regurgitation. It can occur as an early and late complication. The first-line treatment is antireflux medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/208\">",
"     208",
"    </a>",
"    ]. GERD unresponsive to antireflux medical therapy with no clear anatomic abnormalities, such as stoma stenosis or a hiatal hernia, can be effectively treated by conversion to RYGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/209\">",
"     209",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Vertical banded gastroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertical banded gastroplasty (VBG), also known as \"stomach stapling\" is a purely restrictive procedure involving creation of a small proximal gastric pouch lined by a vertical staple line and a tight prosthetic mesh (",
"    <a class=\"graphic graphic_figure graphicRef57137 \" href=\"mobipreview.htm?35/28/36303\">",
"     figure 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/210\">",
"     210",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The theoretical advantages of VBG include the relative simplicity of the procedure, avoidance of rerouting of the gastrointestinal tract and associated malabsorption. The VBG has been largely supplanted by the RYGB, but patients who underwent VBG still present to bariatric surgeons today with complications including staple line disruption, stomal stenosis, band erosion, GERD,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    marginal ulcers, and weight regain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/211,212\">",
"     211,212",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h3\">",
"     Staple line disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disruption of the staple line results in a fistula to the fundus, which can lead to decreased restriction in the VBG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/213,214\">",
"     213,214",
"    </a>",
"    ]. This complication can occur in 27 to 31 percent of the patients and can be as high as 48 percent if assessed on routine postoperative endoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/215\">",
"     215",
"    </a>",
"    ]. Staple line disruption typically leads to weight regain due to increased food consumption, since patients can eat around their restriction without feeling full. Surgical treatment of this complication is conversion to a RYGB or a BPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/216,217\">",
"     216,217",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h3\">",
"     Obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomal stenosis occurs in approximately 20 to 33 percent and can occur due to fibrosis in the stomach or by the band itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/218\">",
"     218",
"    </a>",
"    ]. The resulting obstruction leads to food intolerance, reflux, and often weight regain due to dietary shifts to calorically dense liquids and softer foods. Staple line dehiscence, esophageal dilatation and a fistula between the VBG pouch and occluded stomach have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stomal stenosis following VBG can initially be managed nonoperatively by endoscopic dilation, with surgery reserved for failures. However, dilation may be unsuccessful due to the rigid nature of the prosthetic band. A success rate of 68 percent for endoscopic dilation of stomal stenosis was described in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/99\">",
"     99",
"    </a>",
"    ]. Symptomatic relief following endoscopic dilation is often short -lived, and surgical revision may be necessary when symptoms persist. Dense scarring also presents a significant operative risk when revision is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h3\">",
"     Erosion of mesh band",
"    </span>",
"    &nbsp;&mdash;&nbsp;Band erosion is a frequent late complication of VBG occurring with an incidence of 1 to 7 percent and usually occurs one to three years after the surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/215,219\">",
"     215,219",
"    </a>",
"    ]. Patients generally present with abdominal pain and vomiting. Surgical removal is indicated if erosion is visualized by endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h3\">",
"     Reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux after VBG presents with classic symptoms such as burning pain, heartburn, aspiration, and cough. It typically occurs as a late complication, as a result of stomal stenosis and pouch dilatation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/220\">",
"     220",
"    </a>",
"    ]. GERD unresponsive to antireflux medical therapy often requires reversal of the VBG or conversion to RYGB. In a review of 25 patients undergoing a revision of a VBG for symptomatic reflux, esophagitis was present in 58 percent of patients and Barrett's esophagus in 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/220\">",
"     220",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     Vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent vomiting occurs in approximately 8 to 21 percent of patients following VBG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/221\">",
"     221",
"    </a>",
"    ]. The etiology may be multifactorial, including maladaptive dietary patterns (such as eating too quickly or not chewing properly) as well as functional problems such as stomal stenosis, pouch dilatation, staple line disruption, or GERD. These patients will often become sweet eaters in an attempt to ingest calories in a form that does not cause vomiting.",
"   </p>",
"   <p>",
"    Not all patients with recurrent vomiting require an operative revision. Initial treatment should consist of dietary modification (ie, proper chewing, eating at slower pace, and avoidance of problem foods that give recurrent vomiting) and radiologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopic evaluations for structural problems. Operative revision is required if the vomiting persists and leads to malnutrition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dehydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/217\">",
"     217",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Biliopancreatic diversion and duodenal switch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliopancreatic diversion (BPD) is a malabsorptive procedure that relies limiting absorption of fats and starches to a relatively short segment of small intestine as well as decreasing the gastric reservoir size. BPD has not become widespread because of the technical complexity of the procedure with historically high surgical morbidity and mortality rates and concerns regarding the long-term nutritional outcomes, including significant protein calorie malnutrition, anemia, metabolic bone disease and deficiencies of fat-soluble vitamins (",
"    <a class=\"graphic graphic_figure graphicRef67432 \" href=\"mobipreview.htm?18/53/19284\">",
"     figure 14",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/222,223\">",
"     222,223",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biliopancreatic diversion differs from JIB in that no intestinal limb is excluded from flow, thus avoiding creation of a blind loop (see",
"    <a class=\"local\" href=\"#H56\">",
"     'Jejunoileal bypass'",
"    </a>",
"    below). Excellent weight loss results with morbidity and mortality rates comparable to RYGB have been described by the few centers that perform BPD along with its duodenal switch variant (",
"    <a class=\"graphic graphic_figure graphicRef54159 \" href=\"mobipreview.htm?19/33/19987\">",
"     figure 15",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/224-226\">",
"     224-226",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Jejunoileal bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jejunoileal bypass (JIB) is a purely malabsorptive procedure popular in the 1960s and 1970s. The procedure produces significant weight loss by creating a surgical short bowel syndrome (",
"    <a class=\"graphic graphic_figure graphicRef53171 \" href=\"mobipreview.htm?23/34/24098\">",
"     figure 16",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    JIB is no longer used today because of a 50 percent morbidity rate and 10 percent mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/227\">",
"     227",
"    </a>",
"    ]. Patients who previously underwent JIB should be followed carefully for signs of complications, particularly a deterioration in liver function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/222\">",
"     222",
"    </a>",
"    ]. Studies have shown a high long-term complication rate, with a 21 percent rate of cirrhosis after fifteen years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/228\">",
"     228",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h3\">",
"     Electrolyte imbalances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over half of the patients who underwent JIB developed diarrhea and electrolyte imbalances, and these problems could persist more than five years after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/229,230\">",
"     229,230",
"    </a>",
"    ]. Arthritis, protein malnutrition, vitamin deficiencies, cirrhosis, nephrolithiasis with oxalate stones and renal failure have also been associated with JIB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/229-237\">",
"     229-237",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h3\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased absorption of calcium oxalate leads to deposition in the renal parenchyma. This can lead to a postobstruction nephropathy and renal failure, which has been described in up to 19 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/238\">",
"     238",
"    </a>",
"    ]. Conversion to a gastric bypass or reversal should be considered in patients with metabolic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/239\">",
"     239",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h3\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic abnormalities that may lead to cirrhosis can occur in up to 40 percent of patients and may persist or progress despite reversal in more than one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/231,240\">",
"     231,240",
"    </a>",
"    ]. Some patients have progressed to decompensated cirrhosis requiring transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/232\">",
"     232",
"    </a>",
"    ]. If not already performed, reversal of the jejunoileal bypass at the time of transplant should be considered. Reversal prior to transplant may not be feasible because of the risk of precipitating hepatic decompensation in patients with advanced liver disease. Patients who do not undergo reversal at the time of transplant should be monitored closely, with reversal performed in those who develop progressive liver injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/229,232,233\">",
"     229,232,233",
"    </a>",
"    ]. Progressive liver injury appears histologically as increasing steatosis, lobular lymphocytic inflammation, pericellular fibrosis, Mallory bodies, and deranged architecture, all features resembling those seen in alcoholic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/58/41898/abstract/229,234\">",
"     229,234",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications and mortality following surgical treatment of severe obesity vary based upon the procedure performed. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall 30-day mortality for bariatric surgical procedures is &lt;1 percent. Mortality rates are higher in men than in women and for those aged 65 and older. Both in-hospital and 30-day mortality are decreased when bariatric surgery is performed by surgeons and hospitals that perform more than 100 procedures a year. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of early rehospitalization are nausea, vomiting, and dehydration, abdominal pain, and wound problems. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Rehospitalization and reoperation rates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of early mortality are pulmonary emboli and complications related to leaks. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Early complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Roux-en-Y gastric bypass complications are diverse and include gastric remnant distension, stomal stenosis, marginal ulcer formation, cholelithiasis, ventral hernias, internal hernias, hypoglycemia, dumping, metabolic and nutritional derangements and weight regain. Some complications are seen during the early postoperative periods while others may present weeks to months following the surgery. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Roux-en-Y gastric bypass'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic adjustable gastric banding complications include acute stomal obstruction, band erosion, band slippage leading to gastric prolapse, port malfunction, esophageal dilatation, esophagitis, and infection. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Gastric banding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic sleeve gastrectomy complications include bleeding, narrowing or stenosis of the stoma, leaks, and reflux. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Sleeve gastrectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vertical banded gastroplasty complications include staple line disruption, stomal stenosis, band erosion, reflux,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      marginal ulcers, and weight regain. (See",
"      <a class=\"local\" href=\"#H49\">",
"       'Vertical banded gastroplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biliopancreatic diversion complications include significant protein calorie malnutrition, anemia, metabolic bone disease and deficiencies of fat-soluble vitamins and vitamin B12. (See",
"      <a class=\"local\" href=\"#H55\">",
"       'Biliopancreatic diversion and duodenal switch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Jejunoileal bypass is no longer performed because of a high morbidity and mortality rate. However, patients who underwent this procedure can present years later with significant complications, including arthritis, protein malnutrition, vitamin deficiencies, cirrhosis, nephrolithiasis with oxalate stones and renal failure. (See",
"      <a class=\"local\" href=\"#H56\">",
"       'Jejunoileal bypass'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Society for Metabolic and Bariatric Surgery (2009) Fact Sheet: Metabolic &amp; Bariatric Surgery. Available online at: www.asbs.org/Newsite07/media/asbs_presskit.htm (Accessed on January 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/2\">",
"      Encinosa WE, Bernard DM, Du D, Steiner CA. Recent improvements in bariatric surgery outcomes. Med Care 2009; 47:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/3\">",
"      Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361:445.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, SB, Jones, DB Obesity Surgery: Patient Safety and Best Practices, Cine-Med Inc, Woodbury 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/5\">",
"      Kelly JJ, Shikora S, Jones DB, et al. Best practice updates for surgical care in weight loss surgery. Obesity (Silver Spring) 2009; 17:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/6\">",
"      Mulligan AT, McNamara AM, Boulton HW, et al. Best practice updates for nursing care in weight loss surgery. Obesity (Silver Spring) 2009; 17:895.",
"     </a>",
"    </li>",
"    <li>",
"     Hutter MM. The Betsy Lehman Center Guidelines for Weight Loss Surgery. SAGES Manual. 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/8\">",
"      Schirmer B, Jones DB. The American College of Surgeons Bariatric Surgery Center Network: establishing standards. Bull Am Coll Surg 2007; 92:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/9\">",
"      Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/10\">",
"      Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/11\">",
"      Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005; 294:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/12\">",
"      Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/13\">",
"      DeMaria EJ, Pate V, Warthen M, Winegar DA. Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis 2010; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/14\">",
"      Dimick JB, Welch HG, Birkmeyer JD. Surgical mortality as an indicator of hospital quality: the problem with small sample size. JAMA 2004; 292:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/15\">",
"      Flum DR, Salem L, Elrod JA, et al. Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA 2005; 294:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/16\">",
"      Livingston EH, Langert J. The impact of age and Medicare status on bariatric surgical outcomes. Arch Surg 2006; 141:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/17\">",
"      Hollenbeak CS, Rogers AM, Barrus B, et al. Surgical volume impacts bariatric surgery mortality: a case for centers of excellence. Surgery 2008; 144:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/18\">",
"      Arterburn D, Livingston EH, Schifftner T, et al. Predictors of long-term mortality after bariatric surgery performed in Veterans Affairs medical centers. Arch Surg 2009; 144:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/19\">",
"      Lancaster RT, Hutter MM. Bands and bypasses: 30-day morbidity and mortality of bariatric surgical procedures as assessed by prospective, multi-center, risk-adjusted ACS-NSQIP data. Surg Endosc 2008; 22:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/20\">",
"      Mohr CJ, Nadzam GS, Curet MJ. Totally robotic Roux-en-Y gastric bypass. Arch Surg 2005; 140:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/21\">",
"      Mohr CJ, Nadzam GS, Alami RS, et al. Totally robotic laparoscopic Roux-en-Y Gastric bypass: results from 75 patients. Obes Surg 2006; 16:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/22\">",
"      Sanchez BR, Mohr CJ, Morton JM, et al. Comparison of totally robotic laparoscopic Roux-en-Y gastric bypass and traditional laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/23\">",
"      DeMaria EJ, Portenier D, Wolfe L. Obesity surgery mortality risk score: proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass. Surg Obes Relat Dis 2007; 3:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/24\">",
"      DeMaria EJ, Murr M, Byrne TK, et al. Validation of the obesity surgery mortality risk score in a multicenter study proves it stratifies mortality risk in patients undergoing gastric bypass for morbid obesity. Ann Surg 2007; 246:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/25\">",
"      Powers KA, Rehrig ST, Jones DB. Financial impact of obesity and bariatric surgery. Med Clin North Am 2007; 91:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/26\">",
"      Saunders JK, Ballantyne GH, Belsley S, et al. 30-day readmission rates at a high volume bariatric surgery center: laparoscopic adjustable gastric banding, laparoscopic gastric bypass, and vertical banded gastroplasty-Roux-en-Y gastric bypass. Obes Surg 2007; 17:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/27\">",
"      Pratt GM, Learn CA, Hughes GD, et al. Demographics and outcomes at American Society for Metabolic and Bariatric Surgery Centers of Excellence. Surg Endosc 2009; 23:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/28\">",
"      Smith MD, Patterson E, Wahed AS, et al. Relationship between surgeon volume and adverse outcomes after RYGB in Longitudinal Assessment of Bariatric Surgery (LABS) study. Surg Obes Relat Dis 2010; 6:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/29\">",
"      Zingmond DS, McGory ML, Ko CY. Hospitalization before and after gastric bypass surgery. JAMA 2005; 294:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/30\">",
"      Saunders J, Ballantyne GH, Belsley S, et al. One-year readmission rates at a high volume bariatric surgery center: laparoscopic adjustable gastric banding, laparoscopic gastric bypass, and vertical banded gastroplasty-Roux-en-Y gastric bypass. Obes Surg 2008; 18:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/31\">",
"      Kothari SN, DeMaria EJ, Sugerman HJ, et al. Lap-band failures: conversion to gastric bypass and their preliminary outcomes. Surgery 2002; 131:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/32\">",
"      Schwartz ML, Drew RL, Andersen JN. Induction of pneumoperitoneum in morbidly obese patients. Obes Surg 2003; 13:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/33\">",
"      Madan AK, Taddeucci RJ, Harper JL, Tichansky DS. Initial trocar placement and abdominal insufflation in laparoscopic bariatric surgery. J Surg Res 2008; 148:210.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, DB, Schneider, BE, Maithel ,SK. Atlas of Minimally Invasive Surgery. Cine-Med Inc, Woodbury 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/35\">",
"      Ahmad G, Duffy JM, Phillips K, Watson A. Laparoscopic entry techniques. Cochrane Database Syst Rev 2008; :CD006583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/36\">",
"      Peters TG, Steinmetz SR, Cowan GS Jr. Splenic injury and repair during bariatric surgical procedures. South Med J 1990; 83:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/37\">",
"      Huerta S, Li Z, Livingston EH. Outcome of portal injuries following bariatric operations. Obes Surg 2006; 16:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/38\">",
"      Mitchell MT, Gasparaitis AE, Alverdy JC. Imaging findings in Roux-en-O and other misconstructions: rare but serious complications of Roux-en-Y gastric bypass surgery. AJR Am J Roentgenol 2008; 190:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/39\">",
"      Melinek J, Livingston E, Cortina G, Fishbein MC. Autopsy findings following gastric bypass surgery for morbid obesity. Arch Pathol Lab Med 2002; 126:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/40\">",
"      Schauer P, Ikramuddin S, Hamad G, Gourash W. The learning curve for laparoscopic Roux-en-Y gastric bypass is 100 cases. Surg Endosc 2003; 17:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/41\">",
"      Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up. Obes Surg 2000; 10:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/42\">",
"      Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000; 232:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/43\">",
"      Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg 2001; 234:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/44\">",
"      Westling A, Gustavsson S. Laparoscopic vs open Roux-en-Y gastric bypass: a prospective, randomized trial. Obes Surg 2001; 11:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/45\">",
"      Nguyen NT, Ho HS, Palmer LS, Wolfe BM. A comparison study of laparoscopic versus open gastric bypass for morbid obesity. J Am Coll Surg 2000; 191:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/46\">",
"      Higa KD, Boone KB, Ho T. Complications of the laparoscopic Roux-en-Y gastric bypass: 1,040 patients--what have we learned? Obes Surg 2000; 10:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/47\">",
"      Papasavas PK, Hayetian FD, Caushaj PF, et al. Outcome analysis of laparoscopic Roux-en-Y gastric bypass for morbid obesity. The first 116 cases. Surg Endosc 2002; 16:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/48\">",
"      Luj&aacute;n JA, Hernandez Q, Frutos MD, et al. Laparoscopic gastric bypass in the treatment of morbid obesity. Preliminary results of a new technique. Surg Endosc 2002; 16:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/49\">",
"      Mehran A, Szomstein S, Zundel N, Rosenthal R. Management of acute bleeding after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2003; 13:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/50\">",
"      Nguyen NT, Rivers R, Wolfe BM. Early gastrointestinal hemorrhage after laparoscopic gastric bypass. Obes Surg 2003; 13:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/51\">",
"      Derzie AJ, Silvestri F, Liriano E, Benotti P. Wound closure technique and acute wound complications in gastric surgery for morbid obesity: a prospective randomized trial. J Am Coll Surg 2000; 191:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/52\">",
"      Bohdjalian A, Langer FB, Kranner A, et al. Circular- vs. linear-stapled gastrojejunostomy in laparoscopic Roux-en-Y gastric bypass. Obes Surg 2010; 20:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/53\">",
"      Shang E, Hasenberg T, Magdeburg R, et al. First experiences with A circular stapled gastro-jejunostomy by a new transorally introducible stapler system in laparoscopic Roux-en-Y gastric bypass. Obes Surg 2009; 19:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/54\">",
"      Pories WJ, van Rij AM, Burlingham BT, et al. Prophylactic cefazolin in gastric bypass surgery. Surgery 1981; 90:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/55\">",
"      Lim RB, Blackburn GL, Jones DB. Benchmarking best practices in weight loss surgery. Curr Probl Surg 2010; 47:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/56\">",
"      Schneider BE, Villegas L, Blackburn GL, et al. Laparoscopic gastric bypass surgery: outcomes. J Laparoendosc Adv Surg Tech A 2003; 13:247.",
"     </a>",
"    </li>",
"    <li>",
"     Gonzalez, R, Murr, MM. Anastomotic leaks following gastric bypass surgery. In: Weight Loss Surgery: A Multidisciplinary Approach, Jones, DB, Rosenthal, R (Eds), Matrix Medical Communications, Edgemont 2008. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/58\">",
"      Shikora SA, Kim JJ, Tarnoff ME. Reinforcing gastric staple-lines with bovine pericardial strips may decrease the likelihood of gastric leak after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2003; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/59\">",
"      Liu CD, Glantz GJ, Livingston EH. Fibrin glue as a sealant for high-risk anastomosis in surgery for morbid obesity. Obes Surg 2003; 13:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/60\">",
"      Shikora SA. The use of staple-line reinforcement during laparoscopic gastric bypass. Obes Surg 2004; 14:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/61\">",
"      Shikora SA, Kim JJ, Tarnoff ME. Comparison of permanent and nonpermanent staple line buttressing materials for linear gastric staple lines during laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2008; 4:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/62\">",
"      Fullum TM, Aluka KJ, Turner PL. Decreasing anastomotic and staple line leaks after laparoscopic Roux-en-Y gastric bypass. Surg Endosc 2009; 23:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/63\">",
"      Miller KA, Pump A. Use of bioabsorbable staple reinforcement material in gastric bypass: a prospective randomized clinical trial. Surg Obes Relat Dis 2007; 3:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/64\">",
"      Sapala JA, Wood MH, Schuhknecht MP. Anastomotic leak prophylaxis using a vapor-heated fibrin sealant: report on 738 gastric bypass patients. Obes Surg 2004; 14:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/65\">",
"      Livingston EH, Liu CY, Glantz G, Li Z. Characteristics of bariatric surgery in an integrated VA Health Care System: follow-up and outcomes. J Surg Res 2003; 109:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/66\">",
"      Madan AK, Stoecklein HH, Ternovits CA, et al. Predictive value of upper gastrointestinal studies versus clinical signs for gastrointestinal leaks after laparoscopic gastric bypass. Surg Endosc 2007; 21:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/67\">",
"      Raman R, Raman B, Raman P, et al. Abnormal findings on routine upper GI series following laparoscopic Roux-en-Y gastric bypass. Obes Surg 2007; 17:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/68\">",
"      Sims TL, Mullican MA, Hamilton EC, et al. Routine upper gastrointestinal Gastrografin swallow after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2003; 13:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/69\">",
"      Doraiswamy A, Rasmussen JJ, Pierce J, et al. The utility of routine postoperative upper GI series following laparoscopic gastric bypass. Surg Endosc 2007; 21:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/70\">",
"      White S, Han SH, Lewis C, et al. Selective approach to use of upper gastroesophageal imaging study after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2008; 4:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/71\">",
"      Hamilton EC, Sims TL, Hamilton TT, et al. Clinical predictors of leak after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Surg Endosc 2003; 17:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/72\">",
"      Thodiyil PA, Yenumula P, Rogula T, et al. Selective nonoperative management of leaks after gastric bypass: lessons learned from 2675 consecutive patients. Ann Surg 2008; 248:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/73\">",
"      Gonzalez R, Sarr MG, Smith CD, et al. Diagnosis and contemporary management of anastomotic leaks after gastric bypass for obesity. J Am Coll Surg 2007; 204:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/74\">",
"      Marshall JS, Srivastava A, Gupta SK, et al. Roux-en-Y gastric bypass leak complications. Arch Surg 2003; 138:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/75\">",
"      Durak E, Inabnet WB, Schrope B, et al. Incidence and management of enteric leaks after gastric bypass for morbid obesity during a 10-year period. Surg Obes Relat Dis 2008; 4:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/76\">",
"      Merrifield BF, Lautz D, Thompson CC. Endoscopic repair of gastric leaks after Roux-en-Y gastric bypass: a less invasive approach. Gastrointest Endosc 2006; 63:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/77\">",
"      Fukumoto R, Orlina J, McGinty J, Teixeira J. Use of Polyflex stents in treatment of acute esophageal and gastric leaks after bariatric surgery. Surg Obes Relat Dis 2007; 3:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/78\">",
"      Podnos YD, Jimenez JC, Wilson SE, et al. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg 2003; 138:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/79\">",
"      Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes Surg 2003; 13:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/80\">",
"      Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg 2000; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/81\">",
"      Caruana JA, Anain PM, Pham DT. The pulmonary embolism risk score system reduces the incidence and mortality of pulmonary embolism after gastric bypass. Surgery 2009; 146:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/82\">",
"      Gagner M, Milone L, Yung E, et al. Causes of early mortality after laparoscopic adjustable gastric banding. J Am Coll Surg 2008; 206:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/83\">",
"      Morino M, Toppino M, Forestieri P, et al. Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg 2007; 246:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/84\">",
"      Huerta S, DeShields S, Shpiner R, et al. Safety and efficacy of postoperative continuous positive airway pressure to prevent pulmonary complications after Roux-en-Y gastric bypass. J Gastrointest Surg 2002; 6:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/85\">",
"      Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007; 132:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/86\">",
"      Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: an 18-year report from the International Bariatric Surgery Registry. Am J Surg 2006; 192:657.",
"     </a>",
"    </li>",
"    <li>",
"     ASMBS. The Story of Surgery for Obesity. Brief History and Summary of Bariatric Surgery. Chapter 3: Gastric Bypass. Available online at: www.asbs.org/html/patients/bypass.html (Accessed on April 1, 2009).",
"    </li>",
"    <li>",
"     Jacobs, DO, Robinson, MK. Morbid obesity and operations for morbid obesity. In: Maingot's abdominal operations, 11th ed, Zinner, MJ, Ashley, SW (Eds), McGraw Hill, New York 2007. p. 471.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/89\">",
"      Lee S, Carmody B, Wolfe L, et al. Effect of location and speed of diagnosis on anastomotic leak outcomes in 3828 gastric bypass cases. J Gastrointest Surg 2007; 11:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/90\">",
"      Papasavas PK, Yeaney WW, Caushaj PF, et al. Perforation in the bypassed stomach following laparoscopic Roux-en-Y gastric bypass. Obes Surg 2003; 13:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/91\">",
"      Gagner M, Gentileschi P, de Csepel J, et al. Laparoscopic reoperative bariatric surgery: experience from 27 consecutive patients. Obes Surg 2002; 12:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/92\">",
"      Barba CA, Butensky MS, Lorenzo M, Newman R. Endoscopic dilation of gastroesophageal anastomosis stricture after gastric bypass. Surg Endosc 2003; 17:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/93\">",
"      Sanyal AJ, Sugerman HJ, Kellum JM, et al. Stomal complications of gastric bypass: incidence and outcome of therapy. Am J Gastroenterol 1992; 87:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/94\">",
"      Go MR, Muscarella P 2nd, Needleman BJ, et al. Endoscopic management of stomal stenosis after Roux-en-Y gastric bypass. Surg Endosc 2004; 18:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/95\">",
"      Sapala JA, Wood MH, Sapala MA, Flake TM Jr. Marginal ulcer after gastric bypass: a prospective 3-year study of 173 patients. Obes Surg 1998; 8:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/96\">",
"      Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery. Surg Obes Relat Dis 2006; 2:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/97\">",
"      DeMaria EJ, Sugerman HJ, Kellum JM, et al. Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity. Ann Surg 2002; 235:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/98\">",
"      Gumbs AA, Duffy AJ, Bell RL. Incidence and management of marginal ulceration after laparoscopic Roux-Y gastric bypass. Surg Obes Relat Dis 2006; 2:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/99\">",
"      Sataloff DM, Lieber CP, Seinige UL. Strictures following gastric stapling for morbid obesity. Results of endoscopic dilatation. Am Surg 1990; 56:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/100\">",
"      Rasmussen JJ, Fuller W, Ali MR. Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients. Surg Endosc 2007; 21:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/101\">",
"      Schirmer B, Erenoglu C, Miller A. Flexible endoscopy in the management of patients undergoing Roux-en-Y gastric bypass. Obes Surg 2002; 12:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/102\">",
"      Csendes A, Burgos AM, Smok G, Beltran M. Endoscopic and histologic findings of the foregut in 426 patients with morbid obesity. Obes Surg 2007; 17:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/103\">",
"      Ramaswamy A, Lin E, Ramshaw BJ, Smith CD. Early effects of Helicobacter pylori infection in patients undergoing bariatric surgery. Arch Surg 2004; 139:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/104\">",
"      Printen KJ, Scott D, Mason EE. Stomal ulcers after gastric bypass. Arch Surg 1980; 115:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/105\">",
"      Shiffman ML, Sugerman HJ, Kellum JM, et al. Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol 1991; 86:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/106\">",
"      Shiffman ML, Sugerman HJ, Kellum JM, Moore EW. Changes in gallbladder bile composition following gallstone formation and weight reduction. Gastroenterology 1992; 103:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/107\">",
"      Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg 1995; 169:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/108\">",
"      Villegas L, Schneider B, Provost D, et al. Is routine cholecystectomy required during laparoscopic gastric bypass? Obes Surg 2004; 14:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/109\">",
"      Hamad GG, Ikramuddin S, Gourash WF, Schauer PR. Elective cholecystectomy during laparoscopic Roux-en-Y gastric bypass: is it worth the wait? Obes Surg 2003; 13:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/110\">",
"      Baron TH, Vickers SM. Surgical gastrostomy placement as access for diagnostic and therapeutic ERCP. Gastrointest Endosc 1998; 48:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/111\">",
"      Wright BE, Cass OW, Freeman ML. ERCP in patients with long-limb Roux-en-Y gastrojejunostomy and intact papilla. Gastrointest Endosc 2002; 56:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/112\">",
"      Fobi MA, Chicola K, Lee H. Access to the bypassed stomach after gastric bypass. Obes Surg 1998; 8:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/113\">",
"      Gutierrez JM, Lederer H, Krook JC, et al. Surgical gastrostomy for pancreatobiliary and duodenal access following Roux en Y gastric bypass. J Gastrointest Surg 2009; 13:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/114\">",
"      Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/115\">",
"      Champion JK, Williams M. Small bowel obstruction and internal hernias after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2003; 13:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/116\">",
"      Higa KD, Ho T, Boone KB. Internal hernias after laparoscopic Roux-en-Y gastric bypass: incidence, treatment and prevention. Obes Surg 2003; 13:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/117\">",
"      Nguyen NT, Huerta S, Gelfand D, et al. Bowel obstruction after laparoscopic Roux-en-Y gastric bypass. Obes Surg 2004; 14:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/118\">",
"      Iannuccilli JD, Grand D, Murphy BL, et al. Sensitivity and specificity of eight CT signs in the preoperative diagnosis of internal mesenteric hernia following Roux-en-Y gastric bypass surgery. Clin Radiol 2009; 64:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/119\">",
"      Lockhart ME, Tessler FN, Canon CL, et al. Internal hernia after gastric bypass: sensitivity and specificity of seven CT signs with surgical correlation and controls. AJR Am J Roentgenol 2007; 188:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/120\">",
"      McBride CL, Petersen A, Sudan D, Thompson J. Short bowel syndrome following bariatric surgical procedures. Am J Surg 2006; 192:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/121\">",
"      Fishbein TM. Intestinal transplantation. N Engl J Med 2009; 361:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/122\">",
"      Ukleja A. Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract 2005; 20:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/123\">",
"      MATHEWS DH, LAWRENCE W Jr, POPPELL JW, et al. Change in effective circulating volume during experimental dumping syndrome. Surgery 1960; 48:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/124\">",
"      Nasr SH, D'Agati VD, Said SM, et al. Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol 2008; 3:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/125\">",
"      Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/126\">",
"      Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/127\">",
"      Clancy TE, Moore FD Jr, Zinner MJ. Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 2006; 10:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/128\">",
"      Kellogg TA, Bantle JP, Leslie DB, et al. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 2008; 4:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/129\">",
"      Z'graggen K, Guweidhi A, Steffen R, et al. Severe recurrent hypoglycemia after gastric bypass surgery. Obes Surg 2008; 18:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/130\">",
"      Potoczna N, Harfmann S, Steffen R, et al. Bowel habits after bariatric surgery. Obes Surg 2008; 18:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/131\">",
"      Kalarchian MA, Marcus MD, Wilson GT, et al. Binge eating among gastric bypass patients at long-term follow-up. Obes Surg 2002; 12:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/132\">",
"      Capella JF, Capella RF. Gastro-gastric fistulas and marginal ulcers in gastric bypass procedures for weight reduction. Obes Surg 1999; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/133\">",
"      Carrodeguas L, Szomstein S, Soto F, et al. Management of gastrogastric fistulas after divided Roux-en-Y gastric bypass surgery for morbid obesity: analysis of 1,292 consecutive patients and review of literature. Surg Obes Relat Dis 2005; 1:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/134\">",
"      MacLean LD, Rhode BM, Nohr C, et al. Stomal ulcer after gastric bypass. J Am Coll Surg 1997; 185:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/135\">",
"      Sugerman HJ, Wolper JL. Failed gastroplasty for morbid obesity. Revised gastroplasty versus Roux-Y gastric bypass. Am J Surg 1984; 148:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/136\">",
"      Eisendrath P, Cremer M, Himpens J, et al. Endotherapy including temporary stenting of fistulas of the upper gastrointestinal tract after laparoscopic bariatric surgery. Endoscopy 2007; 39:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/137\">",
"      Spaulding L. Treatment of dilated gastrojejunostomy with sclerotherapy. Obes Surg 2003; 13:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/138\">",
"      Thompson CC, Slattery J, Bundga ME, Lautz DB. Peroral endoscopic reduction of dilated gastrojejunal anastomosis after Roux-en-Y gastric bypass: a possible new option for patients with weight regain. Surg Endosc 2006; 20:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/139\">",
"      Hinojosa MW, Varela JE, Parikh D, et al. National trends in use and outcome of laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2009; 5:150.",
"     </a>",
"    </li>",
"    <li>",
"     Chapman, A, Kiroff, G, Game, P et al. Systematic review of laparoscopic adjustable gastric banding in the treatment of obesity. (ASERNIP-S report no. 31). Adelaide: Australian Safety and Efficacy Register of New Interventional Procedures-Surgical; 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/141\">",
"      DeMaria EJ, Sugerman HJ, Meador JG, et al. High failure rate after laparoscopic adjustable silicone gastric banding for treatment of morbid obesity. Ann Surg 2001; 233:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/142\">",
"      O'Brien PE, Dixon JB. Lap-band: outcomes and results. J Laparoendosc Adv Surg Tech A 2003; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Trial Summary of Safety and Effectivenes Data: The Lap-Band Adjustable Gastric Banding System (P000008). Available online at: www.accessdata.fda.gov/cdrh_docs/pdf/P000008b.pdf (Accessed on June 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/144\">",
"      Angrisani L, Furbetta F, Doldi SB, et al. Lap Band adjustable gastric banding system: the Italian experience with 1863 patients operated on 6 years. Surg Endosc 2003; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/145\">",
"      Himpens J, Cadi&egrave;re GB, Bazi M, et al. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 2011; 146:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/146\">",
"      Ren CJ, Horgan S, Ponce J. US experience with the LAP-BAND system. Am J Surg 2002; 184:46S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/147\">",
"      DeMaria EJ. Laparoscopic adjustable silicone gastric banding: complications. J Laparoendosc Adv Surg Tech A 2003; 13:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/148\">",
"      Png KS, Rao J, Lim KH, Chia KH. Lap-band causing left gastric artery erosion presenting with torrential hemorrhage. Obes Surg 2008; 18:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/149\">",
"      Gagner M. Roux-en-Y gastric bypass after previous unsuccessful gastric restrictive surgery. J Gastrointest Surg 2003; 7:429; author reply 429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/150\">",
"      de Csepel J, Quinn T, Pomp A, Gagner M. Conversion to a laparoscopic biliopancreatic diversion with a duodenal switch for failed laparoscopic adjustable silicone gastric banding. J Laparoendosc Adv Surg Tech A 2002; 12:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/151\">",
"      Romy S, Donadini A, Giusti V, Suter M. Roux-en-Y gastric bypass vs gastric banding for morbid obesity: a case-matched study of 442 patients. Arch Surg 2012; 147:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/152\">",
"      Gravante G, Araco A, Araco F, et al. Laparoscopic adjustable gastric bandings: a prospective randomized study of 400 operations performed with 2 different devices. Arch Surg 2007; 142:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/153\">",
"      Spivak H, Favretti F. Avoiding postoperative complications with the LAP-BAND system. Am J Surg 2002; 184:31S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/154\">",
"      Shen R, Ren CJ. Removal of peri-gastric fat prevents acute obstruction after Lap-Band surgery. Obes Surg 2004; 14:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/155\">",
"      Keidar A, Carmon E, Szold A, Abu-Abeid S. Port complications following laparoscopic adjustable gastric banding for morbid obesity. Obes Surg 2005; 15:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/156\">",
"      Cadi&egrave;re GB, Himpens J, Hainaux B, et al. Laparoscopic adjustable gastric banding. Semin Laparosc Surg 2002; 9:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/157\">",
"      Suter M, Giusti V, H&eacute;raief E, Calmes JM. Band erosion after laparoscopic gastric banding: occurrence and results after conversion to Roux-en-Y gastric bypass. Obes Surg 2004; 14:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/158\">",
"      Abu-Abeid S, Keidar A, Gavert N, et al. The clinical spectrum of band erosion following laparoscopic adjustable silicone gastric banding for morbid obesity. Surg Endosc 2003; 17:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/159\">",
"      Regusci L, Groebli Y, Meyer JL, et al. Gastroscopic removal of an adjustable gastric band after partial intragastric migration. Obes Surg 2003; 13:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/160\">",
"      Neto MP, Ramos AC, Campos JM, et al. Endoscopic removal of eroded adjustable gastric band: lessons learned after 5 years and 78 cases. Surg Obes Relat Dis 2010; 6:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/161\">",
"      Blero D, Eisendrath P, Vandermeeren A, et al. Endoscopic removal of dysfunctioning bands or rings after restrictive bariatric procedures. Gastrointest Endosc 2010; 71:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/162\">",
"      Rubenstein RB. Laparoscopic adjustable gastric banding at a U.S. center with up to 3-year follow-up. Obes Surg 2002; 12:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/163\">",
"      Ren CJ, Fielding GA. Laparoscopic adjustable gastric banding: surgical technique. J Laparoendosc Adv Surg Tech A 2003; 13:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/164\">",
"      Dargent J. Surgical treatment of morbid obesity by adjustable gastric band: the case for a conservative strategy in the case of failure - a 9-year series. Obes Surg 2004; 14:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/165\">",
"      Chevallier JM, Zinzindohou&eacute; F, Douard R, et al. Complications after laparoscopic adjustable gastric banding for morbid obesity: experience with 1,000 patients over 7 years. Obes Surg 2004; 14:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/166\">",
"      Sherwinter DA, Powers CJ, Geiss AC, et al. Posterior prolapse: an important entity even in the modern age of the pars flaccida approach to lap-band placement. Obes Surg 2006; 16:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/167\">",
"      Abuzeid AW, Banerjea A, Timmis B, Hashemi M. Gastric slippage as an emergency: diagnosis and management. Obes Surg 2007; 17:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/168\">",
"      Dargent J. Laparoscopic adjustable gastric banding: lessons from the first 500 patients in a single institution. Obes Surg 1999; 9:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/169\">",
"      Fabry H, Van Hee R, Hendrickx L, Tott&eacute; E. A technique for prevention of port complications after laparoscopic adjustable silicone gastric banding. Obes Surg 2002; 12:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/170\">",
"      Poole N, Al Atar A, Bidlake L, et al. Pouch dilatation following laparoscopic adjustable gastric banding: psychobehavioral factors (can psychiatrists predict pouch dilatation?). Obes Surg 2004; 14:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/171\">",
"      Gulkarov I, Wetterau M, Ren CJ, Fielding GA. Hiatal hernia repair at the initial laparoscopic adjustable gastric band operation reduces the need for reoperation. Surg Endosc 2008; 22:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/172\">",
"      Regan JP, Inabnet WB, Gagner M, Pomp A. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg 2003; 13:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/173\">",
"      Cottam D, Qureshi FG, Mattar SG, et al. Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. Surg Endosc 2006; 20:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/174\">",
"      Chazelet C, Verhaeghe P, Perterli R, et al. [Longitudinal sleeve gastrectomy as a stand-alone bariatric procedure: Results of a multicenter retrospective study]. J Chir (Paris) 2009; 146:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/175\">",
"      Sammour T, Hill AG, Singh P, et al. Laparoscopic sleeve gastrectomy as a single-stage bariatric procedure. Obes Surg 2010; 20:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/176\">",
"      Tucker ON, Szomstein S, Rosenthal RJ. Indications for sleeve gastrectomy as a primary procedure for weight loss in the morbidly obese. J Gastrointest Surg 2008; 12:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/177\">",
"      Fuks D, Verhaeghe P, Brehant O, et al. Results of laparoscopic sleeve gastrectomy: a prospective study in 135 patients with morbid obesity. Surgery 2009; 145:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/178\">",
"      Gagner M, Deitel M, Kalberer TL, et al. The Second International Consensus Summit for Sleeve Gastrectomy, March 19-21, 2009. Surg Obes Relat Dis 2009; 5:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/179\">",
"      Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/180\">",
"      Langer FB, Reza Hoda MA, Bohdjalian A, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 2005; 15:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/181\">",
"      Lalor PF, Tucker ON, Szomstein S, Rosenthal RJ. Complications after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis 2008; 4:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/182\">",
"      Moon Han S, Kim WW, Oh JH. Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients. Obes Surg 2005; 15:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/183\">",
"      Himpens J, Dapri G, Cadi&egrave;re GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg 2006; 16:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/184\">",
"      Silecchia G, Boru C, Pecchia A, et al. Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. Obes Surg 2006; 16:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/185\">",
"      Lee CM, Cirangle PT, Jossart GH. Vertical gastrectomy for morbid obesity in 216 patients: report of two-year results. Surg Endosc 2007; 21:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/186\">",
"      Hamoui N, Anthone GJ, Kaufman HS, Crookes PF. Sleeve gastrectomy in the high-risk patient. Obes Surg 2006; 16:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/187\">",
"      Armstrong J, O'Malley SP. Outcomes of sleeve gastrectomy for morbid obesity: a safe and effective procedure? Int J Surg 2010; 8:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/188\">",
"      Trelles, N, Gagner, M. Sleeve gastrectomy. Operative Techniques in General Surgery 2007; 9:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/189\">",
"      Baltasar A, Serra C, P&eacute;rez N, et al. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. Obes Surg 2005; 15:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/190\">",
"      Frezza EE, Reddy S, Gee LL, Wachtel MS. Complications after sleeve gastrectomy for morbid obesity. Obes Surg 2009; 19:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/191\">",
"      Consten EC, Gagner M, Pomp A, Inabnet WB. Decreased bleeding after laparoscopic sleeve gastrectomy with or without duodenal switch for morbid obesity using a stapled buttressed absorbable polymer membrane. Obes Surg 2004; 14:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/192\">",
"      Dapri G, Cadi&egrave;re GB, Himpens J. Laparoscopic seromyotomy for long stenosis after sleeve gastrectomy with or without duodenal switch. Obes Surg 2009; 19:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/193\">",
"      Dapri G, Vaz C, Cadi&egrave;re GB, Himpens J. A prospective randomized study comparing two different techniques for laparoscopic sleeve gastrectomy. Obes Surg 2007; 17:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/194\">",
"      Lee CW, Kelly JJ, Wassef WY. Complications of bariatric surgery. Curr Opin Gastroenterol 2007; 23:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/195\">",
"      Arias E, Mart&iacute;nez PR, Ka Ming Li V, et al. Mid-term follow-up after sleeve gastrectomy as a final approach for morbid obesity. Obes Surg 2009; 19:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/196\">",
"      Burgos AM, Braghetto I, Csendes A, et al. Gastric leak after laparoscopic-sleeve gastrectomy for obesity. Obes Surg 2009; 19:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/197\">",
"      Roa PE, Kaidar-Person O, Pinto D, et al. Laparoscopic sleeve gastrectomy as treatment for morbid obesity: technique and short-term outcome. Obes Surg 2006; 16:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/198\">",
"      Weiner RA, Weiner S, Pomhoff I, et al. Laparoscopic sleeve gastrectomy--influence of sleeve size and resected gastric volume. Obes Surg 2007; 17:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/199\">",
"      Melissas J, Koukouraki S, Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg 2007; 17:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/200\">",
"      Felberbauer FX, Langer F, Shakeri-Manesch S, et al. Laparoscopic sleeve gastrectomy as an isolated bariatric procedure: intermediate-term results from a large series in three Austrian centers. Obes Surg 2008; 18:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/201\">",
"      Braghetto I, Korn O, Valladares H, et al. Laparoscopic sleeve gastrectomy: surgical technique, indications and clinical results. Obes Surg 2007; 17:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/202\">",
"      Chen B, Kiriakopoulos A, Tsakayannis D, et al. Reinforcement does not necessarily reduce the rate of staple line leaks after sleeve gastrectomy. A review of the literature and clinical experiences. Obes Surg 2009; 19:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/203\">",
"      Yehoshua RT, Eidelman LA, Stein M, et al. Laparoscopic sleeve gastrectomy--volume and pressure assessment. Obes Surg 2008; 18:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/204\">",
"      Eubanks S, Edwards CA, Fearing NM, et al. Use of endoscopic stents to treat anastomotic complications after bariatric surgery. J Am Coll Surg 2008; 206:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/205\">",
"      Serra C, Baltasar A, Andreo L, et al. Treatment of gastric leaks with coated self-expanding stents after sleeve gastrectomy. Obes Surg 2007; 17:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/206\">",
"      Oshiro T, Kasama K, Umezawa A, et al. Successful management of refractory staple line leakage at the esophagogastric junction after a sleeve gastrectomy using the HANAROSTENT. Obes Surg 2010; 20:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/207\">",
"      Casella G, Soricelli E, Rizzello M, et al. Nonsurgical treatment of staple line leaks after laparoscopic sleeve gastrectomy. Obes Surg 2009; 19:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/208\">",
"      Keidar A, Appelbaum L, Schweiger C, et al. Dilated upper sleeve can be associated with severe postoperative gastroesophageal dysmotility and reflux. Obes Surg 2010; 20:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/209\">",
"      Langer FB, Bohdjalian A, Shakeri-Leidenm&uuml;hler S, et al. Conversion from sleeve gastrectomy to Roux-en-Y gastric bypass--indications and outcome. Obes Surg 2010; 20:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/210\">",
"      Mason EE. Vertical banded gastroplasty for obesity. Arch Surg 1982; 117:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/211\">",
"      Balsiger BM, Murr MM, Poggio JL, Sarr MG. Bariatric surgery. Surgery for weight control in patients with morbid obesity. Med Clin North Am 2000; 84:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/212\">",
"      Nightengale ML, Sarr MG, Kelly KA, et al. Prospective evaluation of vertical banded gastroplasty as the primary operation for morbid obesity. Mayo Clin Proc 1991; 66:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/213\">",
"      Sugerman HJ, Sugerman EL, DeMaria EJ, et al. Bariatric surgery for severely obese adolescents. J Gastrointest Surg 2003; 7:102.",
"     </a>",
"    </li>",
"    <li>",
"     Gonzalez RJ. Weight Loss Surgery: A multidisciplinary approach. Matrix Medical Communications, Edgemont 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/215\">",
"      MacLean LD, Rhode BM, Sampalis J, Forse RA. Results of the surgical treatment of obesity. Am J Surg 1993; 165:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/216\">",
"      Calmes JM, Giusti V, Suter M. Reoperative laparoscopic Roux-en-Y gastric bypass: an experience with 49 cases. Obes Surg 2005; 15:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/217\">",
"      Sugerman HJ, Kellum JM Jr, DeMaria EJ, Reines HD. Conversion of failed or complicated vertical banded gastroplasty to gastric bypass in morbid obesity. Am J Surg 1996; 171:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/218\">",
"      Suter M, Jayet C, Jayet A. Vertical banded gastroplasty: long-term results comparing three different techniques. Obes Surg 2000; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/219\">",
"      Moreno P, Alastru&eacute; A, Rull M, et al. Band erosion in patients who have undergone vertical banded gastroplasty: incidence and technical solutions. Arch Surg 1998; 133:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/220\">",
"      Balsiger BM, Murr MM, Mai J, Sarr MG. Gastroesophageal reflux after intact vertical banded gastroplasty: correction by conversion to Roux-en-Y gastric bypass. J Gastrointest Surg 2000; 4:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/221\">",
"      Balsiger BM, Poggio JL, Mai J, et al. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. J Gastrointest Surg 2000; 4:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/222\">",
"      Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/223\">",
"      Guedea ME, Arribas del Amo D, Solanas JA, et al. Results of biliopancreatic diversion after five years. Obes Surg 2004; 14:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/224\">",
"      Ren CJ, Patterson E, Gagner M. Early results of laparoscopic biliopancreatic diversion with duodenal switch: a case series of 40 consecutive patients. Obes Surg 2000; 10:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/225\">",
"      Prachand VN, Ward M, Alverdy JC. Duodenal switch provides superior resolution of metabolic comorbidities independent of weight loss in the super-obese (BMI &gt; or = 50 kg/m2) compared with gastric bypass. J Gastrointest Surg 2010; 14:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/226\">",
"      Prachand VN, Davee RT, Alverdy JC. Duodenal switch provides superior weight loss in the super-obese (BMI &gt; or =50 kg/m2) compared with gastric bypass. Ann Surg 2006; 244:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/227\">",
"      Griffen WO Jr, Bivins BA, Bell RM. The decline and fall of the jejunoileal bypass. Surg Gynecol Obstet 1983; 157:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/228\">",
"      Hocking MP, Davis GL, Franzini DA, Woodward ER. Long-term consequences after jejunoileal bypass for morbid obesity. Dig Dis Sci 1998; 43:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/229\">",
"      D'Souza-Gburek SM, Batts KP, Nikias GA, et al. Liver transplantation for jejunoileal bypass-associated cirrhosis: allograft histology in the setting of an intact bypassed limb. Liver Transpl Surg 1997; 3:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/230\">",
"      Kroyer JM, Talbert WM Jr. Morphologic liver changes in intestinal bypass patients. Am J Surg 1980; 139:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/231\">",
"      Styblo T, Martin S, Kaminski DL. The effects of reversal of jejunoileal bypass operations on hepatic triglyceride content and hepatic morphology. Surgery 1984; 96:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/232\">",
"      Markowitz JS, Seu P, Goss JA, et al. Liver transplantation for decompensated cirrhosis after jejunoileal bypass: a strategy for management. Transplantation 1998; 65:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/233\">",
"      Lowell JA, Shenoy S, Ghalib R, et al. Liver transplantation after jejunoileal bypass for morbid obesity. J Am Coll Surg 1997; 185:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/234\">",
"      Vyberg M, Ravn V, Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity. Liver 1987; 7:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/235\">",
"      Halverson JD, Wise L, Wazna MF, Ballinger WF. Jejunoileal bypass for morbid obesity. A critical appraisal. Am J Med 1978; 64:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/236\">",
"      Clayman RV, Williams RD. Oxalate urolithiasis following jejunoileal bypass. Surg Clin North Am 1979; 59:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/237\">",
"      Deitel M, Shahi B, Anand PK, et al. Long-term Outcome in a Series of Jejunoileal Bypass Patients. Obes Surg 1993; 3:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/238\">",
"      Requarth JA, Burchard KW, Colacchio TA, et al. Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal. Arch Surg 1995; 130:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/239\">",
"      Dean P, Joshi S, Kaminski DL. Long-term outcome of reversal of small intestinal bypass operations. Am J Surg 1990; 159:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/58/41898/abstract/240\">",
"      Hocking MP, Duerson MC, O'Leary JP, Woodward ER. Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases. N Engl J Med 1983; 308:995.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 585 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41898=[""].join("\n");
var outline_f40_58_41898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H60\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Older age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Male gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Chronic disease and superobesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Low-volume surgeons and hospitals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Surgical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Predicting mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      REHOSPITALIZATION AND REOPERATION RATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTRAOPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Trocar injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Splenic injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Portal vein injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bowel ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Misconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EARLY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Wound infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Leaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pulmonary embolism and deep venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cardiovascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LATE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COMPLICATIONS OF SPECIFIC BARIATRIC PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Roux-en-Y gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Gastric remnant distension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Stomal stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Marginal ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Cholelithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Ventral incisional hernia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Internal hernias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Short bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Dumping syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Metabolic and nutritional derangements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14879976\">",
"      - Renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Postoperative hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Change in bowel habits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Failure to lose weight and weight regain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Gastric banding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Stomal obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Port infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Band erosion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Band slippage and gastric prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Port malfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Esophagitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Esophageal dilatation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1199440331\">",
"      - Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Sleeve gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88503966\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88503973\">",
"      - Stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88503994\">",
"      - Gastric leaks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32787735\">",
"      - Reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Vertical banded gastroplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      - Staple line disruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      - Obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      - Erosion of mesh band",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      - Reflux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - Vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Biliopancreatic diversion and duodenal switch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Jejunoileal bypass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      - Electrolyte imbalances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      - Renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      - Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/585\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/585|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/49/26392\" title=\"diagnostic image 1\">",
"      Connected Roux-en-O misconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/14/18664\" title=\"diagnostic image 2\">",
"      Disconnected Roux-en-O misconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/1/5144\" title=\"diagnostic image 3\">",
"      Roux limb inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/11/183\" title=\"diagnostic image 4\">",
"      Short Roux limb misconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/18/44334\" title=\"diagnostic image 5\">",
"      Leak after gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/30/41441\" title=\"diagnostic image 6\">",
"      Mesenteric swirl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/24/44431\" title=\"diagnostic image 7\">",
"      Hiatal hernia after gastric banding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/585|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/34/16932\" title=\"figure 1\">",
"      Internal herniations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/24/31104\" title=\"figure 2\">",
"      Connected Roux-en-O misconstruction depiction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/38/42592\" title=\"figure 3\">",
"      Disconnected Roux-en-O misconstruction figure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/63/3062\" title=\"figure 4\">",
"      Roux-en-Y limb inversion following Roux-en-Y bypass procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/60/1985\" title=\"figure 5\">",
"      Misconstruction short Roux-en-Y limb misconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/50/36641\" title=\"figure 6\">",
"      Treatment of a leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/10/25761\" title=\"figure 7\">",
"      Components of Roux-en-Y gastric bypass procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/35/33329\" title=\"figure 8\">",
"      Roux en Y gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/54/22368\" title=\"figure 9\">",
"      Adjustable gastric band",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/13/11472\" title=\"figure 10\">",
"      Gastric erosion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/24/12673\" title=\"figure 11\">",
"      Gastric prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/40/36480\" title=\"figure 12\">",
"      Sleeve gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/28/36303\" title=\"figure 13\">",
"      Vertical band gastroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/53/19284\" title=\"figure 14\">",
"      Biliopancreatic diversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/33/19987\" title=\"figure 15\">",
"      Duodenal switch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/34/24098\" title=\"figure 16\">",
"      Jejunoileal bypass",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28489?source=related_link\">",
"      Endoscopy in patients who have undergone bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3993?source=related_link\">",
"      Extrahepatic portal vein obstruction (portal vein thrombosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7527?source=related_link\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./imaging-studies-after-bariatric-surgery?source=related_link\">",
"      Imaging studies after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26362?source=related_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44614?source=related_link\">",
"      Noninsulinoma pancreatogenous hypoglycemia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30601?source=related_link\">",
"      Pathophysiology of the short bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/11/3255?source=related_link\">",
"      Postprandial (reactive) hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=related_link\">",
"      Surgical management of complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_58_41899="Common headache syndromes";
var content_f40_58_41899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of common headache syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Migraine headache",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tension headache",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cluster headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Location",
"       </td>",
"       <td>",
"        Unilateral in 60 to 70 percent; bifrontal or global in 30 percent",
"       </td>",
"       <td>",
"        Bilateral",
"       </td>",
"       <td>",
"        Always unilateral, usually begins around the eye or temple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Characteristics",
"       </td>",
"       <td>",
"        Gradual in onset, crescendo pattern; pulsating; moderate or severe intensity; aggravated by routine physical activity",
"       </td>",
"       <td>",
"        Pressure or tightness which waxes and wanes",
"       </td>",
"       <td>",
"        Pain begins quickly, reaches a crescendo within minutes; pain is deep, continuous, excruciating, and explosive in quality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient appearance",
"       </td>",
"       <td>",
"        Patient prefers to rest in a dark, quiet room",
"       </td>",
"       <td>",
"        Patient may remain active or may need to rest",
"       </td>",
"       <td>",
"        Patient remains active",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration",
"       </td>",
"       <td>",
"        4 to 72 hours",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        30 minutes to 3 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated symptoms",
"       </td>",
"       <td>",
"        Nausea, vomiting, photophobia, phonophobia; may have aura (usually visual, but can involve other senses or cause speech or motor deficits)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Ipsilateral lacrimation and redness of the eye; stuffy nose; rhinorrhea; pallor; sweating; Horner's syndrome; focal neurologic symptoms rare; sensitivity to alcohol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41899=[""].join("\n");
var outline_f40_58_41899=null;
var title_f40_58_41900="Hormone regimens in the transsexual persons";
var content_f40_58_41900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hormone regimens in the transsexual persons",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        MTF transsexual persons*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <strong>",
"         Estrogen",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Oral: estradiol",
"       </td>",
"       <td>",
"        2.0 to 6.0 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Transdermal: estradiol patch",
"       </td>",
"       <td>",
"        0.1 to 0.4 mg twice weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Parenteral: estradiol valerate or cypionate",
"       </td>",
"       <td>",
"        5 to 20 mg im every&nbsp;two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 10 mg im every week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <strong>",
"         Antiandrogens",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Spironolactone",
"       </td>",
"       <td>",
"        100 to 200 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cyproterone acetate",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        50 to 100 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        <strong>",
"         GnRH agonist",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        3.75 mg sc monthly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        FTM transsexual persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        <strong>",
"         Testosterone",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Oral: testosterone undecanoate",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        160 to 240 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"2\">",
"        Parenteral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        Testosterone enanthate or cypionate",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        100 to 200 mg im every&nbsp;two weeks or 50 percent weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        Testosterone undecanoate",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        1000 mg every 12 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"2\">",
"        Transdermal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        Testosterone gel 1 percent",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        2.5 to 10 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        Testosterone patch",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        2.5 to 7.5 mg/day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Estrogens used with or without antiandrogens or GnRH agonist.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Not available in the United States.",
"      <br>",
"       &Delta; 1000 mg initially, followed by an injection at&nbsp;six weeks, then at 12-week intervals.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright &copy; 2009 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41900=[""].join("\n");
var outline_f40_58_41900=null;
var title_f40_58_41901="Impact of sleep on disease";
var content_f40_58_41901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Impact of sleep on patients with neuromuscular or chest wall disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 286px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41901=[""].join("\n");
var outline_f40_58_41901=null;
var title_f40_58_41902="Docetaxel cisplatin and FU plus RT HNC ver2";
var content_f40_58_41902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by radiotherapy for locally advanced, squamous cell carcinoma of the head and neck (TAX323)",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: Every 21 days for four cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Docetaxel",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS) to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over 60 minutes. Do not administer with aluminum needles or IV sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        750 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL 5 percent dextrose in water or NS and administer as a continuous infusion over 24 hours.",
"       </td>",
"       <td>",
"        Days 1 through 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for two hours before and two hours after cisplatin administration. Additional hydration of 1 to 2 liters of NS on day 2 to prevent nephrotoxicity. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone prior to docetaxel administration. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        In the original protocol, prophylactic therapy with a fluoroquinolone antibiotic was used on days 5 to 15 of each cycle because of the high frequency of grade 3 or 4 neutropenia",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Docetaxel and cisplatin are irritants, but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Docetaxel should not be given if bilirubin is &gt;ULN, or if AST and/or ALT &gt;1.5 x ULN with AP &gt;2.5 x ULN",
"        <sup>",
"         [2]",
"        </sup>",
"        . Dose adjustments for FU may be needed for patients with hepatic impairment",
"        <sup>",
"         [2]",
"        </sup>",
"        . The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC, differential, and platelet count on day 1 of each cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Creatinine and electrolytes on day 5 or 6 of each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Basic metabolic panel, including creatinine and electrolytes, and liver function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurotoxicity, diarrhea, and palmar plantar erythrodysesthesias prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Gastrointestinal toxicity:",
"        </strong>",
"        Doses of docetaxel and FU should be reduced for grade 3 or 4 diarrhea or mucositis",
"        <sup>",
"         [2]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Toxicity",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Dose adjustment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Diarrhea grade 3",
"       </td>",
"       <td colspan=\"2\">",
"        First episode: Reduce FU dose by 20 percent.",
"        <br/>",
"        Second episode: Reduce docetaxel dose by 20 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Diarrhea grade 4",
"       </td>",
"       <td colspan=\"2\">",
"        First episode: Reduce docetaxel and FU doses by 20 percent.",
"        <br/>",
"        Second episode: Discontinue treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Stomatitis/mucositis grade 3",
"       </td>",
"       <td colspan=\"2\">",
"        First episode: Reduce FU dose by 20 percent.",
"        <br/>",
"        Second episode: Stop FU only at all subsequent cycles.",
"        <br/>",
"        Third episode: Reduce docetaxel dose by 20 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Stomatitis/mucositis grade 4",
"       </td>",
"       <td colspan=\"2\">",
"        First episode: Stop FU only at all subsequent cycles.",
"        <br/>",
"        Second episode: Reduce docetaxel dose by 20 percent.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\" colspan=\"4\">",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression or severe, prolonged neutropenia and/or thrombocytopenia after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        Docetaxel should not be given if bilirubin is &gt;ULN, or if AST and/or ALT &gt;1.5 x ULN with AP &gt;2.5 x ULN",
"        <sup>",
"         [2]",
"        </sup>",
"        . For intracycle increases of AST/ALT &gt;2.5 to &le;5 x ULN and AP &le;2.5 x ULN,",
"        <strong>",
"         OR",
"        </strong>",
"        AST/ALT &gt;1.5 to &le;5 x ULN",
"        <strong>",
"         AND",
"        </strong>",
"        AP &gt;2.5 to &le;5 x ULN , docetaxel should be reduced by 20 percent. In case of AST/ALT &gt;5 x ULN",
"        <strong>",
"         AND/OR",
"        </strong>",
"        AP &gt;5 x ULN, docetaxel should be stopped",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Patients should not be retreated with docetaxel until the neutrophil count is &gt;1500 cells/mm",
"        <sup>",
"         3[2]",
"        </sup>",
"        . In the original protocol, G-CSF was allowed during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than seven days. If an episode of febrile neutropenia, prolonged neutropenia or neutropenic infection occurs despite G-CSF use, FDA guidelines suggest reduction of docetaxel dose from 75 to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . FDA-labeling recommends a docetaxel dose reduction from 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for an episode of febrile neutropenia, prolonged neutropenia, or neutropenic infection. If subsequent episodes of complicated neutropenia occur, the docetaxel dose should be reduced further from 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 45 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . In case of grade 4 thrombocytopenia, the docetaxel dose should be reduced from 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Reduce cisplatin dose 20 percent for grade 2 peripheral neuropathy and discontinue for grade 3 neuropathy or grade 3 ototoxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar plantar erythrodysesthesia:",
"        </strong>",
"        Hold FU for grade 2 or greater palmar plantar erythrodysesthesia, and reduce subsequent dose by 20 percent",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        For other grade 3 or worse toxicity except for alopecia and anemia, delay chemotherapy (maximum of two weeks) until resolution to &lt;grade 1, then restart if medically appropriate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ULN: upper limit of normal; AP: alkaline phosphatase; G-CSF: granulocyte colony-stimulating factors.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Vermorken JB, et al. N Eng J Med 2007; 357:1695.",
"      </li>",
"      <li>",
"       Taxotere (docetaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection FDA-approved package insert US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41902=[""].join("\n");
var outline_f40_58_41902=null;
var title_f40_58_41903="Elbow fat pads";
var content_f40_58_41903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    The elbow fat pads",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some of the coronoid fat pad lies anterior to the shallow coronoid fossa. The olecranon fat pad lies totally within the deeper olecranon fossa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow region: General concepts in the pediatric patient. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_58_41903=[""].join("\n");
var outline_f40_58_41903=null;
